<SEC-DOCUMENT>0001104659-26-040171.txt : 20260407
<SEC-HEADER>0001104659-26-040171.hdr.sgml : 20260407
<ACCEPTANCE-DATETIME>20260407083516
ACCESSION NUMBER:		0001104659-26-040171
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260406
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260407
DATE AS OF CHANGE:		20260407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Transcode Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001829635
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811065054
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40363
		FILM NUMBER:		26843042

	BUSINESS ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		857-301-6857

	MAIL ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2611272d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:rnaz="http://transcodetherapeutics.com/20260406">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_rnaz_transcodetherapeutics.com_20260406 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20260406_20260406 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001829635 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000004" name="dei:EntityCentralIndexKey">0001829635</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rnaz-20260406.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-04-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001829635</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-04-06</xbrli:startDate>
        <xbrli:endDate>2026-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>



<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20260406__20260406_zw2XDeIHgiyc"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20260406__20260406_z5m8zaM7GSmg"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 6, 2026</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityRegistrantName_c20260406__20260406_zescl3GQzLP7"><b><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000011" name="dei:EntityRegistrantName">TRANSCODE
THERAPEUTICS, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20260406__20260406_ztsw0mnoznq3" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_904_edei--EntityFileNumber_c20260406__20260406_z78e9BDlPbEk" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000013" name="dei:EntityFileNumber">001-40363</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 32%"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20260406__20260406_zdumdJxxozc3" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000014" name="dei:EntityTaxIdentificationNumber">81-1065054</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b>(State or other jurisdiction<br/>
    of incorporation)</b></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="text-align: center; vertical-align: top"><b>(Commission<br/>
    File Number)</b></td>
    <td style="vertical-align: bottom"><b>&#160;</b></td>
    <td style="text-align: center; vertical-align: top"><b>(I.R.S. Employer<br/>
    Identification No.)</b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TransCode
Therapeutics, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20260406__20260406_zUZAJ9ARGr4d"><b><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000015" name="dei:EntityAddressAddressLine1">6
Liberty Square</ix:nonNumeric></b></span><b>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20260406__20260406_z2cTdUbAT64h"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000016" name="dei:EntityAddressAddressLine2">#2382</ix:nonNumeric></span></b> <br/>
<span id="xdx_909_edei--EntityAddressCityOrTown_c20260406__20260406_zEhdjuxYklDd"><b><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000017" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric></b></span><b>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20260406__20260406_zGfZTHXALdZe"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric>
</span></b><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20260406__20260406_zXNf4mdssKSh" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000019" name="dei:EntityAddressPostalZipCode">02109</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>(Address
of principal executive offices, including zip code)</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20260406__20260406_zLiq1MQFZDEh"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000020" name="dei:CityAreaCode">857</ix:nonNumeric></span></b><b>)
<span id="xdx_905_edei--LocalPhoneNumber_c20260406__20260406_zPRd88UrNC2i"><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000021" name="dei:LocalPhoneNumber">837-3099</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in"><span id="xdx_905_edei--WrittenCommunications_c20260406__20260406_zSVMXX7YXeS4" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR 230.425)
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in"><span id="xdx_902_edei--SolicitingMaterial_c20260406__20260406_zReiM3mEw0Ef" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleantrue" id="Fact000023" name="dei:SolicitingMaterial">x</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20260406__20260406_zAZmFCMo1Gv5" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17&#160;CFR
    240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.2in"><span id="xdx_905_edei--PreCommencementIssuerTenderOffer_c20260406__20260406_zGghv5A9A5Cg" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17&#160;CFR
    240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><b>Title of each class</b></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 20%; text-align: center"><b>Trading symbol(s)</b></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 38%; text-align: center"><b>Name of each exchange on which <br/>
    registered</b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span id="xdx_90E_edei--Security12bTitle_c20260406__20260406_zYo8HEkgxubi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span id="xdx_901_edei--TradingSymbol_c20260406__20260406_zg3s9PEuzHwg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2026-04-06" id="Fact000027" name="dei:TradingSymbol">RNAZ</ix:nonNumeric></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The <span id="xdx_902_edei--SecurityExchangeName_c20260406__20260406_zlsgg5gL2M58"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric>
    </span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Market</span></b></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Emerging
growth company&#160;&#160;<span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20260406__20260406_zh0EMmBYn113" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span id="xdx_90A_edei--EntityExTransitionPeriod_c20260406__20260406_zcrK63QNqLg8" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2026-04-06" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.01</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;6, 2026</span>, TransCode Therapeutics, Inc., a Delaware corporation, (the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;)
entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, LTD, a Cayman Islands exempt limited partnership
(&#8220;Yorkville&#8221;), pursuant to which the Company has the right to sell to Yorkville up to $14&#160;million of shares of the Company&#8217;s
common stock, par value $0.0001 per share, (&#8220;Common Stock&#8221;) subject to certain limitations and conditions set forth in the
SEPA, from time to time during the term of the SEPA (the &#8220;Commitment Amount&#8221;). Sales of the shares of Common Stock to Yorkville
under the SEPA, and the timing of any such sales, are at the Company&#8217;s option, and the Company is under no obligation to sell any
shares of Common Stock to Yorkville under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
the satisfaction of the conditions to Yorkville&#8217;s purchase obligation set forth in the SEPA, which include, among other things,
(i) having a registration statement registering under the Securities Act of 1933, as amended, (the &#8220;Securities Act&#8221;)&#160;the
resale of the shares of Common Stock issuable under the SEPA (the &#8220;Yorkville Registration Statement&#8221;), and (ii) no balance
being outstanding under any Convertible Note (as defined below) with certain exceptions, the </span>Company can, at its sole discretion,
direct Yorkville to purchase specified amounts of Common Stock (each such event, an &#8220;Advance&#8221;) by delivering written notice
to Yorkville (each, an &#8220;Advance Notice&#8221;) in accordance with the terms of the SEPA. The purchase price per share for each Advance
is set at 97% of the lowest daily volume weighted average price (&#8220;VWAP&#8221;) during the three consecutive trading days beginning
on the date upon which the Advance Notice is delivered (the &#8220;Pricing Period&#8221;), with certain exceptions and with the Company
having the option to set a minimum price. &#160;<span style="background-color: white">While there is no mandatory minimum amount of Common
Stock the Company is required to direct Yorkville to purchase pursuant to any single Advance Notice, an Advance Notice may not direct
Yorkville to purchase a number of shares of Common Stock exceeding the greater of (i) 100% of the average of the daily trading volume
of the Common Stock on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) during the five consecutive trading day-period immediately preceding
an Advance Notice </span>and (ii) 500,000 shares of Common Stock. A<span style="background-color: white">ctual sales of Common Stock to
Yorkville as Advances under the SEPA will depend on a variety of factors to be determined by the Company in its sole discretion, from
time to time, which may include, among other things, market conditions, the trading price of the Common Stock and determinations by the
Company as to appropriate sources of funding for the Company&#8217;s business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the SEPA, and subject to the conditions set forth
therein, Yorkville has also agreed to advance to the Company up to $6.0 million, less certain amounts as described below, to be paid in
two tranches (each, a &#8220;Pre-Paid Advance&#8221; and, together, the &#8220;Pre-Paid Advances&#8221;), in exchange for the Company&#8217;s
issuance to Yorkville of convertible promissory notes (each, a &#8220;Convertible Note&#8221; and, together, the &#8220;Convertible Notes&#8221;).
Pursuant to the Convertible Notes and the SEPA, Yorkville may convert all or any portion of the outstanding principal amount, accrued
and unpaid interest and other amounts outstanding under the Convertible Notes into shares of Common Stock, at any time and from time to
time during the term of the Convertible Notes as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The first Pre-Paid Advance in the amount of $1.0&#160;million is conditioned
upon the Company filing its Annual Report on Form 10-K for the year ended December 31, 2025 on or prior to April 15, 2025 (&#8220;Form
10-K&#8221;) and will be disbursed to the Company concurrently with the Company&#8217;s filing of its Form 10-K. In exchange for the first
Pre-Paid Advance, the Company will issue to Yorkville a Convertible Note in the principal amount of $1.0 million (the &#8220;First Convertible
Note&#8221;), which will be issued with a purchase price discount of 5.0% (or $50,000). The First Convertible Note is convertible into
Common Stock at the lower of (i) a fixed conversion price equal to 115% of the VWAP of the Company&#8217;s Common Stock on the day prior
to the issuance of the First Convertible Note and (ii) 95% of the lowest daily VWAP during the seven consecutive trading days immediately
preceding the conversion date, but in no event lower than 20% of last reported trading price of the Company&#8217;s Common Stock on Nasdaq
as quoted by Bloomberg (the &#8220;First Convertible Note Conversion Price&#8221;) as of the trading day immediately prior to the date
of the SEPA (the &#8220;Floor Price&#8221;). After the purchase price discount, the Company expects to receive gross proceeds of $950,000
pursuant to the First Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The second tranche of the Pre-Paid Advance, in the amount of $5.0 million,
will be disbursed to the Company in exchange for the issuance to Yorkville of a Convertible Note in the principal amount of $5.0&#160;million
(the &#8220;Second Convertible Note&#8221;). The Second Convertible Note will be issued with a purchase price discount of 5.0% (or $250,000)
and will be convertible into Common Stock at the lower of (i) a fixed conversion price equal to 115% of the VWAP of the Company&#8217;s
Common Stock on the day prior to the issuance of the Second Convertible Note and (ii) 95% of the lowest daily VWAP during the seven consecutive
trading days immediately preceding the conversion date, but in no event lower than Floor Price (the &#8220;Second Convertible Note Conversion
Price, and together with the First Convertible Note Conversion Price, the &#8220;Conversion Price&#8221;). The Second Convertible Note
will be issued on the second trading day after the later of (i) the Yorkville Registration Statement described above first becoming effective
under the Securities Act, (ii) the Company&#8217;s receipt of the requisite stockholder approval to issue shares of Common Stock to Yorkville
under the SEPA in excess of the Exchange Cap (defined below), <span style="background-color: white">and (iii) the approval by Nasdaq of
the Initial Listing Application required under Nasdaq Listing Rules 5110 and 5635(b)</span>. After the purchase price discount, the Company
expects to receive gross proceeds of $4,750,000 pursuant to the Second Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest on the outstanding balances of the Convertible Notes will
accrue at an annual rate of 5.0%, subject to an increase to 18% upon an event of default as described below. The maturity date of the
First Convertible Note will be on the 18-month anniversary of the date upon which the First Convertible Note was issued. The maturity
date of the Second Convertible Note will be the 18-month anniversary of the date upon which the Second Convertible Note is issued. The
applicable maturity date of each Convertible Note may be extended by the Company, at its option, for a period of six months on two occasions
by providing written notice to Yorkville. On the applicable maturity date, any portion of the outstanding principal amount and accrued
and unpaid interest that remains outstanding on such Convertible Note will automatically be converted at the then applicable Conversion
Price, provided that if any Equity Condition (as defined in the Convertible Notes ) is not satisfied, the applicable maturity date will
be automatically extended until all Equity Conditions have been satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon an event of default under the Convertible Notes, which includes,
among other things, payment defaults not cured within five (5) days, certain bankruptcy events, certain changes in control transactions
unless the outstanding obligations are repaid at closing or Yorkville consents, failure to timely deliver shares, specified cross-defaults
exceeding $500,000, late SEC periodic reports, trading suspensions of ten (10) consecutive trading days, and material covenant breaches
not cured within the applicable period, the interest rate shall increase to 18% per annum and, at Yorkville&#8217;s election or automatically
upon certain insolvency events, the full outstanding amount, together with a 10% payment premium and all accrued interest and other amounts
owing, shall become immediately due and payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The sale and issuance of shares under the SEPA, including pursuant
to the conversion of the Convertible Notes at Yorkville&#8217;s option and the sale of shares of Common Stock at the option of the Company,
is subject to an exchange cap limiting the total number of shares issuable to Yorkville to 183,301 (19.99% of outstanding shares of Common
Stock before the effective date of the SEPA) (the &#8220;Exchange Cap&#8221;), unless the Company obtains stockholder approval to exceed
this Exchange Cap (the &#8220;Yorkville Issuance Approval&#8221;). Additionally, Yorkville cannot own more than 9.99% of the Company&#8217;s
outstanding Common Stock at any time, unless it provides written notice of its intention to increase this limit, effective after 65 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As consideration for Yorkville&#8217;s commitment to purchase Common
Stock at the Company&#8217;s direction pursuant to the SEPA, the Company (i) paid to Yorkville a cash &#8220;diligence fee&#8221; in the
amount of $25,000 and (ii) shall pay a commitment fee in an amount equal to 2.00% of the Commitment Amount (the &#8220;Commitment Fee&#8221;),
or $280,000, which shall be paid on the earlier of (i) the thirtieth Trading Day following April&#160;6, 2026, or (ii) the initial filing
date of the initial Yorkville Registration Statement (the &#8220;Fee Due Date&#8221;). The Company may pay the Commitment Fee on the Fee
Due Date either in cash or by issuance to the Investor of such number of Common Shares that is equal to the Commitment Fee divided by
the closing price of the Common Shares as of the Trading Day immediately prior to the Fee Due Date (collectively, the &#8220;Commitment
Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the SEPA, the Company and Yorkville entered into a Registration Rights Agreement dated as of April&#160;6, 2026, (the
&#8220;Yorkville Registration Rights Agreement&#8221;) pursuant to which the Company agreed to file the Yorkville Registration Statement
with the SEC by April&#160;30, 2026, </span>and to use commercially reasonable efforts to cause such registration statement to be declared
effective by the SEC within 90 days of the effective date of the SEPA. The Company also granted Yorkville customary piggyback registration
and indemnification rights and entered into customary issuer covenants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEPA and the Yorkville Registration Rights Agreement contain customary
representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants
contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the
parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The foregoing description of the SEPA, the Convertible
Notes and Yorkville Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the
full text of the SEPA, the Convertible Notes and the Yorkville Registration Rights Agreement, copies of which are filed as Exhibits 10.1,
4.1 and 4.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 2.03</b></td><td style="text-align: justify"><b>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet <b>Arrangement of a Registrant.</b></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information set forth in Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 3.02</b></td><td style="text-align: justify"><b>Unregistered Sales of Equity Securities.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in Item 1.01 of this
Current Report is incorporated by reference into this Item 3.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Acquisition PIK Dividend</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously disclosed by the Company, on October&#160;8, 2025, the
Company entered into a Membership Interest Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with DEFJ, LLC, a Delaware limited
liability company (&#8220;DEFJ&#8221;), pursuant to which the Company acquired 100% of the issued and outstanding membership interests
of ABCJ, LLC, a Delaware limited liability company (&#8220;ABCJ&#8221;) (such transaction, the &#8220;Acquisition&#8221;). Prior to the
Acquisition, ABCJ was a wholly owned subsidiary of DEFJ and an indirect wholly owned subsidiary of CK Life Sciences Int&#8217;l., (Holdings)
Inc., a listed entity on the Main Board of the Hong Kong Stock Exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the Purchase Agreement, upon the consummation of
the Acquisition, which occurred concurrently with the execution of the Purchase Agreement, in exchange for all of the membership interests
of ABCJ, the Company issued to DEFJ an aggregate of (i) 83,285 shares of Common Stock, and (ii) 1,152.9568 shares of the Company&#8217;s
Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (&#8220;Series A Preferred Stock&#8221;). Tungsten Advisors
(through its broker-dealer, Finalis Securities LLC)&#160;(&#8220;Tungsten&#8221;) acted as the financial advisor to the Company in connection
with the Acquisition. As partial compensation for services rendered by Tungsten, the Company issued to Tungsten and its affiliates and
designees an aggregate of 59.2255 shares of Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Purchase Agreement and the Amended and Restated Certificate
of Designation of Preferences, Rights and Limitations of Series A Preferred Stock and Series B Preferred Stock (the &#8220;Certificate
of Designation&#8221;) filed with the Secretary of State of Delaware on October&#160;27, 2025, holders of Series A Preferred Stock were
entitled to receive, and the Company was required to pay, payment-in-kind dividends on each share of Series A Preferred Stock (the &#8220;PIK
Dividend&#8221;), accruing at a rate equal to 5% per annum payable in shares of Series A Preferred Stock 180 days after the date of the
original issuance of such Series A Preferred Stock. On April&#160;6, 2026, the Company issued as a PIK Dividend, 28.4291 shares of Series
A Preferred Stock to DEFJ and 1.4604 shares of Series A Preferred Stock to Tungsten.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="background-color: white">The securities
to be issued as described in Item 1.01 and the PIK Dividend to be issued pursuant to the Certificate of Designation will be issued to
accredited investors (as such term is defined in Rule 501(a) of Regulation D under the Securities Act) in transactions not involving any
public offering in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities issued pursuant to the SEPA</span> and the PIK Dividend have not been registered under the Securities Act and none of such
securities may be offered or sold in the United States absent registration or an exemption from registration under the Securities Act
and any applicable state securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">Neither this Current
Report on Form 8-K nor any of the exhibits attached hereto will constitute an offer to sell or the solicitation of an offer to buy any
securities of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 7.01</b></td><td style="text-align: justify"><b>Regulation FD Disclosure.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April&#160;6, 2026, the Company issued a press
release announcing its entering into the transactions with Yorkville, as described more fully in Item 1.01 of this Current Report on Form
8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The information in Item 7.01 of this Current Report
on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, is furnished
pursuant to Item 7.01 of Form 8-K and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report
on Form 8-K shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Important Information and Where to Find It</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company expects to file a proxy statement
with the SEC regarding the approval of the issuance of Common Stock pursuant to the SEPA in excess of the Exchange Cap (the &#8220;Yorkville
Issuance Proposal&#8221;). The definitive proxy statement will be sent to all Company stockholders. Before making any voting decision,
investors and securityholders of the Company are urged to read the proxy statement and all other relevant documents filed or that will
be filed with the SEC in connection with the stockholder meeting at which the Yorkville Issuance Proposal will be voted upon as such documents
become available because they will contain important information about the Yorkville Issuance Proposal to be voted upon. Investors and
securityholders will be able to obtain free copies of the proxy statement and all other relevant documents filed or that will be filed
with the SEC by the Company through the website maintained by the SEC at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Participants in Solicitation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company and its respective directors, executive
officers, and employees may be deemed to be participants in the solicitation of proxies in respect of the Yorkville Issuance Proposal.
Information regarding the Company&#8217;s directors and executive officers is available in the Company&#8217;s Definitive Proxy Statement
filed with the SEC on&#160;July 15, 2025, under &#8220;Proposal No. 1 - Election of Directors&#8221; and in this Current Report on Form
8-K. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description
of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement and other relevant
materials to be filed with the SEC when they become available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">(d)</span></span>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;Number</b></span></td>
    <td style="width: 0.2in">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2611272d1_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2611272d1_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Promissory Notes issued to YA II PN, Ltd.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2611272d1_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2611272d1_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated as of April&#160;6, 2026, by and between TransCode Therapeutics, Inc. and YA II PN, Ltd. </span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2611272d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2611272d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby Equity Purchase Agreement, dated as of April&#160;6, 2026, between TransCode Therapeutics, Inc. and YA II PN, Ltd. </span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm2611272d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm2611272d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of TransCode Therapeutics, Inc., dated April 6, 2026 (furnished herewith).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 3pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Certain annexes, schedules and exhibits have
been omitted pursuant to Item 601(a)(5) of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TRANSCODE THERAPEUTICS,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas A. Fitzgerald</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas A. Fitzgerald</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Secretary</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April&#160;7, 2026</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OcwWhfAxqYgsRCJ6XXKMJd2R2c3yk/rLNiUaBobh3nOvEDOxpY1ukOGyKnM4Yds1yiGUWCOjuaJ3ZLt9Cv6WeNPWsTJufH9gRp5BzyShlMoLo7XXFqsUongu5VzGEC3TREJxEMFXz8jUukLjtGpAmQoKpo41OsXDlHBSLzLUDmPVGdlqMikswmiS3yCjhYQj9epJfLeQ55kIZuMEYsv06Lxr/XJoviSsG2x9nZ3o/wYfB/FKjw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>tm2611272d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH
THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE
SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;<U>SECURITIES
ACT</U>&rdquo;), AND, ACCORDINGLY, MAY&nbsp;NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY&nbsp;BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Convertible
Promissory Note</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Original Principal Amount:&#8239;&#8239;[$1,000,000] [$5,000,000]</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance Date: [_________]</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Number: RNAZ-[1][2]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>FOR VALUE RECEIVED,</B> TRANSCODE
THERAPEUTICS,&nbsp;INC., an entity organized under the laws of the State of Delaware (the &ldquo;<U>Company</U>&rdquo;), hereby promises
to pay to the order of YA II PN,&nbsp;LTD., or its registered assigns (the &ldquo;<U>Holder</U>&rdquo;), the amount set out above as the
Original Principal Amount (or such lesser amount as reduced pursuant to the terms hereof pursuant to repayment, redemption, conversion
or otherwise, the &ldquo;<U>Principal</U>&rdquo;) and the Payment Premium, as applicable, in each case when due, and to pay interest (&ldquo;<U>Interest</U>&rdquo;)
on any outstanding Principal at the applicable Interest Rate (as defined below) from the date set out above as the Issuance Date (the
&ldquo;<U>Issuance Date</U>&rdquo;) until the same becomes due and payable, whether upon the Maturity Date or acceleration, conversion,
redemption or otherwise (in each case in accordance with the terms hereof). Certain capitalized terms used herein are defined in Section&nbsp;&lrm;(12).
The Issuance Date is the date of the first issuance of this Convertible Promissory Note (as amended, amended and restated, extended, supplemented
or otherwise modified in writing from time to time, this &ldquo;<U>Note</U>&rdquo;) regardless of the number of transfers and regardless
of the number of instruments, which may be issued to evidence such Note. The Company and the Holder are referred to herein at times, collectively,
as the &ldquo;<U>Parties</U>,&rdquo; and each, a &ldquo;<U>Party</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Note is being issued pursuant
to Section&nbsp;2.01 of the Standby Equity Purchase Agreement, dated April&nbsp;6, 2026 (as may be amended, amended and restated, extended,
supplemented or otherwise modified in writing from time to time, the &ldquo;<U>SEPA</U>&rdquo;), by and between the Company and YA II
PN,&nbsp;Ltd., as the Investor. This Note may be repaid in accordance with the terms of the SEPA, including, without limitation, pursuant
to Investor Notices and corresponding Advance Notices deemed given by the Company in connection with such Investor Notices. The Holder
also has the option of converting on one or more occasions all or part of the then outstanding balance under this Note by delivering to
the Company one or more Conversion Notices in accordance with Section&nbsp;3 of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>GENERAL
TERMS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Maturity
Date</U>. The &ldquo;<U>Maturity Date</U>&rdquo; shall be [________], 2027<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>. The Company
shall have the right, on two occasions, on each such occasion by providing written notice to the Holder at least 10 Business Days but
no more than 30 Business Days prior to the applicable Maturity Date, to elect to extend the Maturity Date for a period of six months from
the applicable Maturity Date, provided that as of the date of any such notice, no Event of Default has occurred, and no event has occurred
and is continuing that, with the giving of notice, the passage of time, or both, would constitute an Event of Default. On the Maturity
Date, any portion of the outstanding Principal and accrued and unpaid Interest that remains outstanding shall automatically be converted
at the applicable Conversion Price as of such date, provided that if any Equity Condition is not satisfied, then the applicable Maturity
Date shall be automatically extended until all Equity Conditions have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interest
Rate and Payment of Interest</U>. Interest shall accrue on the outstanding Principal balance hereof at an annual rate equal to 5% (&ldquo;<U>Interest
Rate</U>&rdquo;), which Interest Rate shall increase to an annual rate of 18% upon the occurrence of an Event of Default (for so long
as such event remains uncured). Interest shall be calculated based on a 365-day year and the actual number of days elapsed, to the extent
permitted by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Monthly
Payments</U>. If, any time after the Issuance Date set forth above, and from time to time thereafter, an Amortization Event has occurred,
then the Company shall make monthly cash payments beginning on the 7th Trading Day after the Amortization Event Date and continuing on
the same day of each successive Calendar Month until the entire outstanding principal amount of this Note shall have been repaid , or
the obligation of the Company to make monthly cash payments pursuant to this Section&nbsp;1(c)&nbsp;has ceased as set forth below. Each
monthly cash payment shall be in an amount equal to the sum of (i)&nbsp;the Amortization Principal Amount, <I>plus</I> (ii)&nbsp;the Payment
Premium in respect of such Amortization Principal Amount, <I>plus</I> (iii)&nbsp;all accrued and unpaid interest hereunder as of each
payment date. The obligation of the Company to make monthly cash payments related to an Amortization Event pursuant to this Section&nbsp;1(c)&nbsp;shall
cease (with respect to any payment that has not yet come due) if at any time after the Amortization Event Date (A)&nbsp;in the event of
a Floor Price Event, on the date that is the 10th consecutive Trading Day that the daily VWAP is greater than the Floor Price, or (B)&nbsp;in
the event of a Registration Event, the condition or event causing the Registration Event has been cured or the Holder is able to resell
the Common Shares issuable upon conversion of this Note in accordance with Rule&nbsp;144 under the Securities Act, unless a subsequent
Amortization Event occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <B>Note to Draft:</B> Shall be the date that is 18-months
from the closing date of each Pre-Paid Advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Optional
Redemption</U>. The Company at its option shall have the right, but not the obligation, to redeem (&ldquo;<U>Optional Redemption</U>&rdquo;)
early a portion or all amounts outstanding under this Note as described in this Section; <I>provided,</I> that the Company provides the
Holder with written notice (each, a &ldquo;<U>Redemption Notice</U>&rdquo;) of its desire to exercise an Optional Redemption, which Redemption
Notice (i)&nbsp;shall be delivered to the Holder after the close of regular trading hours on a Trading Day, and (ii)&nbsp;may only be
given if the VWAP of the Common Shares was less than the Fixed Price on the date such Redemption Notice is delivered, unless as of the
date of such Redemption Notice, the Equity Conditions are satisfied. Each Redemption Notice shall be irrevocable and shall specify the
outstanding balance of the Note to be redeemed and the Redemption Amount. The &ldquo;<U>Redemption Amount</U>&rdquo; shall be an amount
equal to (a)&nbsp;the outstanding Principal balance being redeemed by the Company <I>plus</I> (b)&nbsp;the Payment Premium in respect
of such Principal amount <I>plus</I> (c)&nbsp;all accrued and unpaid interest hereunder as of the date of such redemption. After receipt
of a Redemption Notice, the Holder shall have ten (10)&nbsp;Trading Days (beginning with the Trading Day immediately following the date
such Redemption Notice is delivered to the Holder in accordance with this term of this Section&nbsp;1(d)) to elect to convert all or any
portion of this Note. On the eleventh (11<SUP>th</SUP>) Trading Day following the delivery of the applicable Redemption Notice, the Company
shall deliver to the Holder the Redemption Amount with respect to the Principal amount redeemed to the extent not converted and otherwise
after giving effect to conversions or other payments made during such ten (10)&nbsp;Trading Day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
Dates</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall be made
on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Other
than as specifically set forth in this Note, the Company shall not have the ability to make any early repayments without the consent of
or at the request of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>EVENTS
OF DEFAULT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>An
&ldquo;<U>Event of Default</U>&rdquo;, wherever used herein, means any one of the following events (whatever the reason and whether it
shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule&nbsp;or regulation of any administrative or governmental body) shall have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company&rsquo;s failure to pay to the Holder any amount of Principal, Redemption Amount, Payment Premium,&nbsp;Interest, or other amounts when
and as due under this Note or any other Transaction Document within five (5)&nbsp;Business Days after such payment is due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(A)&nbsp;The
Company or any Subsidiary of the Company shall commence, or there shall be commenced against the Company or any Subsidiary of the Company
any proceeding under any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or the Company
or any Subsidiary of the Company commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors,
dissolution, insolvency or liquidation or similar law of any jurisdiction, whether now or hereafter in effect relating to the Company
or any Subsidiary of the Company, in any such bankruptcy, insolvency or other proceeding which remains undismissed for a period of sixty
one (61) days; (B)&nbsp;the Company or any Subsidiary of the Company is adjudicated insolvent or bankrupt; or any order of relief or other
order approving any such case or proceeding is entered; (C)&nbsp;the Company or any Subsidiary of the Company suffers any appointment
of any custodian, private or court appointed receiver or the like for it or all or substantially all of its property which continues undischarged
or unstayed for a period of sixty one (61) days; (D)&nbsp;the Company or any Subsidiary of the Company makes a general assignment of all
or substantially all of its assets for the benefit of creditors; (E)&nbsp;the Company or any Subsidiary of the Company shall fail to pay,
or shall state that it is unable to pay, or shall be unable to pay, its debts generally as they become due; (F)&nbsp;the Company or any
Subsidiary of the Company shall call a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of
its debts; (G)&nbsp;the Company or any Subsidiary of the Company shall by any act or failure to act expressly indicate its consent to,
approval of or acquiescence in any of the foregoing; or (H)&nbsp;any corporate or other action is taken by the Company or any Subsidiary
of the Company for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company or any Subsidiary of the Company shall default, in any of its obligations under any note, debenture, mortgage, credit agreement
or other facility, indenture agreement, factoring agreement or other instrument under which there may be issued, or by which there may
be secured or evidenced any indebtedness for borrowed money or money due under any long term leasing or factoring arrangement of the Company
or any Subsidiary of the Company in an amount exceeding $500,000, whether such indebtedness now exists or shall hereafter be created,
and such default is not cured within the time prescribed by the documents governing such indebtedness or if no time is prescribed, within
ten (10)&nbsp;Business Days, and as a result, such indebtedness becomes or is declared due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
final judgment or judgments for the payment of money in excess of $500,000 in the aggregate are rendered against the Company and/or any
of its Subsidiaries and which judgments are not, within thirty (30) days after the entry thereof, bonded, discharged, settled or stayed
pending appeal, or are not discharged within thirty (30) days after the expiration of such stay; provided, however, any judgment which
is covered by insurance or an indemnity from a creditworthy party shall not be included in calculating the $500,000 amount set forth above
so long as the Company provides the Holder a written statement from such insurer or indemnity provider (which written statement shall
be reasonably satisfactory to the Holder) to the effect that such judgment is covered by insurance or an indemnity and the Company or
such Subsidiary (as the case may be) will receive the proceeds of such insurance or indemnity within thirty (30) days of the issuance
of such judgment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(v)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Common Shares shall cease to be quoted or listed for trading, as applicable, on any Principal Market for a period of ten (10)&nbsp;consecutive
Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(vi)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company or any Subsidiary of the Company shall be a party to any Change of Control Transaction unless in connection with such Change
of Control Transaction this Note is retired. Notwithstanding anything herein to the contrary, neither (i)&nbsp;transfer to a wholly-owned
Subsidiary, nor (ii)&nbsp;the conversion of the Company&rsquo;s preferred stock outstanding as of the date hereof (including the conversion
of the preferred stock outstanding on the date hereof issued pursuant to that certain Amended and Restated Certificate of Designation
of Series&nbsp;A Non-Voting Convertible Preferred Stock and Series&nbsp;B Non-Voting Convertible Preferred Stock of TransCode Therapeutics,&nbsp;Inc.,
dated October&nbsp;27, 2025), shall be deemed a Change of Control Transaction under this provision;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(vii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company&rsquo;s (A)&nbsp;failure to deliver the required number of Common Shares to the Holder within two (2)&nbsp;Trading Days after
the applicable Share Delivery Date or (B)&nbsp;notice, written or oral, to any holder of this Note, including by way of public announcement,
at any time, of its intention not to comply with a request for conversion of all or a portion of this Note into Common Shares that is
tendered in accordance with the provisions of this Note;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(viii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall fail for any reason to deliver the payment in cash pursuant to a Buy-In (as defined below) within five (5)&nbsp;Business
Days after such payment is due;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ix)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company&rsquo;s failure to timely file with the Commission any Periodic Report on or before the due date of such filing as established
by the Commission, it being understood, for the avoidance of doubt, that due date includes any permitted filing deadline extension under
Rule&nbsp;12b-25 under the Exchange Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(x)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
representation or warranty made or deemed to be made by or on behalf of the Company in or in connection with any Transaction Document
shall prove to have been incorrect in any material respect (or, in the case of any such representation or warranty already qualified by
materiality, such representation or warranty shall prove to have been incorrect) when made or deemed made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(xi)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company uses the proceeds of the issuance of this Note, whether directly or indirectly, and whether immediately, incidentally or ultimately,
to purchase or carry margin stock (within the meaning of Regulations&nbsp;T,&nbsp;U and&nbsp;X of the Federal Reserve Board, as in effect
from time to time and all official rulings and interpretations thereunder or thereof), or to extend credit to others for the purpose of
purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(xii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
Event of Default (as defined in the Other Notes or in any Transaction Document other than this Note) occurs with respect to any Other
Notes, or any breach of any material term of any other debenture, note, or instrument held by the Holder in the Company or any agreement
between or among the Company and the Holder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(xiii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall fail to observe or perform any material covenant, agreement contained in, or otherwise commit any material breach or default
of any provision of this Note (except as may be otherwise covered by Sections (2)(a)(i)&nbsp;through (2)(a)(xiii)&nbsp;hereof) or any
other Transaction Document, which is not cured or remedied within the time prescribed or if no time is prescribed within ten (10)&nbsp;Business
Days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>During
the time that any portion of this Note is outstanding, if any Event of Default has occurred (other than an event with respect to the Company
described in Section&nbsp;(2)(a)(ii)), the full unpaid Principal amount of this Note, together with the Payment Premium in respect of
such Principal Amount that was due and payable on the date of the Event of Default and all interest and other amounts owing in respect
of this Note to the date of acceleration, shall become, at the Holder&rsquo;s election given by notice pursuant to Section&nbsp;(5), immediately
due and payable in cash; provided that, in the case of any event with respect to the Company described in Section&nbsp;(2)(a)(ii), the
full unpaid Principal amount of this Note, together with the Payment Premium in respect of such Principal Amount that was due and payable
on the date of the Event of Default and all accrued and unpaid interest and other amounts owing in respect of this Note to the date of
acceleration, shall automatically become due and payable, in each case without presentment, demand, protest or other notice of any kind,
all of which are hereby waived by the Company. Furthermore, in addition to any other remedies, the Holder shall have the right (but not
the obligation) to convert, on one or more occasions all or part of the Note in accordance with Section&nbsp;(3)&nbsp;(and subject to
the limitations set out in Section&nbsp;(3)(c)(i)&nbsp;and Section&nbsp;(3)(c)(ii)) at any time after an Event of Default has occurred
and is continuing until all amounts outstanding under this Note have been repaid in full. The Holder need not provide, and the Company
hereby waives, any presentment, demand, protest or other notice of any kind, (other than required notice of conversion) and the Holder
may immediately enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law.
Such declaration may be rescinded and annulled by the Holder in writing at any time prior to payment hereunder. No such rescission or
annulment shall affect any subsequent Event of Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>CONVERSION
OF NOTE</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This Note shall be convertible into Common Shares,
on the terms and conditions set forth in this Section&nbsp;(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conversion
Right</U>. Subject to the limitations of Section&nbsp;(3)(c), at any time or times on or after the Issuance Date, the Holder shall be
entitled to convert any portion of the outstanding and unpaid Conversion Amount into fully paid and nonassessable Common Shares in accordance
with Section&nbsp;(3)(b), at the Conversion Price. The number of Common Shares issuable upon conversion of any Conversion Amount pursuant
to this Section&nbsp;(3)(a)&nbsp;shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price. The
Company shall not issue any fraction of a Common Share upon any conversion. All calculations under this Section&nbsp;(3)&nbsp;shall be
rounded to the nearest $0.0001. If the issuance would result in the issuance of a fraction of a Common Share, the Company shall round
such fraction of a Common Share up to the nearest whole share. The Company shall pay any and all transfer, stamp and similar taxes that
may be payable with respect to the issuance and delivery of Common Shares upon conversion of any Conversion Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Mechanics
of Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Optional
Conversion</U>. To convert any Conversion Amount into Common Shares on any date (a &ldquo;<U>Conversion Date</U>&rdquo;), the Holder shall
(A)&nbsp;transmit by email (or otherwise deliver), for receipt on or prior to 11:59 p.m., New York Time, on such date, a copy of an executed
notice of conversion in the form attached hereto as <U>Exhibit&nbsp;I</U> (the &ldquo;<U>Conversion Notice</U>&rdquo;) to the Company and
(B)&nbsp;if required by Section&nbsp;(3)(b)(iii), surrender this Note to a nationally recognized overnight delivery service for delivery
to the Company (or an indemnification undertaking reasonably satisfactory to the Company with respect to this Note in the case of its
loss, theft or destruction). On or before the first (1<SUP>st</SUP>) Trading Day following the date of receipt of a Conversion Notice
(the &ldquo;<U>Share Delivery Date</U>&rdquo;), the Company shall (X)&nbsp;if legends are not required to be placed on certificates or the
book-entry position of the Common Shares and provided that the Transfer Agent is participating in the Depository Trust Company&rsquo;s (&ldquo;<U>DTC</U>&rdquo;)
Fast Automated Securities Transfer Program, instruct such transfer agent to credit such aggregate number of Common Shares to which the
Holder shall be entitled to the Holder&rsquo;s or its designee&rsquo;s balance account with DTC through its Deposit Withdrawal Agent Commission system
or (Y)&nbsp;if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver to the
address as specified in the Conversion Notice, a certificate or book-entry position, registered in the name of the Holder or its designee,
for the number of Common Shares to which the Holder shall be entitled which certificates shall not bear any restrictive legends unless
required pursuant to rules&nbsp;and regulations of the Commission. If this Note is physically surrendered for conversion and the outstanding
Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company shall as soon
as practicable and in no event later than three (3)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver
to the holder a new Note representing the outstanding Principal not converted. The Person or Persons entitled to receive the Common Shares
issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such Common Shares upon the
transmission of a Conversion Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Company&rsquo;s
Failure to Timely Convert</U>. If the Company shall fail, for any reason or for no reason, on or prior to the applicable Share Delivery
Date to issue and deliver a certificate to the Holder or credit the Holder&rsquo;s balance account with DTC for the number of Common Shares
to which the Holder is entitled upon such Holder&rsquo;s conversion of any Conversion Amount (a &ldquo;<U>Conversion Failure</U>&rdquo;), and
if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) Common Shares to deliver in satisfaction
of a sale by the Holder of Common Shares issuable upon such conversion that the Holder anticipated receiving from the Company (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall, within three (3)&nbsp;Business Days after the Holder&rsquo;s request and in the Holder&rsquo;s discretion, either (i)&nbsp;pay
cash to the Holder in an amount equal to the Holder&rsquo;s total purchase price (including brokerage commissions and other out of pocket expenses,
if any) for the Common Shares so purchased (the &ldquo;<U>Buy-In Price</U>&rdquo;), at which point the Company&rsquo;s obligation to deliver
such certificate (and to issue such Common Shares) shall terminate, or (ii)&nbsp;promptly honor its obligation to deliver to the Holder
a certificate or certificates representing such Common Shares to which the Holder is entitled with respect to such Conversion Notice and
pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A)&nbsp;such number of Common
Shares <I>multiplied by </I>(B)&nbsp;the Closing Price on the Conversion Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Book-Entry</U>.
Notwithstanding anything to the contrary set forth herein, upon conversion of any portion of this Note in accordance with the terms hereof,
the Holder shall not be required to physically surrender this Note to the Company unless (A)&nbsp;the full Conversion Amount represented
by this Note is being converted or (B)&nbsp;the Holder has provided the Company with prior written notice (which notice may be included
in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder and the Company shall maintain
records showing the Principal and Interest converted and the dates of such conversions or shall use such other method, reasonably satisfactory
to the Holder and the Company, so as not to require physical surrender of this Note upon conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
on Conversions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Beneficial
Ownership</U>. The Holder shall not have the right to convert any portion of this Note to the extent that after giving effect to such
conversion, the Holder, together with any affiliate thereof, would beneficially own (as determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;promulgated thereunder) in excess of 9.99% of the number of Common Shares outstanding immediately
after giving effect to such conversion. Since the Holder will not be obligated to report to the Company the number of Common Shares it
may hold at the time of a conversion hereunder, unless the conversion at issue would result in the issuance of Common Shares in excess
of 9.99% of the then outstanding Common Shares without regard to any other shares which may be beneficially owned by the Holder or an
affiliate thereof, the Holder shall have the authority and obligation to determine whether the restriction contained in this Section&nbsp;will
limit any particular conversion hereunder and to the extent that the Holder determines that the limitation contained in this Section&nbsp;applies,
the determination of which portion of the Principal amount of this Note is convertible shall be the responsibility and obligation of the
Holder. If the Holder has delivered a Conversion Notice for a Principal amount of this Note that, without regard to any other shares that
the Holder or its affiliates may beneficially own, would result in the issuance in excess of the permitted amount hereunder, the Company
shall notify the Holder of this fact and shall honor the conversion for the maximum Principal amount permitted to be converted on such
Conversion Date in accordance with Section&nbsp;(3)(a)&nbsp;and, any Principal amount tendered for conversion in excess of the permitted
amount hereunder shall remain outstanding under this Note. The provisions of this Section&nbsp;may be waived by a Holder (but only as
to itself and not to any other Holder) upon not less than 65 days prior notice to the Company. Other Holders shall be unaffected by any
such waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Principal
Market Limitation</U>. Notwithstanding anything in this Note to the contrary, the Company shall not issue any Common Shares upon conversion
of this Note, or otherwise, if the issuance of such Common Shares, together with any Common Shares issued in connection the SEPA, issuable
upon conversion of any Other Notes, and issuable in connection with any other related transactions that may be considered part of the
same series of transactions, would exceed the aggregate number Common Shares that the Company may issue in a transaction in compliance
with the Company&rsquo;s obligations under the rules&nbsp;or regulations of The Nasdaq Stock Market LLC (&ldquo;<U>Nasdaq</U>&rdquo;)
and shall be referred to as the &ldquo;<U>Exchange Cap,</U>&rdquo; except that such limitation shall not apply if the Company&rsquo;s
stockholders have approved such issuances on such terms in excess of the Exchange Cap in accordance with the rules&nbsp;and regulations
of Nasdaq. For the avoidance of doubt, the Exchange Cap applicable under this clause (ii)&nbsp;equals 183,301 Common Shares, as specified
in Section&nbsp;3.02(c)&nbsp;of the SEPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
calculations under this Section&nbsp;(3)&nbsp;shall be rounded to the nearest $0.0001 or whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>So
long as this Note or any Other Notes remain outstanding, the Company shall have reserved from its duly authorized share capital, and shall
have instructed the Transfer Agent to irrevocably reserve, the maximum number of Common Shares issuable upon conversion of this Note and
the Other Notes (assuming for purposes hereof that (x)&nbsp;this Note and such Other Notes are convertible at the Floor Price as of the
date of determination, and (y)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Note or Other
Notes set forth herein or therein (the &ldquo;<U>Required Reserve Amount</U>&rdquo;)), provided that at no time shall the number of Common
Shares reserved pursuant to this Section&nbsp;(3)(d)(ii)&nbsp;be reduced other than pursuant to the conversion of this Note and the Other
Notes in accordance with their terms, and/or cancellation, or reverse stock split. If at any time while this Note or any Other Notes remain
outstanding, the Company does not have a sufficient number of authorized and unreserved Common Shares to satisfy the obligation to reserve
for the issuance the Required Reserve Amount, the Company will promptly take all corporate action necessary to propose to a meeting of
its shareholders an increase of its authorized share capital necessary to meet the Company&rsquo;s obligations pursuant to this Note, and cause
its board of directors to recommend to the shareholders that they approve such proposal. If at any time the number of Common Shares that
remain available for issuance under the Exchange Cap is less than 100% of the maximum number of shares issuable upon conversion of all
the Notes and Other Notes then outstanding (assuming for purposes hereof that (x)&nbsp;the Notes are convertible at the Conversion Price
then in effect, and (y)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Note, other than
the Floor Price but solely with respect to the Variable Price), the Company will use commercially reasonable efforts to promptly call
and hold a shareholder meeting for the purpose of seeking the approval of its shareholders as required by the applicable rules&nbsp;of
the Principal Market, for issuances of shares in excess of the Exchange Cap. The Company covenants that, upon issuance in accordance with
conversion of this Note in accordance with its terms, the Common Shares, when issued, will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Nothing
herein shall limit a Holder&rsquo;s right to pursue actual damages or declare an Event of Default pursuant to Section&nbsp;(2)&nbsp;herein for
the Company&rsquo;s failure to deliver certificates representing Common Shares upon conversion within the period specified herein and
such Holder shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief, in each case without the need to post a bond or provide other security. The exercise of
any such rights shall not prohibit the Holder from seeking to enforce damages pursuant to any other Section&nbsp;hereof or under applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Legal
Opinions</U>. The Company is obligated to cause its legal counsel to deliver legal opinions to the Company&rsquo;s transfer agent in connection
with any legend removal upon the expiration of any holding period or other requirement for which the Underlying Shares may bear legends
restricting the transfer thereof, provided that the Holder shall provide to the Company and its counsel certificates and letters of representation,
if any, that are reasonably required and customary under the circumstances to effect such legend removal. To the extent that a legal opinion
is not provided (either timely or at all), then, in addition to being an Event of Default hereunder, the Company agrees to reimburse the
Holder for all reasonable costs incurred by the Holder in connection with any legal opinions paid for by the Holder in connection with
the removal of such legends in connection with a sale or transfer of the Underlying Common Shares. The Holder shall notify the Company
of any such costs and expenses it incurs that are referred to in this section from time to time and all amounts owed hereunder shall be
paid by the Company with reasonable promptness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
of Conversion Price upon Subdivision or Combination of Common Shares</U>. If the Company, at any time while this Note is outstanding,
shall (i)&nbsp;pay a stock dividend or otherwise make a distribution or distributions on shares of its Common Shares or any other equity
or equity equivalent securities payable in Common Shares, (ii)&nbsp;subdivide outstanding Common Shares into a larger number of shares,
(iii)&nbsp;combine (including by way of reverse stock split) outstanding Common Shares into a smaller number of shares, or (iv)&nbsp;issue
by reclassification of Common Shares any shares of capital stock of the Company, then each of the Fixed Price and the Floor Price shall
be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding treasury shares, if any) outstanding
before such event and of which the denominator shall be the number of Common Shares outstanding after such event. Any adjustment made
pursuant to this Section&nbsp;shall become effective, in the case of a dividend distribution, immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution or, in the case of a subdivision, combination or re-classification,
and shall become effective immediately after the effective date of such subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
of Conversion Price upon Issuance of Common Stock</U>. If the Company, at any time after [________], 2027<FONT STYLE="font-size: 10pt"><SUP>2</SUP></FONT>
while this Note is outstanding, issues or sells any Common Shares or Convertible Securities (other than Excluded Securities and any shares
issued or sold by the Company in connection with any Excluded Securities), for a consideration per share (the &ldquo;<U>New Issuance Price</U>&rdquo;)
less than a price equal to the Fixed Price in effect immediately prior to such issue or sale (such price the &ldquo;<U>Applicable Price</U>&rdquo;)
(the foregoing, a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then immediately after such Dilutive Issuance the Fixed Price then in effect
shall be reduced to an amount equal to the New Issuance Price, but which Fixed Price shall not be lower than the Floor Price. For the
purposes hereof, if the Company in any manner issues or sells any Convertible Securities (other than Excluded Securities and any shares
issued or sold by the Company in connection with any Excluded Securities) and the lowest price per share for one Common Share issuable
upon such conversion or exchange or exercise of such Convertible Securities issued or sold by the Company is less than the Applicable
Price, then such Common Share shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance
or sale of such Convertible Securities for such price per share. No further adjustment of the Conversion Price shall be made upon the
actual issuance of such Common Share upon conversion or exchange or exercise of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Corporate Events</U>. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental
Transaction pursuant to which holders of Common Shares are entitled to receive securities or other assets with respect to or in exchange
for Common Shares (a &ldquo;<U>Corporate Event</U>&rdquo;), the Company shall make appropriate provision to ensure that the Holder will
thereafter have the right to receive upon a conversion of this Note, at the Holder&rsquo;s option, (i)&nbsp;in addition to the Common Shares
receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such Common
Shares had such Common Shares been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations
or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the Common Shares otherwise receivable upon such conversion,
such securities or other assets received by the holders of Common Shares in connection with the consummation of such Corporate Event in
such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form
of such consideration (as opposed to Common Shares) at a conversion rate for such consideration commensurate with the Conversion Price.
Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Required Holders. The provisions
of this Section&nbsp;shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations
on the conversion or redemption of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> <B>Note to Draft:</B> Shall be the date that is 18-months
from the closing date of each Pre-Paid Advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Whenever
the Conversion Price is adjusted pursuant to Section&nbsp;(3)&nbsp;hereof, the Company shall promptly provide the Holder with a written
notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
case of any (1)&nbsp;merger or consolidation of the Company or any Subsidiary of the Company with or into another Person, or (2)&nbsp;sale
by the Company or any Subsidiary of the Company of more than one-half of the assets of the Company in one or a series of related transactions,
a Holder shall have the right to (A)&nbsp;exercise any rights under Section&nbsp;(2)(a)(xiii), (B)&nbsp;convert the aggregate amount of
this Note then outstanding into the shares of stock and other securities, cash and property receivable upon or deemed to be held by holders
of Common Shares following such merger, consolidation or sale, and such Holder shall be entitled upon such event or series of related
events to receive such amount of securities, cash and property as the Common Shares into which such aggregate Principal amount of this
Note could have been converted immediately prior to such merger, consolidation or sales would have been entitled, or (C)&nbsp;in the case
of a merger or consolidation, require the surviving entity to issue to the Holder a convertible Note with a Principal amount equal to
the aggregate Principal amount of this Note then held by such Holder, plus all accrued and unpaid interest and other amounts owing thereon,
which such newly issued convertible Note shall have terms identical (including with respect to conversion) to the terms of this Note,
and shall be entitled to all of the rights and privileges of the Holder of this Note set forth herein and the agreements pursuant to which
this Note was issued. In the case of clause (C), the conversion price applicable for the newly issued shares of convertible preferred
stock or convertible debentures shall be based upon the amount of securities, cash and property that each Common Shares would receive
in such transaction and the Conversion Price in effect immediately prior to the effectiveness or closing date for such transaction. The
terms of any such merger, sale or consolidation shall include such terms so as to continue to give the Holder the right to receive the
securities, cash and property set forth in this Section&nbsp;upon any conversion or redemption following such event. This provision shall
similarly apply to successive such events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>REISSUANCE
OF THIS NOTE</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer</U>.
If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith issue and
deliver upon the order of the Holder a new Note (in accordance with Section&nbsp;(4)(d)), registered in the name of the registered transferee
or assignee, representing the outstanding Principal being transferred by the Holder (along with any accrued and unpaid interest thereof)
and, if less than the entire outstanding Principal is being transferred, a new Note (in accordance with Section&nbsp;(4)(d)) to the Holder
representing the outstanding Principal not being transferred. The Holder and any assignee, by acceptance of this Note, acknowledge and
agree that, by reason of the provisions of Section&nbsp;(3)(b)(iii)&nbsp;following conversion or redemption of any portion of this Note,
the outstanding Principal represented by this Note may be less than the Principal stated on the face of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Lost,
Stolen or Mutilated Note</U>. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Note, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company
in customary form and substance and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute
and deliver to the Holder a new Note (in accordance with Section&nbsp;(4)(d)) representing the outstanding Principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Note
Exchangeable for Different Denominations</U>. This Note is exchangeable, upon the surrender hereof by the Holder at the principal office
of the Company, for a new Note or Notes (in accordance with Section&nbsp;(4)(d)) representing in the aggregate the outstanding Principal
of this Note, and each such new Note will represent such portion of such outstanding Principal as is designated by the Holder at the time
of such surrender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of New Notes</U>. Whenever the Company is required to issue a new Note pursuant to the terms hereof, such new Note (i)&nbsp;shall be of
like tenor with this Note, (ii)&nbsp;shall represent, as indicated on the face of such new Note, the Principal remaining outstanding (or
in the case of a new Note being issued pursuant to Section&nbsp;(4)(a)&nbsp;or Section&nbsp;(4)(c), the Principal designated by the Holder
which, when added to the Principal represented by the other new Note(s)&nbsp;issued in connection with such issuance, does not exceed
the Principal remaining outstanding under this Note immediately prior to such issuance of such new Note), (iii)&nbsp;shall have an issuance
date, as indicated on the face of such new Note, which is the same as the Issuance Date of this Note, (iv)&nbsp;shall have the same rights
and conditions as this Note, and (v)&nbsp;shall represent accrued and unpaid Interest from the Issuance Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(5)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT><U>NOTICES</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
notices, consents, waivers or other communications required or permitted to be given under the terms hereof must be in writing by letter
or electronic mail (&ldquo;e-mail&rdquo;) and will be deemed to have been delivered (i)&nbsp;upon receipt, when delivered personally,
(ii)&nbsp;one (1)&nbsp;Business Day after deposit with an overnight courier service with next day delivery specified, as applicable or
(iii)&nbsp;receipt, when sent by e-mail, and, in each case of the foregoing clauses (i), (ii)&nbsp;and (iii), properly addressed to the
party to receive the same. The addresses and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to the Company, to:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">TransCode Therapeutics,&nbsp;Inc</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="text-underline-style: double"><B>&nbsp;</B></FONT></TD>
    <TD>6 Liberty Square - #2382<BR> Boston, MA 02109<BR> Attn: Philippe P. Calais<BR> E-mail: &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>With copies (which shall not constitute notice or delivery of process) to:</TD>
    <TD>Orrick, Herrington&nbsp;&amp; Sutcliffe LLP<BR> 405 Howard Street<BR> San Francisco, California 94105<BR> Attn: Niki Fang,&nbsp;Esq.; David Schulman,&nbsp;Esq.<BR> E-mail:</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to the Holder:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">YA II PN, Ltd</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="text-underline-style: double"><B>&nbsp;</B></FONT></TD>
    <TD>c/o Yorkville Advisors Global, LLC<BR> 1012 Springfield Avenue</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="text-underline-style: double"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mountainside, NJ 07092</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="text-underline-style: double"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention: Mark Angelo</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:&#8239;&#8239;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or at such other address and/or e-mail address
and/or to the attention of such other person as the recipient party has specified by written notice given to each other party in accordance
with this Section&nbsp;at least three (3)&nbsp;Business Days prior to the effectiveness of such change. Written confirmation of receipt
(a)&nbsp;given by the recipient of such notice, consent, waiver or other communication, (b)&nbsp;electronically generated by the sender&rsquo;s
email service provider containing the time, date, recipient email address or (c)&nbsp;provided by a nationally recognized overnight delivery
service, shall be rebuttable evidence of personal service, receipt from a nationally recognized overnight delivery service or receipt
by e-mail in accordance with clause (i), (ii)&nbsp;or (iii)&nbsp;above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(6)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Except
as expressly provided herein, no provision of this Note shall alter or impair the obligations of the Company, which are absolute and unconditional,
to pay the Principal of, and interest and other charges (if any) on, this Note at the time, place, and rate, and in the currency, herein
prescribed. This Note is a direct obligation of the Company. As long as this Note is outstanding, the Company shall not and shall cause
each of its Subsidiaries not to, without the consent of the Holder, enter into any agreement, arrangement or transaction in or of which
the terms thereof would restrict, materially delay, conflict with or impair the ability of the Company to perform its obligations under
the this Note, including, without limitation, the obligation of the Company to make cash payments hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(7)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Note shall not entitle the Holder to any of the rights of a stockholder of the Company, including without limitation, the right to vote,
to receive dividends and other distributions, or to receive any notice of, or to attend, meetings of stockholders or any other proceedings
of the Company, unless and to the extent converted into Common Shares in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(8)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>CHOICE
OF LAW; VENUE; WAIVER OF JURY TRIAL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>. This Note and the rights and obligations of the Parties hereunder shall, in all respects, be governed by, and construed in accordance
with, the laws (excluding the principles of conflict of laws) of the State of New York (the &ldquo;<U>Governing Jurisdiction</U>&rdquo;)
(including Section&nbsp;5-1401 and Section&nbsp;5-1402 of the General Obligations Law of the State of New York), including all matters
of construction, validity and performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Jurisdiction;
Venue; Service.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company hereby irrevocably consents to the non-exclusive personal jurisdiction of the state courts of the Governing Jurisdiction and,
if a basis for federal jurisdiction exists, the non-exclusive personal jurisdiction of any United States District Court for the Governing
Jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees that venue shall be proper in any court of the Governing Jurisdiction selected by the Holder or, if a basis for federal
jurisdiction exists, in any United States District Court in the Governing Jurisdiction selected by the Holder. The Company waives any
right to object to the maintenance of any suit, claim, action, litigation or proceeding of any kind or description, whether in law or
equity, whether in contract or in tort or otherwise, in any of the state or federal courts of the Governing Jurisdiction on the basis
of improper venue or inconvenience of forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
suit, claim, action, litigation or proceeding of any kind or description, whether in law or equity, whether in contract or tort or otherwise,
brought by the Company against the Holder arising out of or based upon this Note or any matter relating to this Note, or any other Transaction
Document, or any contemplated transaction, shall be brought in a court only in the Governing Jurisdiction. The Company shall not file
any counterclaim against the Holder in any suit, claim, action, litigation or proceeding brought by the Holder against the Company in
a jurisdiction outside of the Governing Jurisdiction unless under the rules&nbsp;of the court in which the Holder brought such suit, claim,
action, litigation or proceeding the counterclaim is mandatory, and not permissive, and would be considered waived unless filed as a counterclaim
in the suit, claim, action, litigation or proceeding instituted by the Holder against the Company. The Company agrees that any forum outside
the Governing Jurisdiction is an inconvenient forum and that any suit, claim, action, litigation or proceeding brought by the Company
against the Holder in any court outside the Governing Jurisdiction should be dismissed or transferred to a court located in the Governing
Jurisdiction. Furthermore, the Company irrevocably and unconditionally agrees that it will not bring or commence any suit, claim, action,
litigation or proceeding of any kind or description, whether in law or equity, whether in contract or in tort or otherwise, against the
Holder arising out of or based upon this Note or any matter relating to this Note, or any other Transaction Document, or any contemplated
transaction, in any forum other than the courts of the State of New York sitting in New York County, and the United States District Court
of the Southern District of New York, and any appellate court from any thereof, and each of the parties hereto irrevocably and unconditionally
submits to the jurisdiction of such courts and agrees that all claims in respect of any such suit, claim, action, litigation or proceeding
may be heard and determined in such New York State Court or, to the fullest extent permitted by applicable law, in such federal court.
The Company and the Holder agree that a final judgment in any such suit, claim, action, litigation or proceeding shall be conclusive and
may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(iv)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company and the Holder irrevocably consent to the service of process out of any of the aforementioned courts in any such suit, claim,
action, litigation or proceeding by e-mail or the mailing of copies thereof by registered or certified mail postage prepaid, to it at
the e-mail address or physical address, as applicable, provided for notices in this Note, such service to become effective thirty (30)
days after the date of such e-mail or mailing, as applicable. The Company and the Holder each irrevocably waive any defense it may have
on the grounds of insufficient or improper service with respect to service of process effected in accordance with this Section&nbsp;(8)(b)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(v)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Nothing
herein shall affect the right of the Holder to serve process in any other manner permitted by law or to commence legal proceedings or
to otherwise proceed against the Company or any other Person in the Governing Jurisdiction or in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>THE
PARTIES MUTUALLY WAIVE ALL RIGHT TO TRIAL BY JURY OF ALL CLAIMS OF ANY KIND ARISING OUT OF OR BASED UPON THIS NOTE OR ANY MATTER RELATING
TO THIS NOTE, OR ANY OTHER TRANSACTION DOCUMENT, OR ANY CONTEMPLATED TRANSACTION. THE PARTIES ACKNOWLEDGE THAT THIS IS A WAIVER OF A LEGAL
RIGHT AND THAT THE PARTIES EACH MAKE THIS WAIVER VOLUNTARILY AND KNOWINGLY AFTER CONSULTATION WITH COUNSEL OF THEIR RESPECTIVE CHOICE.
THE PARTIES AGREE THAT ALL SUCH CLAIMS SHALL BE TRIED BEFORE A JUDGE OF A COURT HAVING JURISDICTION, WITHOUT A JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company expressly acknowledges and agrees that this Note constitutes an&nbsp;instrument for the payment of money only&nbsp;within the
meaning of section 3213 of the New York Civil Practice Law and Rules&nbsp;(&ldquo;<U>CPLR &sect;3213</U>&rdquo;), and that upon any default
under or breach of the terms of this Note, the Holder may immediately commence an action by motion for summary judgment in lieu of complaint
without any further notice or demand. The Company irrevocably waives (i)&nbsp;any right to require the Holder to commence any action by
summons and complaint, (ii)&nbsp;any right to assert defenses, setoffs, counterclaims or delays in any CPLR &sect;3213 proceeding (other
than the defense of full payment of any amount that the Holder seeks to recover), and (iii)&nbsp;any right to object to the sufficiency
of this Note as an instrument for the payment of money only within the meaning of CPLR &sect;3213 and agrees not to assert that this Note
is not such an instrument. The Company agrees that all amounts due under this Note shall be deemed liquidated, unconditional and immediately
due and payable for purposes of CPLR &sect;3213.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(9)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
the Company fails to strictly comply with the terms of this Note, then the Company shall reimburse the Holder promptly for all fees, costs
and expenses, including, without limitation, attorneys&rsquo; fees and expenses incurred by the Holder in any action in connection with
this Note, including, without limitation, those incurred: (i)&nbsp;during any workout, attempted workout, and/or in connection with the
rendering of legal advice as to the Holder&rsquo;s rights, remedies and obligations, (ii)&nbsp;collecting any sums which become due to
the Holder, (iii)&nbsp;defending or prosecuting any proceeding or any counterclaim to any proceeding or appeal; or (iv)&nbsp;the protection,
preservation or enforcement of any rights or remedies of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(10)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
waiver by the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach
of such provision or of any breach of any other provision of this Note. The failure of the Holder to insist upon strict adherence to any
term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon
strict adherence to that term or any other term of this Note. No provision of this Note may be waived or amended other than by a written
agreement signed by the parties to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(11)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision
is inapplicable to any person or circumstance, it shall nevertheless remain applicable to all other persons and circumstances. If it shall
be found that any interest or other amount deemed interest due hereunder shall violate applicable laws governing usury, the applicable
rate of interest due hereunder shall automatically be lowered to equal the maximum permitted rate of interest. The Company covenants (to
the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim or take the
benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying all or
any portion of the Principal of or interest on this Note as contemplated herein, wherever enacted, now or at any time hereafter in force,
or which may affect the covenants or the performance of this Note, and the Company (to the extent it may lawfully do so) hereby expressly
waives all benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the
execution of any power herein granted to the Holder, but will suffer and permit the execution of every such power as though no such law
has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(12)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>CERTAIN
DEFINITIONS.</U> For purposes of this Note, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amortization
Event</U>&rdquo; shall mean (i)&nbsp;the daily VWAP is less than the Floor Price for five Trading Days during a period of seven consecutive
Trading Days (a &ldquo;<U>Floor Price Event</U>&rdquo;), or (ii)&nbsp;any time after the Effectiveness Deadline (as defined in the Registration
Rights Agreement), the Investor is unable to utilize a Registration Statement to resell Underlying Shares for a period of ten (10)&nbsp;consecutive
Trading Days (a &ldquo;<U>Registration Event</U>&rdquo;) (the day of each such occurrence, an &ldquo;<U>Amortization Event Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Amortization
Principal Amount</U>&rdquo; shall mean the Principal amount equal to 18% of the outstanding Principal of this Note as of the applicable
Amortization Event Date (or the outstanding Principal if less than such amount).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Applicable
Price</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Approved
Stock Plan</U>&rdquo; means any employee benefit plan or any share incentive plan (including, without limitation, Nasdaq equity inducement
grants or inducement plans) which has been approved by the Board of Directors of the Company, pursuant to which the Company&rsquo;s securities
may be issued to any employee, officer or, director, consultant or other eligible participant under any such plans, in each case for services
provided to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Bloomberg</U>&rdquo;
means Bloomberg Financial Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; means any day except Saturday, Sunday and any day which shall be a federal legal holiday in the United States or a day
on which banking institutions are authorized or required by law or other government action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section&nbsp;(3)(b)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Buy-In
Price</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(b)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Calendar
Month</U>&rdquo; means one of the twelve months of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Change
of Control Transaction</U>&rdquo; means the occurrence of (a)&nbsp;an acquisition after the date hereof by an individual or legal entity
or &ldquo;group&rdquo; (as described in Rule&nbsp;13d-5(b)(1)&nbsp;promulgated under the Exchange Act) of effective control (whether through
legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of fifty percent (50%) of the voting
power of the Company (except that the acquisition of voting securities by the Holder or any other current holder of convertible securities
of the Company shall not constitute a Change of Control Transaction for purposes hereof), (b)&nbsp;a replacement at one time or over time
of more than one-half of the members of the board of directors of the Company (other than as due to the death or disability of a member
of the board of directors) which is not approved by a majority of those individuals who are members of the board of directors on the date
hereof (or by those individuals who are serving as members of the board of directors on any date whose nomination to the board of directors
was approved by a majority of the members of the board of directors who are members on the date hereof), (c)&nbsp;the merger, consolidation
or sale of fifty percent (50%) or more of the assets of the Company or any Subsidiary of the Company in one or a series of related transactions
with or into another entity, or (d)&nbsp;the execution by the Company of an agreement to which the Company is a party or by which it is
bound, providing for any of the events set forth above in (a), (b)&nbsp;or (c). Neither (i)&nbsp;transfer to a wholly-owned Subsidiary,
nor (ii)&nbsp;the conversion of the Company&rsquo;s preferred stock outstanding as of the date hereof (including the conversion of the
preferred stock outstanding on the date hereof issued pursuant to that certain&nbsp; Amended and Restated Certificate of Designation of
Series&nbsp;A Non-Voting Convertible Preferred Stock and Series&nbsp;B Non-Voting Convertible Preferred Stock of TransCode Therapeutics,&nbsp;Inc.,
dated October&nbsp;27, 2025, shall be deemed a Change of Control Transaction under this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Closing
Price</U>&rdquo; means the price per share in the last reported trade of the Common Shares on a Principal Market or on the exchange which
the Common Shares are then listed as quoted by Bloomberg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Commission</U>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Common
Shares</U>&rdquo; means the shares of common stock, par value $0.0001, of the Company and stock of any other class into which such shares
may hereafter be changed or reclassified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Conversion
Amount</U>&rdquo; means the portion of the Principal,&nbsp;Interest, or other amounts outstanding under this Note to be converted, redeemed
or otherwise with respect to which this determination is being made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(l)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(m)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Conversion
Failure</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(b)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(n)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Conversion
Notice</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(o)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Conversion
Price</U>&rdquo; means, as of any Conversion Date or other date of determination the lower of (i)&nbsp;[$___]<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT>
per Common Share (the &ldquo;<U>Fixed Price</U>&rdquo;), or (ii)&nbsp;95% of the lowest daily VWAP during the 7 consecutive Trading Days
immediately preceding the Conversion Date or other date of determination (the &ldquo;<U>Variable Price</U>&rdquo;), but which Variable
Price shall not be lower than the Floor Price. The Conversion Price shall be adjusted from time to time pursuant to the other terms and
conditions of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(p)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Convertible
Securities</U>&rdquo; means any stock or securities directly or indirectly convertible into or exercisable or exchangeable for Common
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(q)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Dilutive
Issuance</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(r)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Equity
Conditions</U>&rdquo; means that each of the following conditions is satisfied: (i)&nbsp;on each Trading Day during the three consecutive
Trading Days prior to the date of determination (the &ldquo;<U>Equity Conditions Measuring Period</U>&rdquo;), either (x)&nbsp;the Registration
Statement filed pursuant to the Registration Rights Agreement shall be effective and available for the resale of all applicable Common
Shares to be issued in connection with the event requiring determination or (y)&nbsp;all applicable Common Shares to be issued in connection
with the event requiring determination shall be eligible for sale without restriction and without the need for registration under any
applicable federal or state securities laws; (ii)&nbsp;on each day during the Equity Conditions Measuring Period, the Common Shares are
designated for quotation on the Principal Market and shall not have been suspended from trading on such exchange or market nor shall delisting
or suspension by such exchange or market have been threatened or pending either (A)&nbsp;in writing by such exchange or market or (B)&nbsp;by
falling below the then effective minimum listing maintenance requirements of such exchange or market; (iii)&nbsp;any applicable Common
Shares to be issued in connection with the event requiring determination may be issued in full without violating Section&nbsp;(4)(c)&nbsp;hereof;
and (iv)&nbsp;during the Equity Conditions Measuring Period, there shall not have occurred either (A)&nbsp;an Event of Default, (B)&nbsp;an
Amortization Event, or (C)&nbsp;an event that with the passage of time or giving of notice would constitute an Event of Default or an
Amortization Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(s)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Excluded
Securities</U>&rdquo; means any Common Shares issued or issuable or deemed to be issued by the Company: (i)&nbsp;under any Approved Stock
Plan, (ii)&nbsp;pursuant to advances pursuant to the SEPA or upon conversion of any securities issued pursuant to the SEPA (including
Common Shares issued in connection with this Note and any of the Other Notes); (iii)&nbsp;upon conversion, exercise or exchange of any
Options or Convertible Securities which are outstanding on the day immediately preceding the date of the SEPA; provided, that such issuance
of Common Shares upon exercise of such Options or Convertible Securities is made pursuant to the terms of such Options or Convertible
Securities in effect on such date and such Options or Convertible Securities are not amended, modified or changed on or after such date,
(iv)&nbsp;pursuant to that certain&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Amended and Restated Certificate
of Designation of Series&nbsp;A Non-Voting Convertible Preferred Stock and Series&nbsp;B Non-Voting Convertible Preferred Stock of TransCode
Therapeutics,&nbsp;Inc., dated October&nbsp;27, 2025, (v)&nbsp;pursuant to acquisitions, divestitures, licenses, partnerships, collaborations
or other strategic transactions approved by the board of directors or a duly authorized committee thereof, provided that any such issuance
shall only be to a Person (or to the equity holders of a Person) that is, itself or through its subsidiaries, an operating company or
owns or has rights to an asset that is synergistic with the business of the Company and such transaction provides to the Company additional
benefits in addition to the investment of funds, and is not primarily for the purpose of raising capital, or (vi)&nbsp;upon a stock split,
reverse stock split, distribution of bonus shares, share combination or other recapitalization events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> <B>Note to Draft:</B> To be the price equal to 115% of
the VWAP on the day prior to the Issuance Date of each Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(u)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Floor
Price</U>&rdquo; solely with respect to the Variable Price, the Fixed Price, and an Amortization Event shall mean [$____]<FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT>
per Common Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Fundamental
Transaction</U><B>&rdquo; </B>means any of the following: (1)&nbsp;the Company effects any merger or consolidation of the Company with
or into another Person and the Company is the non-surviving company (other than a merger or consolidation with a wholly owned Subsidiary
of the Company for the purpose of redomiciling the Company), (2)&nbsp;the Company effects any sale of all or substantially all of its
assets in one or a series of related transactions, (3)&nbsp;any tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Shares are permitted to tender or exchange their shares for other securities, cash or
property, or (4)&nbsp;the Company effects any reclassification of the Common Shares or any compulsory share exchange pursuant to which
the Common Shares is effectively converted into or exchanged for other securities, cash or property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(w)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>New
Issuance Price</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(x)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Options</U>&rdquo;
means any rights, warrants or options to subscribe for or purchase Common Shares or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(y)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Other
Notes</U>&rdquo; means any other notes issued pursuant to the SEPA and any other debentures, notes, or other instruments issued in exchange,
replacement, or modification of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(z)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Payment
Premium</U>&rdquo; means 10% of the Principal amount being paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Periodic
Reports</U>&rdquo; shall mean all of the Company&rsquo;s reports required to be filed by the Company with the Commission under applicable
laws and regulations (including, without limitation, Regulation S-K), including annual reports (on Form&nbsp;10-K), quarterly reports
(on Form&nbsp;10-Q), and current reports (on Form&nbsp;8-K), for so long as any amounts are outstanding under this Note or any Other Note;
<I>provided</I> that all such Periodic Reports shall include, when filed, all information, financial statements, audit reports (when applicable)
and other information required to be included in such Periodic Reports in compliance with all applicable laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> <B>Note to Draft:</B> To be the price equal to 20% of
the Closing Price as of the Trading Day immediately prior to the date of the SEPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Person</U>&rdquo;
means a corporation, an association, a partnership, organization, a business, an individual, a government or political subdivision thereof
or a governmental agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Principal
Market</U>&rdquo; means any of The New York Stock Exchange, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market or
the Nasdaq Global Select Market, and any successor to any of the foregoing markets or exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the registration rights agreement entered into between the Company and the Holder on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement, covering
among other things the resale of the Underlying Shares and naming the Holder as a &ldquo;selling stockholder&rdquo; thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Share
Delivery Date</U>&rdquo; shall have the meaning set forth in Section&nbsp;(3)(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Subsidiary</U>&rdquo;
shall mean any Person in which the Company, directly or indirectly, (x)&nbsp;owns a majority of the outstanding capital stock or holds
a majority of the equity or similar interest of such Person or (y)&nbsp;controls or operates all or substantially all of the business,
operations or administration of such Person, and the foregoing are collectively referred to herein as &ldquo;<U>Subsidiaries</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Shares are quoted or traded on a Principal Market on which the Common Shares are then quoted
or listed; provided, that in the event that the Common Shares are not listed or quoted, then Trading Day shall mean a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Transaction
Document</U>&rdquo; means this Note, the Other Notes, the SEPA, the Registration Rights Agreement and any and all other documents, agreements,
instruments or other items executed or delivered in connection with this Note or any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>Underlying
Shares</U>&rdquo; means the Common Shares issuable upon conversion of this Note or as payment of interest in accordance with the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<U>VWAP</U>&rdquo;
means, for any Trading Day, the daily volume weighted average price of the Common Shares for such Trading Day on the Principal Market
during regular trading hours as reported by Bloomberg L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Signature Page&nbsp;Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Company has caused this Convertible Promissory Note to be duly executed by a duly authorized officer as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;I<BR>
<U>CONVERSION NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(To be executed by the Holder in order to Convert
the Note)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>TO: </B></FONT><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Via Email:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby irrevocably
elects to convert a portion of the outstanding and unpaid Conversion Amount of Note No.&nbsp;<U>RNAZ-[1][2]</U> into Common Shares of
<B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B>, according to the conditions stated therein, as of the Conversion Date written below.&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt; width: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion Date:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal Amount to be Converted:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued Interest to be Converted:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Conversion Amount to be converted:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fixed Price: </B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Variable Price:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicable Conversion Price:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Common Shares to be issued:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please issue the Common Shares in the following name and deliver them to the following account:</B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue to:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Broker DTC Participant Code:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account Number:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding-bottom: 3pt; vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized Signature:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-bottom: 3pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="padding-bottom: 3pt; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>tm2611272d1_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>REGISTRATION RIGHTS AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>THIS
REGISTRATION RIGHTS AGREEMENT</B></FONT> (this &ldquo;<U>Agreement</U>&rdquo;) dated as of April&nbsp;6, 2026 is made by and between YA
II PN,&nbsp;LTD., a Cayman Islands exempt limited company (the &ldquo;<U>Investor</U>&rdquo;), and TRANSCODE THERAPEUTICS,&nbsp;INC.,
a company incorporated under the laws of the State of Delaware (the &ldquo;<U>Company</U>&rdquo;). The Investor and the Company may be
referred to herein individually as a &ldquo;Party&rdquo; and collectively as the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>WHEREAS</B></FONT>,
the Company and the Investor have entered into that certain Standby Equity Purchase Agreement, dated as of the date hereof (the &ldquo;<U>Purchase
Agreement</U>&rdquo;), pursuant to which the Company may issue, from time to time, to the Investor up to $14 million of newly issued shares
of the Company&rsquo;s shares of Common Stock, par value $0.0001 per share (the &ldquo;<U>Common Shares</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>WHEREAS,
</B></FONT>pursuant to the terms of, and in consideration for the Investor entering into, the Purchase Agreement, and to induce the Investor
to execute and deliver the Purchase Agreement, the Company has agreed to provide the Investor with certain registration rights under the
Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder, or any similar successor statute&nbsp;(collectively,
the &ldquo;<U>Securities Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>NOW,
THEREFORE,</B></FONT> in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>DEFINITIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms used herein and not otherwise
defined herein shall have the respective meanings set forth in the Purchase Agreement. As used in this Agreement, the following terms
shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Applicable
Date</U>&rdquo; means the earlier to occur of (I)&nbsp;the first date on which the initial Registration Statement is declared effective
by the SEC (and each Prospectus contained therein is available for use on such date) or (II)&nbsp;the first date on which all of the Registrable
Securities are eligible to be resold by the Investor pursuant to Rule&nbsp;144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Business
Day</U>&rdquo; shall mean any day on which the New York Stock Exchange is open for trading, other than any day on which commercial banks
are authorized or required to be closed in New York City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Effectiveness
Deadline</U>&rdquo; means, with respect to the initial Registration Statement filed hereunder, the 90th calendar day following the date
hereof, provided, however, in the event the Company is notified by the SEC that the Registration Statement will not be reviewed or is
no longer subject to further review and comments, the Effectiveness Deadline as to such Registration Statement shall be the fifth Business
Day following the date on which the Company is so notified if such date precedes the date required above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Filing
Deadline</U>&rdquo; means, with respect to the initial Registration Statement required hereunder, by April&nbsp;30, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Person</U>&rdquo;
means a corporation, a limited liability company, an association, a partnership, an organization, a business, an individual, a governmental
or political subdivision thereof or a governmental agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule&nbsp;430A promulgated under the Securities
Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable
Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments,
and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Registrable
Securities</U>&rdquo; means all of (i)&nbsp;the Common Shares and Commitment Shares (each as defined in the Purchase Agreement) and (ii)&nbsp;any
capital stock issued or issuable with respect to such Common Shares and Commitment Shares, including, without limitation, (1)&nbsp;as
a result of any stock split, stock dividend or other distribution, recapitalization or similar event or otherwise, and (2)&nbsp;shares
of capital stock of the Company into which the Common Shares are converted or exchanged and shares of capital stock of a successor entity
into which the Common Shares are converted or exchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement of the Company filed pursuant to this Agreement, including the Prospectus, amendments
and supplements to such registration statement or Prospectus, including post-effective amendments, all exhibits thereto, and all material
incorporated by reference or deemed to be incorporated by reference in such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Required
Registration Amount</U>&rdquo; means (i)&nbsp;with respect to the initial Registration Statement, at least [1,500,000] shares of Common
Shares issued or to be issued pursuant to the Purchase Agreement and the Commitment Shares, if applicable, and (ii)&nbsp;with respect
to subsequent Registration Statements, such number of shares of Common Stock as requested by the Investor not to exceed the maximum number
of Common Shares issuable upon conversion of all Promissory Notes then outstanding (assuming for purposes hereof that (x)&nbsp;such Promissory
Notes are convertible at the Floor Price (as defined in each respective Promissory Note) in effect as of the date of determination, and
(y)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Promissory Notes set forth therein),
in each case subject to any cutback set forth in Section&nbsp;2(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 under the Securities Act or any successor rule&nbsp;thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Rule&nbsp;415</U>&rdquo;
means Rule&nbsp;415 promulgated by the SEC pursuant to the Securities Act, as such Rule&nbsp;may be amended from time to time, or any
similar rule&nbsp;or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>SEC</U>&rdquo;
means the Securities and Exchange Commission or any other federal agency administering the Securities Act and the Exchange Act at the
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;<U>Securities
Act</U>&rdquo; shall have the meaning set forth in the Recitals above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>REGISTRATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company&rsquo;s registration obligations set forth in this Section&nbsp;2 including its obligations to file Registration Statements, obtain
effectiveness of Registration Statements, and maintain the continuous effectiveness of any Registration Statement that has been declared
effective shall begin on the date hereof and continue until the earlier of (i)&nbsp;the date on which the Investor has sold all of the
Registrable Securities and (ii)&nbsp;the date of termination of the Purchase Agreement if as of such termination date the Investor holds
no Registrable Securities (the &ldquo;<U>Registration Period</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the terms and conditions of this Agreement, the Company shall (i)&nbsp;as soon as practicable, but in no case later than the Filing
Deadline, prepare and file with the SEC an initial Registration Statement on Form&nbsp;S-3 (or, if the Company is not then eligible, on
Form&nbsp;S-1) or any successor form thereto covering the resale by the Investor of the Required Registration Amount in accordance with
applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the Investor under
Rule&nbsp;415 at then prevailing market prices (and not fixed prices). The Registration Statement shall contain &ldquo;<U>Selling Stockholders</U>&rdquo;
and &ldquo;<U>Plan of Distribution</U>&rdquo; sections. The Company shall use its commercially reasonable efforts to have the Registration
Statement declared effective by the SEC as soon as practicable, but in no event later than the Effectiveness Deadline. By 9:30 am on the
business day following the date of effectiveness, the Company shall file with the SEC in accordance with Rule&nbsp;424 under the Securities
Act the final Prospectus to be used in connection with sales pursuant to such Registration Statement. Prior to the filing of the Registration
Statement with the SEC, the Company shall furnish a draft of the Registration Statement to the Investor for their review and comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sufficient
Number of Shares Registered</U>. If at any time all Registrable Securities are not covered by a Registration Statement filed pursuant
to Section&nbsp;2(a)&nbsp;as a result of Section&nbsp;2(e)&nbsp;or otherwise, the Company shall use its commercially reasonable efforts
to file with the SEC one (1)&nbsp;or more additional Registration Statements so as to cover all of the Registrable Securities not covered
by such initial Registration Statement, in each case as soon as practicable (taking into account any position of the staff of the SEC
with respect to the date on which the Staff will permit such additional Registration Statement(s)&nbsp;to be filed with the SEC and the
rules&nbsp;and regulations of the SEC). The Company shall use its commercially reasonable efforts to cause each such new Registration
Statement to become effective as soon as reasonably practicable following the filling thereof with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>During
the Registration Period, the Company shall (i)&nbsp;promptly prepare and file with the SEC such amendments&nbsp;(including post-effective
amendments) and supplements to a Registration Statement and the Prospectus used in connection with a Registration Statement, which Prospectus
is to be filed pursuant to Rule&nbsp;424 promulgated under the Securities Act, as may be necessary to keep such Registration Statement
effective at all times during the Registration Period, (ii)&nbsp;prepare and file with the SEC additional Registration Statements in order
to register for resale under the Securities Act all of the Registrable Securities; (iii)&nbsp;cause the related Prospectus to be amended
or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and as so supplemented or amended to be
filed pursuant to Rule&nbsp;424; (iv)&nbsp;respond as promptly as reasonably possible to any comments received from the SEC with respect
to a Registration Statement or any amendment thereto and as promptly as reasonably possible provide the Investor true and complete copies
of all correspondence from and to the SEC relating to a Registration Statement (provided that the Company may excise any information contained
therein which would constitute material non-public information as to any Investor which has not executed a confidentiality agreement with
the Company); and (v)&nbsp;comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities
of the Company covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of
in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. In
the case of amendments and supplements to a Registration Statement which are required to be filed pursuant to this Agreement (including
pursuant to this Section&nbsp;2(c)) by reason of the Company&rsquo;s filing a report on Form&nbsp;10-K, Form&nbsp;10-Q, or Form&nbsp;8-K
or any analogous report under the Exchange Act, the Company shall incorporate such report by reference into the Registration Statement,
if applicable, or shall file such amendments or supplements with the SEC on the same day on which the Exchange Act report is filed which
created the requirement for the Company to amend or supplement the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reduction
of Registrable Securities Included in a Registration Statement</U>. Notwithstanding anything contained herein, in the event that the SEC
requires the Company to reduce the number of Registrable Securities to be included in a Registration Statement in order to allow the Company
to rely on Rule&nbsp;415 with respect to a Registration Statement, then the Company shall reduce the number of Registrable Securities
to be included in such Registration Statement (after consultation with the Investor as to the specific Registrable Securities to be removed
therefrom) to the maximum number of securities as is permitted to be registered by the SEC. In the event of any reduction in Registrable
Securities pursuant to this paragraph, the Company shall use its commercially reasonable efforts to file one (1)&nbsp;or more new Registration
Statements with the Commission in accordance with Section&nbsp;2(c)&nbsp;until such time as all Registrable Securities have been included
in Registration Statements that have been declared effective and the Prospectuses contained therein are available for use by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Failure
to File or Obtain Effectiveness of the Registration Statement or Remain Current</U>. If: (i)&nbsp;a Registration Statement is not filed
on or prior to its Filing Date, or (ii)&nbsp;a Registration Statement is not declared effective on or prior to the Effectiveness Deadline,
or the Company fails to file with the SEC a request for acceleration in accordance with Rule&nbsp;461 promulgated under the Securities
Act, within five (5)&nbsp;Business Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the SEC
that a Registration Statement will not be &ldquo;reviewed,&rdquo; or not subject to further review, or (iii)&nbsp;after the effectiveness,
a Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities for which it is required
to be effective for a period of ten (10)&nbsp;consecutive Trading Days, or (iv)&nbsp;the Investor is not permitted to utilize the Prospectus
therein to resell such Registrable Securities for more than 10 consecutive Trading Days, or (v)&nbsp;if after the date that is six (6)&nbsp;months
from the date hereof, the Company does not have available adequate current public information as set forth in Rule&nbsp;144(c)&nbsp;(any
such failure or breach being referred to as an &ldquo;<U>Event</U>&rdquo;), then in addition to any other rights the Investor may have
hereunder or under applicable law, such Event shall be deemed an Event of Default (as defined in each respective Promissory Notes) for
so long as such Event remains uncured. During the period of the existence of an uncured Event, the Investor shall have no obligation to
accept an Advance Notice or accept or purchase any Advance Shares (other than any Advance Shares purchased by the Investor prior to the
occurrence of the Event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Piggy-Back
Registrations</U>. If at any time there is not an effective Registration Statement covering all of the Registrable Securities and the
Company proposes to register the offer and sale of any Common Shares under the Securities Act (other than a registration (i)&nbsp;pursuant
to a Registration Statement on Form&nbsp;S-8 (or other registration solely relating to an offering or sale to employees or directors of
the Company pursuant to any employee stock plan or other employee benefit arrangement), (ii)&nbsp;pursuant to a Registration Statement
on Form&nbsp;S-4 (or similar form that relates to a transaction subject to Rule&nbsp;145 under the Securities Act or any successor rule&nbsp;thereto),
or (iii)&nbsp;in connection with any dividend or distribution reinvestment or similar plan), whether for its own account or for the account
of one (1)&nbsp;or more stockholders of the Company and the form of Registration Statement to be used may be used for any registration
of Registrable Securities, the Company shall give prompt written notice (in any event no later than five (5)&nbsp;days prior to the filing
of such Registration Statement) to the holders of Registrable Securities of its intention to effect such a registration and, shall include
in such registration all Registrable Securities with respect to which the Company has received written requests for inclusion from the
holders of Registrable Securities; <U>provided</U>, <U>however</U>, that, the Company shall not be required to register any Registrable
Securities pursuant to this Section&nbsp;2(g)&nbsp;that have been sold or may permanently be sold without any restrictions pursuant to
Rule&nbsp;144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable
to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Inclusion of Other Securities; Other Registration Statements</U>. In no event shall the Company (i)&nbsp;include any securities other
than Registrable Securities on any Registration Statement pursuant to Section&nbsp;2(b)&nbsp;or Section&nbsp;2(c)&nbsp;without the Investor&rsquo;s
prior written consent or (ii)&nbsp;prior to the Applicable Date, or at any time thereafter while any Registration Statement is not effective
or the Prospectus contained therein is not available for use, the Company shall not file a registration statement or an offering statement
under the Securities Act relating to securities that are not the Registrable Securities (other than a registration statement on Form&nbsp;S-8
or such supplements or amendments to registration statements that are outstanding and have been declared effective by the SEC as of the
date hereof) (solely to the extent necessary to keep such registration statements effective and available and not for any other reason).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>RELATED
OBLIGATIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall, not less than three (3)&nbsp;Business Days prior to the filing of each Registration Statement and not less than one (1)&nbsp;business
day prior to the filing of any related amendments and supplements to all Registration Statements (except for annual reports on Form&nbsp;10-K,
supplements and amendments to update the Registration Statement solely for information reflected in the Company&rsquo;s annual reports
on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q or current reports on Form&nbsp;8-K), furnish to each Investor copies of all such
documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject
to the reasonable and prompt review of such Investor. The Company shall not file a Registration Statement or any such Prospectus or any
amendments or supplements thereto to which the Investor shall reasonably object in good faith; <I>provided</I> that, the Company is notified
of such objection in writing no later than two (2)&nbsp;Business Days after the Investor have been so furnished copies of a Registration
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall furnish to each Investor whose Registrable Securities are included in any Registration Statement, without charge (i)&nbsp;at
least one (1)&nbsp;copy (which may be in electronic form) of such Registration Statement as declared effective by the SEC and any amendment(s)&nbsp;thereto,
including financial statements and schedules, all documents incorporated therein by reference, all exhibits and each preliminary prospectus,
(ii)&nbsp;at least one (1)&nbsp;copy (which may be in electronic form) of the final prospectus included in such Registration Statement
and all amendments and supplements thereto, and (iii)&nbsp;any documents, which are not publicly available through EDGAR, as such Investor
may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by such Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall use its commercially reasonable efforts to (i)&nbsp;register and qualify the Registrable Securities covered by a Registration
Statement under such other securities or &ldquo;blue sky&rdquo; laws of such jurisdictions in the United States as any Investor reasonably
requests, (ii)&nbsp;prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to
such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii)&nbsp;take
such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration
Period, and (iv)&nbsp;take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such
jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (w)&nbsp;make
any change to its certificate of incorporation or by-laws, (x)&nbsp;qualify to do business in any jurisdiction where it would not otherwise
be required to qualify but for this Section&nbsp;3(c), (y)&nbsp;subject itself to general taxation in any such jurisdiction, or (z)&nbsp;file
a general consent to service of process in any such jurisdiction. The Company shall promptly notify each Investor who holds Registrable
Securities of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any
of the Registrable Securities for sale under the securities or &ldquo;blue sky&rdquo; laws of any jurisdiction in the United States or
its receipt of actual notice of the initiation or threat of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
promptly as practicable after becoming aware of such event or development, the Company shall notify each Investor in writing of the happening
of any event as a result of which the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement
of a material fact or omission to state a material fact required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material,
nonpublic information), and promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement
or omission and deliver one (1)&nbsp;electronic copy of such supplement or amendment to the Investor. The Company shall also promptly
notify each Investor in writing (i)&nbsp;when a Prospectus or any Prospectus supplement or post-effective amendment has been filed, and
when a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered
to each Investor by email on the same day of such effectiveness), (ii)&nbsp;of any request by the SEC for amendments or supplements to
a Registration Statement or related prospectus or related information, and (iii)&nbsp;of the Company&rsquo;s reasonable determination
that a post-effective amendment to a Registration Statement would be appropriate. The Company shall respond as promptly as reasonably
practicable to any comments received from the SEC with respect to a Registration Statement or any amendment thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall use its commercially reasonable efforts to prevent the issuance of any stop order or other suspension of effectiveness of
a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction within
the United States of America and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the
earliest possible moment and to notify each Investor who holds Registrable Securities being sold of the issuance of such order and the
resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
limiting any obligation of the Company under the Purchase Agreement, the Company shall use its commercially reasonable efforts to cause
all of the Registrable Securities covered by each Registration Statement to be listed on the Principal Market. The Company shall pay all
fees and expenses in connection with satisfying its obligation under this Section&nbsp;3(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall hold in confidence and not make any disclosure of information concerning the Investor provided to the Company unless (i)&nbsp;disclosure
of such information is necessary to comply with federal or state securities laws, (ii)&nbsp;the disclosure of such information is necessary
to avoid or correct a material misstatement or omission in any Registration Statement, (iii)&nbsp;the release of such information is ordered
pursuant to a subpoena or other final, non-appealable order from a court or governmental body of competent jurisdiction, or (iv)&nbsp;such
information has been made generally available to the public other than by disclosure in violation of this Agreement or any other agreement.
The Company agrees that it shall, upon learning that disclosure of such information concerning the Investor is sought in or by a court
or governmental body of competent jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor,
at the Investor&rsquo;s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates
representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule&nbsp;144 free of any restrictive legends
and representing such number of Common Shares and registered in such names as the holders of the Registrable Securities may reasonably
request prior to sales of Registrable Securities pursuant to such Registration Statement or Rule&nbsp;144; <U>provided</U>, that the Company
may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company's Direct
Registration System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall use its commercially reasonable efforts to cause the Registrable Securities to be registered with or approved by such other
governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall otherwise use its commercially reasonable efforts to comply with all applicable rules&nbsp;and regulations of the SEC in
connection with any registration hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Within
two (2)&nbsp;Business Days after a Registration Statement which covers Registrable Securities is declared effective by the SEC, the Company
shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies
to the Investor whose Registrable Securities are included in such Registration Statement) confirmation that such Registration Statement
has been declared effective by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall take all other reasonable actions necessary to expedite and facilitate disposition by each Investor of Registrable Securities
pursuant to a Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>OBLIGATIONS
OF THE INVESTOR</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Investor agrees that upon receipt of any notice from the Company of the happening of any event of the kind described in Section&nbsp;3(d)&nbsp;the
Investor shall as soon as reasonably practicable discontinue disposition of Registrable Securities pursuant to any Registration Statement
covering such Registrable Securities until the Investor&rsquo;s receipt of the copies of the supplemented or amended prospectus contemplated
by Section&nbsp;3(d)&nbsp;or receipt of notice that no supplement or amendment is required. Notwithstanding anything to the contrary
contained herein, subject to compliance with the securities laws, the Company shall cause its transfer agent to deliver unlegended certificates
for Common Shares to a transferee of the Investor in accordance with the terms of the Purchase Agreement in connection with any sale
of Registrable Securities with respect to which the Investor has entered into a contract for sale prior to the Investor&rsquo;s receipt
of a notice from the Company of the happening of any event of the kind described in Section&nbsp;3(d)&nbsp;and for which the Investor
has not yet settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Investor covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it
or an exemption therefrom in connection with sales of Registrable Securities pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company
in connection with the preparation and filing of each Registration Statement hereunder, unless the Investor has notified the Company
in writing of the Investor&rsquo;s election to exclude all of the Investor&rsquo;s Registrable Securities from such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>EXPENSES
OF REGISTRATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All expenses incurred by the
Company in complying with its obligations pursuant to this Agreement and in connection with the registration and disposition of Registrable
Securities shall be paid by the Company, including, without limitation, all registration, listing and qualifications fees, printers, fees
and expenses of the Company's counsel and accountants (except legal fees of Investor&rsquo;s counsel associated with the review of the
Registration Statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to Registrable
Securities which are included in a Registration Statement under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend the Investor and its directors,
officers, partners, employees, agents, and representatives, and each Person, if any, who controls the Investor within the meaning of the
Securities Act or the Exchange Act (each, an &ldquo;<U>Investor Indemnified Person</U>&rdquo;), against any losses, claims, damages, liabilities,
judgments, fines, penalties, charges, costs, reasonable attorneys&rsquo; fees, amounts paid in settlement or expenses, joint or several
(collectively, &ldquo;<U>Indemnified Damages</U>&rdquo;), incurred in investigating, preparing or defending any action, claim, suit, inquiry,
proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory
agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&ldquo;<U>Claims</U>&rdquo;),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact in a Registration
Statement or any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under the
securities or other &ldquo;blue sky&rdquo; laws of any jurisdiction in which Registrable Securities are offered&nbsp;(&ldquo;<U>Blue Sky
Filing</U>&rdquo;), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the
statements therein not misleading; (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any final
prospectus (as amended or supplemented, if the Company files any amendment or supplement thereto with the SEC) or the omission or alleged
omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the
statements therein were made, not misleading; or (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act, the
Exchange Act, any other law, including, without limitation, any state securities law, or any rule&nbsp;or regulation thereunder relating
to the offer or sale of the Registrable Securities pursuant to a Registration Statement (the matters in the foregoing clauses (i)&nbsp;through
(iii)&nbsp;being, collectively, &ldquo;<U>Violations</U>&rdquo;). The Company shall reimburse the Investor and each such Investor Indemnified
Person promptly as Indemnified Damages are incurred and are due and payable, including reasonable legal fees, disbursements and other
expenses incurred by an Investor Indemnified Person in connection with investigating or defending any such Claim. Notwithstanding anything
to the contrary contained herein, the indemnification agreement contained in this Section&nbsp;6(a): (x)&nbsp;shall not apply to a Claim
arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the
Company by such Investor Indemnified Person expressly for use in connection with the preparation of the Registration Statement or any
such amendment thereof or supplement thereto; (y)&nbsp;shall not be available to the extent such Claim is based on a failure of the Investor
to deliver or to cause to be delivered the prospectus made available by the Company, if such prospectus was timely made available by the
Company pursuant to Section&nbsp;3(c); and (z)&nbsp;shall not apply to amounts paid in settlement of any Claim if such settlement is effected
without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of an Investor Indemnified Person. The foregoing
notwithstanding, this Section&nbsp;6(a)&nbsp;shall not inure to the benefit of any Investor Indemnified Person if the untrue statement
or omission of material fact contained in the prospectus was corrected and such new prospectus was delivered to the Investor prior to
the Investor&rsquo;s use of the prospectus to which the Claim relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
connection with a Registration Statement, the Investor agrees to indemnify, hold harmless and defend, to the same extent and in the same
manner as is set forth in Section&nbsp;6(a), the Company, each of its directors, each of its officers, employees, representatives, or
agents and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each a &ldquo;<U>Company
Indemnified Person</U>&rdquo;), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities
Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or is based upon any Violation, in each
case to the extent, and only to the extent, that such Violation occurs (i)&nbsp;in reliance upon and in conformity with written information
furnished to the Company by such Investor expressly for use in connection with such Registration Statement or (ii)&nbsp;from the Investor&rsquo;s
violation of any prospectus delivery requirements under the Securities Act, the Exchange Act, any other law, including, without limitation,
any state securities law, or any rule&nbsp;or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant
to a Registration Statement; and, subject to Section&nbsp;6(d), such Investor will reimburse any legal or other expenses reasonably incurred
by them in connection with investigating or defending any such Claim; provided, that the indemnity agreement contained in this Section&nbsp;6(b)&nbsp;and
the agreement with respect to contribution contained in Section&nbsp;7 shall not apply to amounts paid in settlement of any Claim if such
settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld, conditioned
or delayed; provided, further, that, other than in connection with fraud or gross negligence on the part of the Investor, the Investor
shall be liable under this Section&nbsp;6(b)&nbsp;for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds
to such Investor as a result of the sale of Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain
in full force and effect regardless of any investigation made by or on behalf of such Company Indemnified Person. Notwithstanding anything
to the contrary contained herein, the indemnification agreement contained in this Section&nbsp;6(b)&nbsp;with respect to any prospectus
shall not inure to the benefit of any Company Indemnified Person if the untrue statement or omission of material fact contained in the
prospectus was corrected and such new prospectus was delivered to the Investor prior to such Investor&rsquo;s use of the prospectus to
which the Claim relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Promptly
after receipt by an Investor Indemnified Person or Company Indemnified Person under this Section&nbsp;6 of notice of the commencement
of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Investor Indemnified Person or Company
Indemnified Person shall, if indemnification in respect of such Claim is to be sought from any indemnifying party under this Section&nbsp;6,
deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate
in and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, assume control of
the defense thereof with counsel reasonably and mutually satisfactory to the indemnifying party and the Investor Indemnified Person or
the Company Indemnified Person, as the case may be; provided, however, that an Investor Indemnified Person or Company Indemnified Person
shall have the right to retain its own counsel with the fees and expenses of not more than one (1)&nbsp;counsel for such Investor Indemnified
Person or Company Indemnified Person to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying
party, the representation by such counsel of the Investor Indemnified Person or Company Indemnified Person and the indemnifying party
would be inappropriate due to actual or potential differing interests between such Investor Indemnified Person or Company Indemnified
Person and any other party represented by such counsel in such proceeding. The Investor Indemnified Person or Company Indemnified Person
shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any Claim by the indemnifying
party and shall furnish to the indemnifying party all information reasonably available to the Investor Indemnified Person or Company Indemnified
Person which relates to such action or claim. The indemnifying party shall keep the Investor Indemnified Person or Company Indemnified
Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying
party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent; provided, however,
that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the
prior written consent of the Investor Indemnified Person or Company Indemnified Person, as the case may be, which consent shall not be
unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement or other compromise which
does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Investor Indemnified Person or Company
Indemnified Person of a full and unconditional release from all liability in respect to such claim or litigation. Following indemnification
as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Investor Indemnified Person or Company Indemnified
Person with respect to all third parties, firms or corporations relating to the Claim(s)&nbsp;for which indemnification has been made.
The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such Claim shall not
relieve such indemnifying party of any liability to the Investor Indemnified Person or Company Indemnified Person under this Section&nbsp;6,
except to the extent that the indemnifying party is prejudiced in its ability to defend such Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
indemnification required by this Section&nbsp;6 shall be made by periodic payments of the amount thereof during the course of the investigation
or defense, as and when bills are received or Indemnified Damages are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
indemnity agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Investor Indemnified
Person or Company Indemnified Person against the indemnifying party or others and (ii)&nbsp;any liabilities the indemnifying party may
be subject to pursuant to the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>CONTRIBUTION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under Section&nbsp;6 to the fullest extent permitted by law; provided, however,
that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of
the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation
and (ii)&nbsp;contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds received by
such seller from the sale of such Registrable Securities other than in connection with fraud or gross negligence on the part of such seller
of Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>REPORTS
UNDER THE EXCHANGE ACT</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With a view to making available
to the Investor the benefits of Rule&nbsp;144 promulgated under the Securities Act or any similar rule&nbsp;or regulation of the SEC that
may at any time permit the Investor to sell securities of the Company to the public without registration, and as a material inducement
to the Investor&rsquo;s purchase of the Promissory Notes, the Company represents, warrants, and covenants to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company is subject to the reporting requirements of section 13 or 15(d)&nbsp;of the Exchange Act and has timely filed all required reports
under section 13 or 15(d)&nbsp;of the Exchange Act during the 12 months prior to the date hereof (or for such shorter period that the
issuer was required to file such reports), other than Form&nbsp;8-K reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>During
the Registration Period, the Company shall file with the SEC in a timely manner all required reports under section 13 or 15(d)&nbsp;of
the Exchange Act (it being understood that nothing herein shall limit the Company&rsquo;s obligations under the Purchase Agreement) and
such reports shall conform to the requirement of the Exchange Act and the SEC for filing thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall furnish to the Investor so long as such Investor owns Registrable Securities, promptly upon request, (i)&nbsp;a written
statement by the Company that it has complied with the reporting requirements of Rule&nbsp;144, (ii)&nbsp;to the extent not publicly available
through EDGAR, a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the
Company, and (iii)&nbsp;such other information as may be reasonably requested to permit the Investor to sell such securities pursuant
to Rule&nbsp;144 without registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>AMENDMENT
OF REGISTRATION RIGHTS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of this Agreement
may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively)
only with the written consent of the Company and the Investor. Any amendment or waiver effected in accordance with this Section&nbsp;9
shall be binding upon each of the Investor and the Company. No such amendment shall be effective to the extent that it applies to fewer
than all of the holders of the Registrable Securities. No consideration shall be offered or paid to any Person to amend or consent to
a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the Parties to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>MISCELLANEOUS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed to own of record such Registrable Securities
or owns the right to receive the Registrable Securities. If the Company receives conflicting instructions, notices or elections from two
(2)&nbsp;or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice
or election received from the registered owner of such Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
this Agreement nor any rights or obligations of the Investor or the Company hereunder may be assigned to any other Person, except for
assignments by the Investor to any of its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered pursuant to the notice provisions of the Purchase Agreement or to such other address and/or
electronic mail address and/or to the attention of such other person as the recipient Party has specified by written notice given to each
other Party five (5)&nbsp;days prior to the effectiveness of such change. Written confirmation of receipt (A)&nbsp;given by the recipient
of such notice, consent, waiver or other communication, (B)&nbsp;electronically generated by the sender&rsquo;s email service provider
containing the time, date, and recipient email or (C)&nbsp;provided by a courier or overnight courier service shall be rebuttable evidence
of personal service, receipt by email or receipt from a nationally recognized overnight delivery service in accordance with this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Failure
of any Party to exercise any right or remedy under this Agreement or otherwise, or delay by a Party in exercising such right or remedy,
shall not operate as a waiver thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
laws of the State of New York shall govern all issues concerning the relative rights of the Company and the Investor as its stockholder.
All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule&nbsp;(whether of the State
of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York.
Each Party hereby irrevocably submits to the non-exclusive jurisdiction of the Supreme Court of the State of New York, sitting in New
York County, New York and federal courts for the Southern District of New York sitting New York, New York, for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by mailing a copy thereof to such Party at the address for such notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable
in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement
in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY&nbsp;HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR
IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall inure to the benefit of and be binding upon the permitted successors and assigns of each of the Parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement may be executed in identical counterparts, both of which shall be considered one (1)&nbsp;and the same agreement and shall become
effective when counterparts have been signed by each Party and delivered to the other Party. Electronically scanned and delivered signatures
(including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com), including by e-mail attachment, shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such
other agreements, certificates, instruments and documents, as the other Party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
language used in this Agreement will be deemed to be the language chosen by the Parties to express their mutual intent and no rules&nbsp;of
strict construction will be applied against any Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement is intended for the benefit of the Parties hereto and their respective permitted successors and assigns, and is not for the
benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>IN
WITNESS WHEREOF,</B></FONT> the Investor and the Company have caused their signature page&nbsp;to this Registration Rights Agreement to
be duly executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Thomas A. Fitzgerald</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas A. Fitzgerald</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>YA II PN,&nbsp;Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yorkville Advisors Global, LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Manager</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD>Yorkville Advisors Global II, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Its:</TD>
    <TD>General Partner</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthew Beckman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Beckman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>tm2611272d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STANDBY EQUITY PURCHASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS STANDBY EQUITY PURCHASE
AGREEMENT</B> (this &ldquo;<U>Agreement</U>&rdquo;) dated as of April&nbsp;6, 2026 is made by and between <B>YA II PN,&nbsp;LTD.</B>,
a Cayman Islands exempt limited company (the &ldquo;<U>Investor</U>&rdquo;), and <B>TRANSCODE THERAPEUTICS,&nbsp;INC., </B>a company incorporated
under the laws of the State of Delaware (the &ldquo;<U>Company</U>&rdquo;). The Investor and the Company may be referred to herein individually
as a &ldquo;<U>Party</U>&rdquo; and collectively as the &ldquo;<U>Parties</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the
Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $14 million of the Company&rsquo;s
shares of common stock, par value $0.0001 per share (the &ldquo;<U>Common Shares</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Common
Shares are listed for trading on the Nasdaq Capital Market under the symbol &ldquo;RNAZ;&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the offer
and sale of the Common Shares issuable hereunder will be made in reliance upon Section&nbsp;4(a)(2)&nbsp;under the Securities Act of 1933,
as amended, and the rules&nbsp;and regulations promulgated thereunder (the &ldquo;<U>Securities Act</U>&rdquo;), or upon such other exemption
from the registration requirements of the Securities Act as may be available with respect to any or all of the transactions to be made
hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Parties
are concurrently entering into a Registration Rights Agreement in the form attached as <U>Exhibit&nbsp;A</U> hereto (the &ldquo;<U>Registration
Rights Agreement</U>&rdquo;), pursuant to which the Company shall register the resale of the Registrable Securities (as defined in the
Registration Rights Agreement), upon the terms and subject to the conditions set forth therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, in consideration
of the Investor&rsquo;s execution and delivery of this Agreement, the Company shall issue to the Investor the Commitment Shares pursuant
to and in accordance with Section&nbsp;12.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW</B>, <B>THEREFORE</B>,
the Parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;I. Certain Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms used in this Agreement shall
have the meanings ascribed to such terms in <U>Annex&nbsp;I</U> hereto, and hereby made a part hereof, or as otherwise set forth in this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;II. Pre-Paid Advances</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;2.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pre-Paid
Advances</U>. Subject to the satisfaction of the conditions set forth in <U>Annex II</U> attached hereto, the Investor shall advance to
the Company the principal amount of $6,000,000 (the &ldquo;<U>Pre-Paid Advance</U>&rdquo;), which shall be evidenced by convertible promissory
notes in the form attached hereto as <U>Exhibit&nbsp;B</U> (each, a &ldquo;<U>Promissory Note</U>&rdquo;) in two tranches. The first tranche
of the Pre-Paid Advance shall be in a principal amount of $1,000,000 and, subject to the satisfaction of the conditions set forth in <U>Annex
II</U> attached hereto, advanced on the date upon which the Company files with the SEC the Company&rsquo;s Annual Report on Form&nbsp;10-K
for the year ended December&nbsp;31, 2025 (the &ldquo;<U>First Pre-Advance Closing</U>&rdquo;), the second tranche of the Pre-Paid Advance
shall be in a principal amount of $5,000,000 and, subject to the satisfaction of the conditions set forth in <U>Annex II</U> attached
hereto, advanced on the second Trading Day after the later of (i)&nbsp;the initial Registration Statement first becoming effective and
(ii)&nbsp;the Company&rsquo;s receipt of shareholder approval to issue Common Shares in connection with the transactions contemplated
by the Transaction Documents in excess of the Exchange Cap (the &ldquo;<U>Second Pre-Advance Closing</U>&rdquo;) (each of the First Pre-Advance
Closing and the Second Pre-Advance Closing individually referred to as a &ldquo;<U>Pre-Advance Closing</U>&rdquo; and collectively referred
to as the &ldquo;<U>Pre-Advance Closings</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;2.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pre-Advance
Closing</U>. Each Pre-Advance Closing shall occur remotely by conference call and electronic delivery of documentation. The First Pre-Advance
Closing shall take place at 10:00 a.m., New York time, on the date upon which the Company files with the SEC the Company&rsquo;s Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2025, provided that the conditions set forth on <U>Annex II</U> have been
satisfied (or such other date as is mutually agreed to by the Company and the Investor). The Second Pre-Advance Closing shall take place
at 10:00 a.m., New York time, on the second Trading Day after the later of (i)&nbsp;the initial Registration Statement first becoming
effective, (ii)&nbsp;the Company&rsquo;s receipt of shareholder approval to issue Common Shares in connection with the transactions contemplated
by the Transaction Documents in excess of the Exchange Cap, and (iii)&nbsp;the approval by the Principal Market of the initial listing
application required under Nasdaq Listing Rules&nbsp;5110 and 5635(b), provided that the conditions set forth on <U>Annex II</U> have
been satisfied within 180 calendar days of the date of this Agreement (or such other date as is mutually agreed to by the Company and
the Investor). At each Pre-Advance Closing, the Investor shall advance to the Company the principal amount of the applicable tranche of
the Pre-Paid Advance, less a discount in the amount equal to 5.00% of the principal amount of such tranche of the Pre-Paid Advance netted
from the purchase price due, in immediately available funds to an account designated by the Company in writing, and the Company shall
deliver a Promissory Note with a principal amount equal to the full amount of the applicable tranche of the Pre-Paid Advance, duly executed
on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Article&nbsp;III. Advances</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Advances;
Mechanics</U>. Upon the terms and subject to the conditions of this Agreement, during the Commitment Period, (i)&nbsp;the Company, at
its sole discretion, shall have the right, but not the obligation, to issue and sell to the Investor, and the Investor shall subscribe
for and purchase from the Company, Advance Shares by the delivery to the Investor of Advance Notices, provided (x)&nbsp;no more than 10%
of the amount of the Pre-Paid Advance that has been funded hereunder is outstanding under Promissory Note(s), or, (y)&nbsp;if more than
10% of the amount of the Pre-Paid Advance that has been funded hereunder is outstanding under Promissory Note(s), then in accordance with
&lrm;Section&nbsp;3.01(a)(iii)&nbsp;hereof, and (ii)&nbsp;for as long as there is a balance outstanding under a Promissory Note, the Investor,
at its sole discretion shall have the right, but not the obligation, by the delivery to the Company of Investor Notices, to cause an Advance
Notice to be deemed delivered to the Investor and the issuance and sale of Common Shares to the Investor pursuant to an Advance, on the
following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Advance Notice</U>. At any time during the Commitment Period, the Company may require the Investor
to purchase Common Shares by delivering an Advance Notice to the Investor, subject to the satisfaction or waiver by the Investor of the
conditions set forth in <U>Annex III</U>, and in accordance with the following provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Company shall, in its sole discretion, select the number of Advance Shares, not to exceed the Maximum
Advance Amount (unless otherwise agreed to in writing by the Company and the Investor), it desires to issue and sell to the Investor in
each Advance Notice, and the time it desires to deliver each Advance Notice.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">There shall be no mandatory minimum Advances and there shall be no non-usage fee for not utilizing the
Commitment Amount or any part thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">For so long as 10% of the amount of the Pre-Paid Advances remains outstanding under a Promissory Note,
without the prior written consent of the Investor, the Company may only (other than with respect to a deemed Advance Notice pursuant to
an Investor Notice) submit an Advance Notice (A)&nbsp;if an Amortization Event has occurred and the obligation of the Company to make
monthly prepayments under the Promissory Note has not ceased, and (B)&nbsp;the aggregate purchase price owed to the Company from such
Advances (&ldquo;<U>Advance Proceeds</U>&rdquo;) shall be paid by the Investor by offsetting the amount of the Advance Proceeds against
an equal amount outstanding under the subject Promissory Note (first towards accrued and unpaid interest, and then towards outstanding
principal).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Investor Notice</U>. At any time during the Commitment Period, provided that there is a balance remaining
outstanding under a Promissory Note, the Investor may, by delivering an Investor Notice to the Company, cause an Advance Notice to be
deemed delivered to the Investor and the issuance and sale of Common Shares to the Investor pursuant to an Advance, in accordance with
the following provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Investor shall, in its sole discretion, select the amount of the Advance up to the Maximum Advance
Amount applicable to the Investor, and the time it desires to deliver each Investor Notice; provided that the amount of the Advance selected
shall not exceed the balance owed under all Promissory Notes outstanding on the date of delivery of the Investor Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Purchase Price of the Common Shares in respect of any Advance Notice deemed delivered pursuant to
an Investor Notice shall be equal to the Conversion Price (as defined in the Promissory Note) that would be applicable to the amount of
the Advance selected by the Investor if such amount were to be converted as of the date of delivery of the Investor Notice in accordance
with the Promissory Note. The Investor shall pay the Purchase Price for the Common Shares to be issued pursuant to the Investor Notice
by offsetting the amount of the Purchase Price to be paid by the Investor against an equal amount outstanding under a Promissory Note
(first towards accrued and unpaid interest, if any, then towards principal).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">Each Investor Notice shall set forth the amount of the Advance requested, the Purchase Price (determined
in accordance with Section&nbsp;3.01(b)(ii)) along with a report by Bloomberg L.P. indicating the relevant VWAP used in calculating the
Conversion Price, the number of Common Shares to be issued by the Company and purchased by the Investor, the aggregate amount of accrued
and unpaid interest under the subject Promissory Note (if any) that shall be offset by the issuance of Common Shares, the aggregate amount
of principal of the Promissory Note that shall be offset by the issuance of Common Shares, and the total amount of the applicable Promissory
Note or Promissory Notes that shall be outstanding following the closing of the Advance, and each Investor Notice shall serve as the Settlement
Document in respect of such Advance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">Upon the delivery of an Investor Notice, a corresponding Advance Notice shall simultaneously and automatically
be deemed to have been delivered by the Company to the Investor requesting the amount of the Advance set forth in the Investor Notice,
and any conditions precedent to such Advance Notice under the terms of this Agreement that have not been satisfied shall be deemed to
have been waived by the Investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Date of Delivery of Advance Notice</U>. Advance Notices shall be delivered in accordance with the instructions
set forth on the bottom of <U>Exhibit&nbsp;C</U> attached hereto. An Advance Notice shall be deemed delivered on (i)&nbsp;the day it is
received by the Investor if such notice is received by e-mail at or before 9:00 a.m.&nbsp;New York City time (or at such later time if
agreed to by the Investor in its sole discretion), or (ii)&nbsp;the immediately succeeding day if it is received by e-mail after 9:00
a.m.&nbsp;New York City time. An Advance Notice deemed delivered pursuant to an Investor Notice shall be deemed delivered on the same
date upon which the Investor Notice is received by the Company. Upon receipt of an Advance Notice, the Investor shall promptly provide
written confirmation (which may be by e-mail) of receipt of such Advance Notice, and which confirmation shall specify the commencement
time of the applicable Pricing Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the repayment in cash or the conversion of all or a portion of the Pre-Paid
Advance will not reduce the Commitment Amount, other than with respect to delivery of an Advance Notice in accordance with Section&nbsp;3.01(a)(iii).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Advance
Limitations, Regulatory</U>. Regardless of the Advance requested in an Advance Notice, including an Advance Notice deemed delivered pursuant
to an Investor Notice (except with respect to the limitations in 3.02(b)&nbsp;below, which shall not apply to Investor Notices), and notwithstanding
any provision to the contrary herein, the final number of Common Shares to be issued and sold pursuant to such Advance Notice shall be
reduced (if at all) in accordance with each of the following limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Ownership Limitation; Commitment Amount</U>. At the request of the Company, the Investor shall inform
the Company of the number of Common Shares the Investor and each of its Affiliates beneficially owns. Notwithstanding anything to the
contrary contained in this Agreement, the Investor shall not be obligated to purchase or acquire, and shall not purchase or acquire, any
Common Shares under this Agreement which, when aggregated with all other Common Shares beneficially owned by the Investor and its Affiliates
(as calculated pursuant to Section&nbsp;13(d)&nbsp;of the Exchange Act and Rule&nbsp;13d-3 promulgated thereunder), would result in the
beneficial ownership by the Investor and its Affiliates (on an aggregated basis) of a number of Common Shares exceeding 9.99% of the then
outstanding voting power or number of Common Shares (the &ldquo;<U>Ownership Limitation</U>&rdquo;). Upon the written request of the Investor,
the Company shall promptly (but no later than the next Business Day on which the transfer agent for the Common Shares is open for business)
confirm orally or in writing to the Investor the number of Common Shares then outstanding. In connection with each Advance Notice, any
portion of an Advance that would (i)&nbsp;cause the Investor to exceed the Ownership Limitation or (ii)&nbsp;cause the aggregate number
of Common Shares issued and sold to the Investor hereunder to exceed the Commitment Amount shall automatically be withdrawn with no further
action required by the Company, and such Advance Notice shall be deemed automatically modified to reduce the Advance by an amount equal
to such withdrawn portion; provided that in the event of any such automatic withdrawal and automatic modification, the Investor will promptly
notify the Company of such event.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Registration Limitation</U>. In no event shall an Advance exceed the number of Common Shares registered
in respect of the transactions contemplated hereby under the Registration Statement then in effect (the &ldquo;<U>Registration Limitation</U>&rdquo;).
In connection with each Advance Notice, any portion of an Advance that would exceed the Registration Limitation shall automatically be
withdrawn with no further action required by the Company and such Advance Notice shall be deemed automatically modified to reduce the
aggregate amount of the requested Advance by an amount equal to such withdrawn portion; provided that in the event of any such automatic
withdrawal and automatic modification, the Investor will promptly notify the Company of such event.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Compliance with Rules&nbsp;of Principal Market</U>. Notwithstanding anything to the contrary herein,
the Company shall not effect any sales under this Agreement and the Investor shall not have the obligation to purchase Common Shares under
this Agreement to the extent (but only to the extent) that after giving effect to such purchase and sale the aggregate number of Common
Shares issued under this Agreement (including, without limitation, any Commitment Shares and Common Shares underlying the Promissory Notes)
would exceed 183,301 Common Shares (representing 19.99% of the aggregate number of Common Shares issued and outstanding as of the signing
of this Agreement (subject to adjustment for any stock splits, combinations or the like)), calculated in accordance with the rules&nbsp;of
the Principal Market, which number shall be reduced, on a share-for-share basis, by the number of Common Shares issued or issuable pursuant
to any transaction or series of transactions that may be aggregated with the transactions contemplated by this Agreement under the applicable
rules&nbsp;of the Principal Market (such maximum number of Common Shares, the &ldquo;<U>Exchange Cap</U>&rdquo;) <I>provided that, </I>the
Exchange Cap will not apply if the Company&rsquo;s stockholders have approved the issuance of Common Shares pursuant to this Agreement
in excess of the Exchange Cap in accordance with the applicable rules&nbsp;of the Principal Market. In connection with each Advance Notice,
any portion of an Advance that would exceed the Exchange Cap shall automatically be withdrawn with no further action required by the Company
and such Advance Notice shall be deemed automatically modified to reduce the aggregate amount of the requested Advance by an amount equal
to such withdrawn portion in respect of each Advance Notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Advance
Limitations, Minimum Acceptable Price</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">With respect to each Advance Notice the Company may notify the Investor of the Minimum Acceptable Price
with respect to such Advance by indicating a Minimum Acceptable Price on such Advance Notice. If no Minimum Acceptable Price is specified
in an Advance Notice, then no Minimum Acceptable Price shall be in effect in connection with such Advance. Each Trading Day during a Pricing
Period for which (A)&nbsp;with respect to each Advance Notice with a Minimum Acceptable Price, the VWAP of the Common Shares is below
the Minimum Acceptable Price in effect with respect to such Advance Notice, or (B)&nbsp;there is no VWAP (each such day in the foregoing
clauses (A)&nbsp;and (B), an &ldquo;<U>Excluded Day</U>&rdquo;), shall result in an automatic reduction to the number of Advance Shares
set forth in such Advance Notice by one third (1/3) (the resulting amount of each Advance being the &ldquo;<U>Adjusted Advance Amount</U>&rdquo;),
and each Excluded Day shall be excluded from the Pricing Period for purposes of determining the Market Price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The total Advance Shares in respect of each Advance with any Excluded Day(s)&nbsp;(after reductions have
been made to arrive at the Adjusted Advance Amount) shall be automatically increased by such number of Common Shares (the &ldquo;<U>Additional
Shares</U>&rdquo;) equal to the greater of (a)&nbsp;the number of Common Shares sold by the Investor on such Excluded Day(s), if any,
or (b)&nbsp;such number of Common Shares elected to be subscribed for by the Investor, and the subscription price per share for each Additional
Share shall be equal to the Minimum Acceptable Price in effect with respect to such Advance Notice multiplied by 97%, provided that this
increase shall not cause the total Advance Shares to exceed the amount set forth in the applicable Advance Notice or any limitations set
forth in &lrm;Section&nbsp;3.02.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Unconditional
Contract</U>. Notwithstanding any other provision in this Agreement, the Company and the Investor acknowledge and agree that upon the
Investor&rsquo;s receipt of a valid Advance Notice from the Company the Parties shall be deemed to have entered into an unconditional
contract binding on both Parties for the purchase and sale of the applicable number of Advance Shares pursuant to such Advance Notice
in accordance with the terms of this Agreement and (i)&nbsp;subject to Applicable Laws and (ii)&nbsp;subject to &lrm;Section&nbsp;7.21,
the Investor may sell Common Shares during the Pricing Period for such Advance Notice (including with respect to any Advance Shares subject
to such Pricing Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closings</U>.
The closing of each Advance and each sale and purchase of Advance Shares (whether pursuant to an Advance Notice delivered by the Company
or in connection with an Advance Notice deemed delivered by the Company in connection with an Investor Notice) (each, a &ldquo;<U>Closing</U>&rdquo;)
shall take place as soon as practicable on or after each applicable Advance Date in accordance with the procedures set forth below. The
Company acknowledges that, other than in connection with an Investor Notice, the Purchase Price is not known at the time an Advance Notice
is delivered (at which time the Investor is irrevocably bound) but shall be determined on each Closing based on the daily prices of the
Common Shares that are the inputs to the determination of the Purchase Price. In connection with each Closing, the Company and the Investor
shall fulfill each of its obligations as set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">On or prior to each Advance Date, the Investor shall deliver to the Company a Settlement Document along
with a report by Bloomberg L.P. (or, if not reported on Bloomberg L.P., another reporting service reasonably agreed to by the parties)
indicating the VWAP for each of the Trading Days during the Pricing Period or period for determining the applicable Conversion Price,
in each case in accordance with the terms and conditions of this Agreement. In connection with an Investor Notice, the Investor Notice
shall serve as the Settlement Document.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Promptly after receipt of the Settlement Document with respect to each Advance (and, in any event, not
later than one Trading Day after such receipt), the Company will, or will cause its transfer agent to, electronically transfer such number
of Advance Shares to be purchased by the Investor (as set forth in the Settlement Document) by crediting the Investor&rsquo;s account
or its designee&rsquo;s account at the Depository Trust Company through its Deposit Withdrawal at Custodian System or by such other means
of delivery as may be mutually agreed upon by the parties hereto, and transmit notification to the Investor that such share transfer has
been requested. Promptly upon receipt of such notification, the Investor shall pay to the Company the aggregate purchase price of the
Common Shares (as set forth in the Settlement Document) either (i)&nbsp;in the case of an Advance Notice submitted other than after the
occurrence of an Amortization Event, in cash in immediately available funds to an account designated by the Company in writing and transmit
notification to the Company that such funds transfer has been requested, or (ii)&nbsp;in the case of an Investor Notice or an Advance
Notice submitted after the occurrence of an Amortization Event, as an offset of amounts owed under the Promissory Note as described Section&nbsp;3.01(b).
No fractional shares shall be issued, and any fractional shares that would otherwise be issued in connection with an Advance shall be
rounded to the next higher whole number of shares. To facilitate the transfer of the Common Shares by the Investor, the Common Shares
will not bear any restrictive legends so long as there is an effective Registration Statement covering the resale of such Common Shares
(it being understood and agreed by the Investor that notwithstanding the lack of restrictive legends, the Investor may only sell such
Common Shares pursuant to the Plan of Distribution set forth in the Prospectus included in the applicable Registration Statement and otherwise
in compliance with the requirements of the Securities Act (including any applicable prospectus delivery requirements) or pursuant to an
available exemption).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">On or prior to the Advance Date, each of the Company and the Investor shall deliver to the other all documents,
instruments and writings expressly required to be delivered by either of them pursuant to this Agreement in order to implement and effect
the transactions contemplated herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in this Agreement, other than in respect of Advance Notices deemed
to be given pursuant to Investor Notices, if on any day during the Pricing Period (i)&nbsp;the Company notifies Investor that a Material
Outside Event has occurred, or (ii)&nbsp;the Company notifies the Investor of a Black Out Period, the parties agree that any pending Advance
shall end and the final number of Advance Shares to be purchased by the Investor at the Closing for such Advance shall be equal to the
number of Common Shares sold by the Investor during the applicable Pricing Period prior to the notification from the Company of a Material
Outside Event or Black Out Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;3.06<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Hardship</U>.
In the event the Company fails to perform its obligations as mandated in this Agreement after the Investor&rsquo;s receipt (or deemed
receipt, in the case of an Investor Notice) of an Advance Notice, the Company agrees that in addition to and in no way limiting the rights
and obligations set forth in Article&nbsp;VI hereto and in addition to any other remedy to which the Investor is entitled at law or in
equity, including, without limitation, specific performance, it will hold the Investor harmless against any loss, claim, damage, or expense
(including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and acknowledges
that irreparable damage may occur in the event of any such default. It is accordingly agreed that the Investor shall be entitled to an
injunction or injunctions to prevent such breaches of this Agreement and to specifically enforce (subject to Applicable Laws and the rules&nbsp;of
the Principal Market), without the posting of a bond or other security, the terms and provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Article&nbsp;IV. Representations
and Warranties of the Investor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor represents, warrants,
and covenants to the Company, as of the date hereof, as of each Advance Notice Date and as of each Advance Date that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
and Authorization</U>. The Investor is duly organized, validly existing and in good standing under the laws of the Cayman Islands and
has the requisite corporate power and authority to enter into and perform its obligations under the Transaction Documents to which it
is a party and to purchase or acquire the Common Shares in accordance with the terms hereof. The decision to invest and the execution
and delivery of the Transaction Documents to which it is a party by the Investor, the performance by the Investor of its obligations hereunder
and the consummation by the Investor of the transactions contemplated hereby have been duly authorized and require no other proceedings
on the part of the Investor. The undersigned has the right, power and authority to execute and deliver the Transaction Documents to which
it is a party and all other instruments on behalf of the Investor or its shareholders. This Agreement and the Transaction Documents to
which it is a party have been duly executed and delivered by the Investor and, assuming the execution and delivery hereof and acceptance
thereof by the Company, will constitute the legal, valid and binding obligations of the Investor, enforceable against the Investor in
accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Evaluation
of Risks</U>. The Investor has such knowledge and experience in financial, tax and business matters as to be capable of evaluating the
merits and risks of, and bearing the economic risks entailed by, an investment in the Common Shares and of protecting its interests in
connection with the transactions contemplated hereby. The Investor acknowledges and agrees that its investment in the Company involves
a high degree of risk, and that the Investor may lose all or a part of its investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Legal,&nbsp;Investment or Tax Advice from the Company</U>. The Investor acknowledges that it had the opportunity to review the Transaction
Documents, and the transactions contemplated by the Transaction Documents with its own legal counsel and investment and tax advisors.
The Investor is relying solely on such counsel and advisors and not on any statements or representations of the Company or any of the
Company&rsquo;s representatives or agents for legal, tax, investment or other advice with respect to the Investor&rsquo;s acquisition
of Common Shares hereunder, the transactions contemplated by this Agreement or the laws of any jurisdiction, and the Investor acknowledges
that the Investor may lose all or a part of its investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Purpose</U>. The Investor is acquiring the Common Shares and any Promissory Note for its own account, for investment purposes and not
with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered under
or exempt from the registration requirements of the Securities Act or any applicable state securities laws;&nbsp;provided,&nbsp;however,
that by making the representations herein, the Investor does not agree, or make any representation or warranty, to hold any of the Common
Shares for any minimum or other specific term and reserves the right to dispose of the Shares at any time in accordance with, or pursuant
to, a Registration Statement filed pursuant to this Agreement or an applicable exemption under the Securities Act. The Investor does not
presently have any agreement or understanding, directly or indirectly, with any Person to sell or distribute any of the Common Shares.
The Investor acknowledges that it will be disclosed as an &ldquo;underwriter&rdquo; and a &ldquo;selling stockholder&rdquo; in each Registration
Statement and in any Prospectus contained therein to the extent required by applicable law and to the extent any such Prospectus is related
to the resale of Common Shares issuable pursuant to Advance Notices. The <FONT STYLE="background-color: white">Investor is acquiring the
Common Shares and the Promissory Notes hereunder in the ordinary course of its business</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accredited
Investor</U>. The Investor is an &ldquo;<U>Accredited Investor</U>&rdquo; as that term is defined in Rule&nbsp;501(a)(3)&nbsp;of Regulation
D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.06<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Information</U>.
The Investor and its advisors (and its counsel), if any, have been furnished with all materials relating to the business, finances and
operations of the Company and information the Investor deemed material to making an informed investment decision. The Investor and its
advisors (and its counsel), if any, have been afforded the opportunity to ask questions of the Company and its management and have received
answers to such questions. Neither such inquiries nor any other due diligence investigations conducted by such Investor or its advisors
(and its counsel), if any, or its representatives shall modify, amend or affect the Investor&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement. The Investor acknowledges and agrees that the Company has not made to the
Investor, and the Investor acknowledges and agrees it has not relied upon, any representations and warranties of the Company, its employees
or any third party other than the representations and warranties of the Company contained in this Agreement. The Investor understands
that its investment involves a high degree of risk. The Investor has sought such accounting, legal and tax advice, as it has considered
necessary to make an informed investment decision with respect to the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.07<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Not
an Affiliate</U>. The Investor is not an officer, director or a person that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with the Company or any &ldquo;<U>Affiliate</U>&rdquo; of the Company (as that
term is defined in Rule&nbsp;405 promulgated under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.08<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General
Solicitation</U>. Neither the Investor, nor any of its affiliates, nor any person acting on its or their behalf, has engaged or will
engage in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with any offer or
sale of the Common Shares by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;4.09<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Trading
Activities</U>. The Investor has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding
with the Investor, engaged in any transactions in the securities of the Company (including, without limitation, any Short Sales (as defined
below) involving the Company's securities) during the period commencing as of the time that the Investor first contacted the Company
or the Company's agents regarding the specific investment in the Company contemplated by this Agreement and ending immediately prior
to the execution of this Agreement by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;V. Representations and Warranties
of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in the
SEC Documents, the Company represents and warrants to the Investor that, as of the date hereof, each Advance Notice Date and each Advance
Date (other than representations and warranties which address matters only as of a certain date, which shall be true and correct as written
as of such certain date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
and Qualification</U>. The Company and each of its Subsidiaries are entities duly incorporated or otherwise organized and validly existing
and in good standing under the laws of their respective jurisdiction of their incorporation or organization and has the requisite power
and authority to own its properties and to carry on its business as now being conducted. Each of the Company and its Subsidiaries is duly
qualified to do business and is in good standing (to the extent applicable) in every jurisdiction in which the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing has
not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization,
Enforcement, Compliance with Other Instruments.</U> The Company has the requisite corporate power and authority to enter into and perform
its obligations under this Agreement and the other Transaction Documents and to issue the Common Shares in accordance with the terms hereof
and thereof. The execution and delivery by the Company of this Agreement and the other Transaction Documents, and the consummation by
the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) have
been or (with respect to consummation) will be duly authorized by the Company&rsquo;s board of directors and no further consent or authorization
will be required by the Company, its board of directors or its shareholders. This Agreement and the other Transaction Documents to which
the Company is a party have been (or, when executed and delivered, will be) duly executed and delivered by the Company and, assuming the
execution and delivery thereof and acceptance by the Investor, constitute (or, when duly executed and delivered, will be) the legal, valid
and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability
may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other
laws relating to, or affecting generally, the enforcement of applicable creditors&rsquo; rights and remedies and except as rights to indemnification
and to contribution may be limited by federal or state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization
of the Shares</U>. The Common Shares to be issued under this Agreement have been, or with respect to Common Shares to be purchased by
the Investor pursuant to an Advance Notice, will be, when issued and delivered pursuant to the terms approved by the board of directors
of the Company or a duly authorized committee thereof, or a duly authorized executive committee, against payment therefor as provided
herein, duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security
interest or other claim, including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar
rights, and will be registered pursuant to Section&nbsp;12 of the Exchange Act. The Common Shares, when issued, will conform to the description
thereof set forth in or incorporated into the Prospectus. As of the date of each Pre-Advance Closing, and at all times thereafter, the
Company shall have reserved from its duly authorized capital stock not less than the number of Common Shares issuable upon conversion
of all Promissory Notes (assuming for purposes hereof that (x)&nbsp;such Promissory Note is convertible at a conversion price equal to
the Floor Price as of the date of determination, and (y)&nbsp;any such conversion shall not take into account any limitations on the conversion
of the Promissory Note set forth therein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflict</U>. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Common Shares) will not (i)&nbsp;result
in a violation of the certificates of incorporation or other organizational documents of the Company or its Subsidiaries (with respect
to consummation, as the same may be amended prior to the date on which any of the transactions contemplated hereby are consummated), (ii)&nbsp;conflict
with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others
any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or
its Subsidiaries is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws and regulations) applicable to the Company or its Subsidiaries or by which any property or asset of the Company
or its Subsidiaries is bound or affected except, in the case of clause (ii)&nbsp;or (iii)&nbsp;above, to the extent such violations have
not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acknowledgment</U>.
The Company understands and acknowledges that the number of Common Shares issuable upon conversion of the Promissory Notes will increase
in certain circumstances. The Company further acknowledges its obligation to issue the Common Shares upon conversion of the Promissory
Notes in accordance with the terms thereof or upon delivery of an Advance Notice (including upon receipt of an Investor Notice) is absolute
and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.06<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>SEC
Documents; Financial Statements</U>. For the past two years the Company the Company has filed all reports, schedules, forms, statements
and other documents required to be filed by it with the SEC pursuant to the Exchange Act, including, without limitation, the Current Report,
each Registration Statement, as the same may be amended from time to time, the Prospectus contained therein and each Prospectus Supplement
thereto, and all information contained in such filings and all documents and disclosures that have been or may in the future be incorporated
by reference therein (all such documents hereinafter referred to as the &ldquo;<U>SEC Documents</U>&rdquo;) and all such filings required
to be filed within the last 12 months (or since the Company has been subject to the requirements of Section&nbsp;12 of the Exchange Act,
if shorter) have been made on a timely basis (giving effect to permissible extensions in accordance with Rule&nbsp;12b-25 under the Exchange
Act). The Company has delivered or made available to the Investor through the SEC&rsquo;s website at http://www.sec.gov, true and complete
copies of the SEC Documents, as applicable. Except as disclosed in amendments or subsequent filings to the SEC Documents, as of its filing
date (or, if amended or superseded by a filing prior to the date hereof, on the date of such amended or superseded filing), each of the
SEC Documents complied in all material respects with the requirements of the Exchange Act or the Securities Act, as applicable, and the
rules&nbsp;and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and did not contain any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.07<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Financial
Statements</U>. The consolidated financial statements of the Company included or incorporated by reference in the SEC Documents, together
with the related notes and schedules, present fairly, in all material respects, the consolidated financial position of the Company and
the Subsidiaries as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity
of the Company for the periods specified and have been prepared in compliance with the requirements of the Securities Act and Exchange
Act and in conformity with generally accepted accounting principles in the United States (&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent
basis (except for (i)&nbsp;such adjustments to accounting standards and practices as are noted therein, (ii)&nbsp;in the case of unaudited
interim financial statements, to the extent such financial statements may not include footnotes required by GAAP or may be condensed or
summary statements and (iii)&nbsp;such adjustments which are not material, either individually or in the aggregate) during the periods
involved; the other financial and statistical data with respect to the Company and the Subsidiaries contained or incorporated by reference
in the SEC Documents are accurately and fairly presented and prepared on a basis consistent with the financial statements and books and
records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated by
reference in the SEC Documents that are not included or incorporated by reference as required; the Company and the Subsidiaries do not
have any material liabilities or obligations, direct or contingent (including any off-balance sheet obligations), not described in the
SEC Documents (excluding the exhibits thereto); and all disclosures contained or incorporated by reference in the SEC Documents regarding
&ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules&nbsp;and regulations of the SEC) comply in all material
respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to the extent applicable. The interactive
data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Documents fairly presents the information
called for in all material respects and has been prepared in accordance with the SEC&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.08<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Statement and Prospectus</U>. The Company and the transactions contemplated by this Agreement meet the requirements for and comply with
the conditions for the use of Form&nbsp;S-1 under the Securities Act. Each Registration Statement and the offer and sale of Common Shares
as contemplated hereby, if and when filed, will meet the requirements of Rule&nbsp;415 under the Securities Act and comply in all material
respects with said rule. Any statutes, regulations, contracts or other documents that are required to be described in a Registration Statement
or a Prospectus, or any amendment or supplement thereto, or to be filed as exhibits to a Registration Statement have been so described
or filed. Copies of each Registration Statement, any Prospectus, and any such amendments or supplements thereto and all documents incorporated
by reference therein that were filed with the SEC on or prior to the date of this Agreement have been delivered, or are available through
EDGAR, to the Investor and its counsel. The Company has not distributed and, prior to the later to occur of each Advance Notice Date and
completion of the distribution of the Common Shares, will not distribute any offering material in connection with the offering or sale
of the Common Shares other than a Registration Statement, the Prospectus contained therein, and any required prospectus supplement, in
each case as reviewed and consented to by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.09<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Misstatement or Omission</U>. Each Registration Statement, when it became or becomes effective, and any Prospectus, on the date of such
Prospectus or any amendment or supplement thereto, conformed and will conform in all material respects with the requirements of the Securities
Act. At each Advance Notice Date and applicable Advance Date, the Registration Statement, and the Prospectus, as of such date, will conform
in all material respects with the requirements of the Securities Act. Each Registration Statement, when it became or becomes effective,
did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading. Each Prospectus, as amended or supplemented, as of its date and at all subsequent
times, did not, or will not, include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by reference in a Prospectus
or any Prospectus Supplement did not, and any further documents filed and incorporated by reference therein will not, when filed with
the SEC, contain an untrue statement of a material fact or omit to state a material fact required to be stated in such document or necessary
to make the statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing shall
not apply to statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished
to the Company by the Investor specifically for use in the preparation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.10<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conformity
with Securities Act and Exchange Act</U>. Each Registration Statement, each Prospectus, or any amendment or supplement thereto, and the
documents incorporated by reference in each Registration Statement, Prospectus or any amendment or supplement thereto, when such documents
were or are filed with the SEC under the Securities Act or the Exchange Act or became or become effective under the Securities Act, as
the case may be, conformed or will conform in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.11<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Equity
Capitalization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorized and Outstanding
Capital Stock</U>. As of the date hereof, the authorized capital stock of the Company consists of 290,000,000 shares of common stock,
$0.0001 par value, of which 916,968 are issued and outstanding and 10&nbsp;million shares of preferred stock, par value $0.0001 per share,
of which 1,242.0718 shares are designated as Series&nbsp;A Non-Voting Preferred Stock, each of which is convertible into 10,000 shares
of Common Stock; 223.7337 shares are designated as Series&nbsp;B Non-Voting Preferred Stock, each of which is convertible into 10,000
shares of Common Stock; and 1,214,204 shares are designated as Series&nbsp;C Non-Voting Preferred Stock, each of which is convertible
into one (1)&nbsp;share of Common Stock; and 8,748,329.56 shares of preferred stock are undesignated. As of the date hereof, the Company
has reserved 16,357,905 Common Shares for issuance to parties or Persons other than the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Valid
Issuance&#894; Available Shares</U>. All of such outstanding shares are duly authorized and have been validly issued and are fully paid
and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(C)<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Existing
Securities&#894; Obligations</U>. Except as disclosed in the SEC Documents: (A)&nbsp;none of the Company&rsquo;s or any Subsidiary&rsquo;s
shares, interests or capital stock is subject to preemptive rights or any other similar rights or liens suffered or permitted by the Company
or any Subsidiary&#894; (B)&nbsp;there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests
or capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company
or any of its Subsidiaries is or may become bound to issue additional shares, interests or capital stock of the Company or any of its
Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities
or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of the Company or any of its Subsidiaries&#894;
(C)&nbsp;there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale
of any of their securities under the Securities Act (except pursuant to this Agreement)&#894; (D)&nbsp;there are no outstanding securities
or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security
of the Company or any of its Subsidiaries&#894; (E)&nbsp;there are no securities or instruments containing anti-dilution or similar provisions
that will be triggered by the issuance of the Common Shares&#894; and (F)&nbsp;neither the Company nor any Subsidiary has entered into
any Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.12<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property Rights</U>. The Company and its Subsidiaries own or possess adequate rights or licenses to use all material trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and rights, if any, necessary to conduct their respective businesses as now conducted, except
as has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The Company
and its Subsidiaries have not received written notice of any infringement by the Company or its Subsidiaries of trademark, trade name
rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, or trade secrets,
except as has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. To the
knowledge of the Company, there is no claim, action or proceeding being made or brought against, or to the Company&rsquo;s knowledge,
being threatened against the Company or its Subsidiaries regarding trademark, trade name, patents, patent rights, invention, copyright,
license, service names, service marks, service mark registrations, trade secret or other infringement; and, except as has not had and
would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect, the Company is not aware of any
facts or circumstances which might give rise to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.13<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Employee
Relations</U>. Neither the Company nor any of its Subsidiaries is involved in any labor dispute nor, to the knowledge of the Company or
any of its Subsidiaries, has any such dispute threatened, in each case which would not be reasonably expected to have, individually or
in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.14<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Laws</U>. The Company and its Subsidiaries (i)&nbsp;have not received written notice alleging any failure to comply in all material respects
with all Environmental Laws (as defined below), (ii)&nbsp;have received all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;have not received written notice alleging any failure
to comply with all terms and conditions of any such permit, license or approval, except, in each of the foregoing clauses (i), (ii)&nbsp;and
(iii), as has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term
&ldquo;<U>Environmental Laws</U>&rdquo; means all applicable federal, state and local laws relating to pollution or protection of human
health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata),
including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.15<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title</U>.
Except as has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect, the Company
(or its Subsidiaries) has indefeasible fee simple or leasehold title to its properties and material assets owned by it, free and clear
of any pledge, lien, security interest, encumbrance, claim or equitable interest other than (i)&nbsp;such as are not material to the business
of the Company and (ii)&nbsp;such that are for the payment of federal, state or other taxes, for which appropriate reserves have been
made therefor in accordance with GAAP and the payment of which is neither delinquent nor subject to penalties. Any real property and facilities
held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its
Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.16<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries
are engaged. The Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not be reasonably
expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.17<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Regulatory
Permits</U>. Except as has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect, the Company and its Subsidiaries possess all material certificates, authorizations and permits issued by the appropriate federal,
state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary
has received any written notice of proceedings relating to the revocation or modification of any such certificate, authorization or permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.18<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Internal
Accounting Controls</U>. The Company maintains a system of internal accounting controls designed to provide reasonable assurance that
(i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access
to assets is permitted only in accordance with management&rsquo;s general or specific authorization and (iv)&nbsp;the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences,
and management is not aware of any material weaknesses that are not disclosed in the SEC Documents as and when required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.19<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Litigation</U>. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending against or affecting the Company, the Common Shares or any of the Company&rsquo;s Subsidiaries,
wherein an unfavorable decision, ruling or finding would have or be reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.20<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Certain Changes</U>. Since the date of the Company&rsquo;s most recent audited financial statements contained in a Form&nbsp;10-K,
there has been no Material Adverse Effect, nor any event or occurrence specifically affecting the Company or its Subsidiaries that would
be reasonably expected to result, individually or in the aggregate, in a Material Adverse Effect. Since the date of the Company&rsquo;s
most recent audited financial statements contained in a Form&nbsp;10-K and except as disclosed in the SEC Documents, neither the Company
nor any of its Subsidiaries has (i)&nbsp;declared or paid any dividends, (ii)&nbsp;sold any material assets, individually or in the aggregate,
outside of the ordinary course of business, or (iii)&nbsp;made any material capital expenditures, individually or in the aggregate, outside
of the ordinary course of business. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to
any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or
any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.21<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsidiaries</U>.
Except as disclosed in the SEC Documents, the Company does not own or control, directly or indirectly, any interest in any other corporation,
partnership, association or other business entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.22<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, each of the Company and its Subsidiaries (i)&nbsp;has timely filed all foreign, federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has timely paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations,
except those being contested in good faith and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. The Company has not received written
notification of any unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company and its Subsidiaries know of no basis for any such claim where the failure to pay would have or would be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.23<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Transactions</U>. Except as disclosed in the SEC Documents or as not required to be disclosed pursuant to Applicable Laws, none of the
officers or directors of the Company is presently a party to any transaction with the Company (other than for services as employees, officers
and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for
rental of real or personal property to or from, or otherwise requiring payments to or from any officer or director, or to the knowledge
of the Company, any corporation, partnership, trust or other entity in which any officer or director has a substantial interest or is
an officer, director, trustee or partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.24<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rights
of First Refusal</U>. Except as disclosed in the SEC Documents, the Company is not obligated to offer the Common Shares or the Promissory
Notes offered hereunder on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or
former stockholders of the Company, underwriters, brokers, agents or other third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.25<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dilution</U>.
The Company is aware and acknowledges that issuance of Common Shares hereunder could cause dilution to existing stockholders and could
significantly increase the outstanding number of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.26<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acknowledgment
Regarding Investor&rsquo;s Purchase of Shares</U>. The Company acknowledges and agrees that the Investor is acting solely in the capacity
of an arm&rsquo;s length investor with respect to this Agreement and the transactions contemplated hereunder. The Company further acknowledges
that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement
and the transactions contemplated hereunder and any advice given by the Investor or any of its representatives or agents in connection
with this Agreement and the transactions contemplated hereunder is merely incidental to the Investor&rsquo;s purchase of the Common Shares
hereunder or the Promissory Note. The Company is aware and acknowledges that it shall not be able to request Advances under this Agreement
if a Registration Statement is not effective or if any issuances of Common Shares pursuant to any Advances would violate any rules&nbsp;of
the Principal Market. The Company acknowledges and agrees that it is capable of evaluating and understanding, and understands and accepts,
the terms, risks and conditions of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.27<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Finder&rsquo;s
Fees</U>. Except for fees and commissions payable by the Company to Tungsten Advisors (through its broker-dealer, Finalis Securities LLC),
in connection with this transaction, neither the Company nor any of the Subsidiaries has incurred any liability for any finder&rsquo;s
fees, brokerage commissions or similar payments in connection with the transactions herein contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.28<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Relationship
of the Parties</U>. Neither the Company, nor any of its Subsidiaries or Affiliates, nor any Person acting on its or their behalf is a
client or customer of the Investor or any of its Affiliates and neither the Investor nor any of its Affiliates has provided, or will provide,
any services to the Company or any of its Affiliates, its subsidiaries, or any Person acting on its or their behalf. The Investor&rsquo;s
relationship to the Company is solely as investor as provided for in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.29<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Operations</U>.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with Applicable Law and <FONT STYLE="font-size: 10pt">&nbsp;</FONT>neither
the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or any Subsidiary nor, to the Company&rsquo;s
knowledge, any agent, Affiliate or other Person acting on behalf of the Company or any Subsidiary has, not complied with Applicable Law;
and no action, suit or proceeding by or before any governmental authority involving the Company or any of its Subsidiaries with respect
to Applicable Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.30<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) contained in the Registration Statement or a Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.31<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Laws</U>. The Company and each of its Subsidiaries are in compliance with Applicable Law; the Company has not received a notice of
non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that any director, officer, or employee of the Company
or any Subsidiary nor, to the Company&rsquo;s knowledge, any agent, Affiliate or other Person acting on behalf of the Company or any Subsidiary
has, has not complied with Applicable Laws, or could give rise to a notice of non-compliance with Applicable Laws, and is not aware of
any pending change or contemplated change to any Applicable Law or regulation or governmental position; in each case that would have or
would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.32<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sanctions
Matters</U>. Neither the Company nor any of its Subsidiaries or, to the knowledge of the Company, any director, officer or controlled
Affiliate of the Company or any director or officer of any Subsidiary, is a Person that is, or is owned or controlled by a Person that
is (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Asset Control
(&ldquo;<U>OFAC</U>&rdquo;), the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or other relevant
sanctions authorities, including, without limitation, designation on OFAC&rsquo;s Specially Designated Nationals and Blocked Persons List
or OFAC&rsquo;s Foreign Sanctions Evaders List or other relevant sanctions authority (collectively, &ldquo;<U>Sanctions</U>&rdquo;), or
(ii)&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with
that country or territory (including, without limitation, the Crimea, Zaporizhzhia and Kherson regions of Ukraine, the Donetsk People&rsquo;s
Republic and Luhansk People&rsquo;s Republic in Ukraine, Cuba,&nbsp;Iran, North Korea, Russia, Sudan and Syria (the &ldquo;<U>Sanctioned
Countries</U>&rdquo;)). Neither the Company nor any of its Subsidiaries will, directly or indirectly, use the proceeds from the sale of
Advance Shares or any Pre-Paid Advance, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture
partner or other Person (a)&nbsp;for the purpose of funding or facilitating any activities or business of or with any Person or in any
country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or is a Sanctioned Country, or (b)&nbsp;in
any other manner that will result in a violation of Sanctions or Applicable Laws by any Person (including any Person participating in
the transactions contemplated by this Agreement, whether as underwriter, advisor, investor or otherwise). For the past five years, neither
the Company nor any of its Subsidiaries has engaged in, and is now not engaged in, any dealings or transactions with any Person, or in
any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or was a Sanctioned Country.
Neither the Company nor any of its Subsidiaries nor any director, officer or controlled Affiliate of the Company or any of its Subsidiaries,
has ever had funds blocked by a United States bank or financial institution, temporarily or otherwise, as a result of OFAC concerns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;5.33<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General
Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged or will engage
in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of
the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;VI. Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor and the Company
represent to the other the following with respect to itself:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;6.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
by the Company</U>. In consideration of the Investor&rsquo;s execution and delivery of this Agreement and acquiring the Common Shares
hereunder, and in addition to all of the Company&rsquo;s other obligations under this Agreement, the Company shall defend, protect, indemnify
and hold harmless the Investor, its investment manager, Yorkville Advisors Global, LP, and their respective Affiliates, and each of the
foregoing&rsquo;s respective officers, directors, managers, members, partners, employees and agents (including, without limitation, those
retained in connection with the transactions contemplated by this Agreement) and each Person who controls any of the foregoing within
the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &ldquo;<U>Investor Indemnitees</U>&rdquo;)
from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and reasonable
and documented expenses in connection therewith (irrespective of whether any such Investor Indemnitee is a party to the action for which
indemnification hereunder is sought), and including reasonable and documented attorneys&rsquo; fees and disbursements (the &ldquo;<U>Indemnified
Liabilities</U>&rdquo;), incurred by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (a)&nbsp;any
untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration of the Common
Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement thereto,
or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading; <U>provided</U>, <U>however</U>, that the Company will not be liable in any such case to
the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement
or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or
on behalf of the Investor specifically for inclusion therein; (b)&nbsp;any material misrepresentation or breach of any material representation
or material warranty made by the Company in this Agreement or any other certificate, instrument or document contemplated hereby or thereby;
or (c)&nbsp;any material breach of any material covenant, material agreement or material obligation of the Company contained in this Agreement
or any other certificate, instrument or document contemplated hereby or thereby. To the extent that the foregoing undertaking by the Company
may be unenforceable under Applicable Law, the Company shall make the maximum contribution to the payment and satisfaction of each of
the Indemnified Liabilities, which is permissible under Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;6.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
by the Investor</U>. In consideration of the Company&rsquo;s execution and delivery of this Agreement, and in addition to all of the Investor&rsquo;s
other obligations under this Agreement, the Investor shall defend, protect, indemnify and hold harmless the Company, its Subsidiaries
and all of their respective officers, directors, stockholders, employees and agents (including, without limitation, those retained in
connection with the transactions contemplated by this Agreement) and each Person who controls the Company within the meaning of Section&nbsp;15
of the Securities Act or Section&nbsp;20 of the Exchange Act (collectively, the &ldquo;<U>Company Indemnitees</U>&rdquo;) from and against
any and all Indemnified Liabilities incurred by the Company Indemnitees or any of them as a result of, or arising out of, or relating
to (a)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement for the registration
of the Common Shares as originally filed or in any amendment thereof, or in any related prospectus, or in any amendment thereof or supplement
thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading; <U>provided</U>, <U>however</U>, that the Investor will only be liable for
written information relating to the Investor furnished to the Company by or on behalf of the Investor specifically for inclusion in the
documents referred to in the foregoing indemnity, and will not be liable in any such case to the extent that any such loss, claim, damage
or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made
therein in reliance upon and in conformity with written information furnished to the Investor by or on behalf of the Company specifically
for inclusion therein; (b)&nbsp;any misrepresentation or breach of any representation or warranty made by the Investor in this Agreement
or any instrument or document contemplated hereby or thereby executed by the Investor; or (c)&nbsp;any breach of any covenant, agreement
or obligation of the Investor contained in this Agreement or any other certificate, instrument or document contemplated hereby or thereby
executed by the Investor. To the extent that the foregoing undertaking by the Investor may be unenforceable under Applicable Laws, the
Investor shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible
under Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;6.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
of Claim</U>. Promptly after receipt by an Investor Indemnitee or Company Indemnitee of notice of the commencement of any action or proceeding
(including any governmental action or proceeding) involving an Indemnified Liability, such Investor Indemnitee or Company Indemnitee,
as applicable, shall, if a claim for an Indemnified Liability in respect thereof is to be made against any indemnifying party under this
Article&nbsp;VI, deliver to the indemnifying party a written notice of the commencement thereof; but the failure to so notify the indemnifying
party will not relieve it of liability under this Article&nbsp;VI except to the extent the indemnifying party is prejudiced by such failure.
The indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any
other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually reasonably satisfactory to
the indemnifying party and the Investor Indemnitee or Company Indemnitee, as the case may be; provided, however, that an Investor Indemnitee
or Company Indemnitee shall have the right to retain its own counsel with the actual and reasonable third party fees and expenses of
not more than one counsel for such Investor Indemnitee or Company Indemnitee to be paid by the indemnifying party, if, in the reasonable
opinion of counsel retained by the indemnifying party, the representation by such counsel of the Investor Indemnitee or Company Indemnitee
and the indemnifying party would be inappropriate due to actual or potential differing interests between such Investor Indemnitee or
Company Indemnitee and any other party represented by such counsel in such proceeding. The Investor Indemnitee or Company Indemnitee
shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying
party and shall furnish to the indemnifying party all information reasonably available to the Investor Indemnitee or Company Indemnitee
which relates to such action or claim, unless (i)&nbsp;such cooperation or furnishing of information is likely to, in the opinion of
the applicable Investor Indemnitee&rsquo;s or Company Indemnitee&rsquo;s counsel, result in the waiver of attorney client privilege,
or (ii)&nbsp;the interests of the Investor Indemnitee or Company Indemnitee, as the case may be, and the indemnifying party conflict
or are adverse with respect to a particular action or claim. The indemnifying party shall keep the Investor Indemnitee or Company Indemnitee
reasonably apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall
be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the
indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written
consent of the Investor Indemnitee or Company Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise
which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Investor Indemnitee or Company
Indemnitee of a release from all liability in respect to such claim or litigation. Following indemnification as provided for hereunder,
the indemnifying party shall be subrogated to all rights of the Investor Indemnitee or Company Indemnitee with respect to all third parties,
firms or corporations relating to the matter for which indemnification has been made. The indemnification required by this Article&nbsp;VI
shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received
and payment therefor is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;6.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
The remedies provided for in this Article&nbsp;VI are not exclusive and shall not limit any right or remedy which may be available to
any indemnified Person at law or equity. The obligations of the parties to indemnify or make contribution under this Article&nbsp;VI
shall survive expiration or termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;6.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitation
of liability</U>. Notwithstanding the foregoing, no Party shall seek, nor shall any be entitled to recover from the other Party be liable
for, punitive, indirect, incidental, consequential or exemplary damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;VII.<BR>
Covenants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company covenants with
the Investor, and the Investor covenants with the Company, as follows, which covenants of one party are for the benefit of the other party,
during the Commitment Period:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effective
Registration Statement</U>. During the Commitment Period, the Company shall maintain the continuous effectiveness of each Registration
Statement filed with the SEC under the Securities Act pursuant to and in accordance with the Registration Rights Agreement; provided,
however, that in the event there are no Pre-Paid Advances outstanding, the Company shall only be required to use its commercially reasonable
efforts to maintain the continuous effectiveness of the Registration Statement and each subsequent Registration Statement filed with the
SEC under the Securities Act pursuant to and in accordance with the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
and Listing</U>. The Company shall cause the Common Shares to continue to be registered as a class of securities under Section&nbsp;12(b)&nbsp;of
the Exchange Act, and to comply with its reporting and filing obligations under the Exchange Act, and shall not take any action or file
any document (whether or not permitted by the Securities Act or the Exchange Act) to terminate or suspend such registration or to terminate
or suspend its reporting and filing obligations under the Exchange Act or Securities Act, except as permitted herein. The Company shall
continue the listing and trading of its Common Shares and the listing of the Common Shares purchased by the Investor hereunder on the
Principal Market and to comply with the Company&rsquo;s reporting, filing and other obligations under the rules&nbsp;and regulations of
the Principal Market. If the Company receives any final and non-appealable written notice that the listing or quotation of the Common
Shares on the Principal Market shall be terminated on a date certain, the Company shall promptly (and in any case within 24 hours of the
receipt thereof) notify the Investor of such fact in writing and shall use its commercially reasonable efforts to cause the Common Shares
to be listed or quoted on another Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Blue
Sky</U>. The Company shall take such action, if any, as is necessary by the Company in order to obtain an exemption for or to qualify
the Common Shares for sale by the Company to the Investor pursuant to the Transaction Documents, and at the request of the Investor, the
subsequent resale of Registrable Securities by the Investor, in each case, under applicable state securities or &ldquo;Blue Sky&rdquo;
laws and shall provide evidence of any such action so taken to the Investor from time to time during the Commitment Period; <U>provided</U>,
<U>however</U>, that the Company shall not be required in connection therewith or as a condition thereto to (w)&nbsp;make any change to
its Certificate of Incorporation or Bylaws or any other organizational documents of the Company or any of its Subsidiaries, (x)&nbsp;qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section&nbsp;7.03, (y)&nbsp;subject
itself to general taxation in any such jurisdiction, or (z)&nbsp;file a general consent to service of process in any such jurisdiction.
The Company shall promptly notify the Investor of the receipt by the Company of any notification with respect to the suspension of the
registration or qualification of any of the Common Shares for sale under the securities or &ldquo;blue sky&rdquo; laws of any jurisdiction
in the United States or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Suspension
of Registration Statement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><U>Establishment
of a Black Out Period</U>. During the Commitment Period, the Company from time to time may suspend the use of a Registration Statement
by written notice to the Investor in the event that the Company determines in good faith that such suspension is necessary to (i)&nbsp;delay
the disclosure of material non-public information concerning the Company, the disclosure of which at the time is not, in good faith opinion,
in the best interests of the Company or (ii)&nbsp;amend or supplement the Registration Statement or Prospectus so that such Registration
Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (a &ldquo;<U>Black
Out Period</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>No Sales by Investor During the Black Out Period</U>. During such Black Out Period, the Investor agrees
not to sell any Common Shares of the Company pursuant to such Registration Statement, but may sell shares pursuant to an exemption from
registration, if available, subject to the Investor&rsquo;s compliance with Applicable Laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><U>Limitations on the Black Out Period</U>. The Company shall not impose any Black Out Period that is
longer than 20 days or in a manner that is more restrictive (including, without limitation, as to duration) than the comparable restrictions
that the Company may impose on transfers of the Company&rsquo;s equity securities by its directors and senior executive officers. In addition,
the Company shall not deliver any Advance Notice during any Black Out Period. If the public announcement of such material, nonpublic information
is made during a Black Out Period, the Black Out Period shall terminate immediately after such announcement, and the Company shall immediately
notify the Investor of the termination of the Black Out Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing
of Common Shares</U>. As of each Advance Notice Date and the applicable Advance Date, the Common Shares to be sold by the Company from
time to time hereunder will have been registered under Section&nbsp;12(b)&nbsp;of the Exchange Act and approved for listing on the Principal
Market, subject to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.06<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Opinion
of Counsel</U>. Prior to the date of the delivery by the Company of the first Advance Notice and each Pre-Paid Advance, the Investor shall
have received an opinion letter from counsel to the Company in form and substance reasonably satisfactory to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.07<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exchange
Act Registration</U>. The Company will file in a timely manner all reports and other documents required of it as a reporting company under
the Exchange Act (giving effect to permissible extensions in accordance with Rule&nbsp;12b-25 under the Exchange Act) and, during the
Commitment Period, will not take any action or file any document (whether or not permitted by Exchange Act or the rules&nbsp;thereunder)
to terminate or suspend its reporting and filing obligations under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.08<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
Agent Instructions</U>. During the Commitment Period and subject to Applicable Laws, the Company shall cause (including, if necessary,
by causing legal counsel for the Company to deliver an opinion) the transfer agent for the Common Shares to remove restrictive legends
from Common Shares purchased by the Investor pursuant to this Agreement, provided that counsel for the Company shall have been furnished
with such documents as they may require for the purpose of enabling them to render the opinions or make the statements requested by the
transfer agent, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the covenants,
obligations or conditions, contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.09<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Corporate
Existence</U>. The Company will use commercially reasonable efforts to preserve and continue the corporate existence of the Company during
the Commitment Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.10<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
of Certain Events Affecting Registration; Suspension of Right to Make an Advance</U>. The Company will promptly notify the Investor, and
confirm in writing, upon its becoming aware of the occurrence of any of the following events in respect of a Registration Statement or
related Prospectus (in each of which cases, if the information constitutes material non-public information, the information provided to
the Investor will be kept confidential until disclosed by the Company): (i)&nbsp;receipt of any request for additional information by
the SEC or any other Federal or state governmental authority during the period of effectiveness of the Registration Statement, the response
to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus, or any request for
amendments or supplements to the Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the SEC or any other Federal governmental
authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose;
(iii)&nbsp;receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the
Common Shares for sale in any jurisdiction or the initiation or written threat of any proceeding for such purpose; (iv)&nbsp;the happening
of any event that makes any statement made in the Registration Statement or related Prospectus or any document incorporated or deemed
to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, related Prospectus or documents so that, in the case of the Registration Statement, it will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading,
and that in the case of the related Prospectus, it will not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading, or of the necessity to amend the Registration Statement or supplement a related Prospectus to comply with the Securities
Act or any other law (and the Company will promptly make available to the Investor any such supplement or amendment to the related Prospectus
provided, however, the Company shall not be required to furnish any document to the extent such document is available on EDGAR); (v)&nbsp;the
Company&rsquo;s reasonable determination that a post-effective amendment to the Registration Statement would be required under Applicable
Law; (vi)&nbsp;the Common Shares shall cease to be authorized for listing on the Principal Market; or (vii)&nbsp;the Company fails to
file in a timely manner all reports and other documents required of it as a reporting company under the Exchange Act. The Company shall
not deliver to the Investor any Advance Notice, and the Company shall not sell any Common Shares pursuant to any pending Advance Notice
(other than as required pursuant to Section&nbsp;3.05(d)), during the continuation of any of the foregoing events (each of the events
described in the immediately preceding clauses (i)&nbsp;through (vii), inclusive, a &ldquo;<U>Material Outside Event</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.11<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consolidation</U>.
If an Advance Notice has been delivered to the Investor, then the Company shall not effect any consolidation of the Company with or into,
or a transfer of all or substantially all the assets of the Company to another entity before the transaction contemplated in such Advance
Notice has been closed in accordance with &lrm;Section&nbsp;3.05 hereof, and all Common Shares in connection with such Advance have been
received by the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.12<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Issuance
of the Company&rsquo;s Common Shares.</U> The issuance and sale of the Common Shares hereunder shall be made in accordance with the provisions
and requirements of Section&nbsp;4(a)(2)&nbsp;of the Securities Act and any applicable state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.13<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reservation
of Shares</U>. As of the date of each Pre-Advance Closing, and at all times thereafter, the Company shall have reserved from its duly
authorized capital stock not less than the number of Common Shares issuable upon conversion of all Promissory Notes (assuming for purposes
hereof that (x)&nbsp;such Promissory Note is convertible at a conversion price equal to the Floor Price as of the date of determination,
and (y)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Promissory Note set forth therein)
(the &ldquo;<U>Maximum Conversion Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.14<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stockholder
Approval</U>. Within 180 calendar days of the date of this Agreement, the Company shall hold a special meeting of stockholders (which
may also be at the annual meeting of stockholders) (the &ldquo;<U>Special Meeting</U>&rdquo;) for the purpose of seeking the approval
by the Company&rsquo;s stockholders of (i)&nbsp;the issuance of the Common Shares issuable pursuant to the this Agreement (without regard
to the Exchange Cap) in compliance with the rules&nbsp;and regulations of the Principal Market, including Rule&nbsp;5635(d)&nbsp;thereof)
(the &ldquo;<U>SEPA Stockholder Approval</U>&rdquo;) and (ii)&nbsp;the issuance of the Maximum Conversion Shares issuable upon conversion
of the Promissory Notes (without regard to the Exchange Cap) in compliance with the rules&nbsp;and regulations of the Principal Market,
including Rule&nbsp;5635(d)&nbsp;thereof (without regard to any limitation on conversion or exercise thereof) (the &ldquo;<U>Promissory
Note Approval</U>&rdquo;), with the recommendation of the Company&rsquo;s Board of Directors that such proposals be approved. The Company
shall include the SEPA Stockholder Approval and the Promissory Note Approval in the Proxy Statement and shall use its commercially reasonable
efforts to solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in the Proxy
Statement, and all management-appointed proxyholders shall vote their proxies in favor of such proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.15<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay all reasonable
and documented expenses incident to the performance of its obligations hereunder, including but not limited to (i)&nbsp;the preparation,
printing and filing of the Registration Statement and each amendment and supplement thereto, of each Prospectus and of each amendment
and supplement thereto; (ii)&nbsp;the preparation, issuance and delivery of any Common Shares issued pursuant to this Agreement, (iii)&nbsp;all
fees and disbursements of the Company&rsquo;s counsel, accountants and other advisors (but not, for the avoidance doubt, the fees and
disbursements of Investor&rsquo;s counsel, accountants and other advisors), (iv)&nbsp;the qualification of the Common Shares under securities
laws in accordance with the provisions of this Agreement, including filing fees in connection therewith, (v)&nbsp;the printing and delivery
of copies of any Prospectus and any amendments or supplements thereto reasonably requested by the Investor, (vi)&nbsp;the fees and expenses
incurred in connection with the listing or qualification of the Common Shares for trading on the Principal Market, and (vii)&nbsp;filing
fees of the SEC and the Principal Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.16<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Current
Report and Form&nbsp;10-K.</U> The Company shall, not later than 9:00 a.m., New York City time, on the fourth business day after the date
of this Agreement, file with the SEC a current report on Form&nbsp;8-K&nbsp;describing all the material terms of the transactions contemplated
by the Transaction Documents in the form required by the Exchange Act and attaching all the material Transaction Documents (including
any exhibits thereto, the &ldquo;<U>Current Report</U>&rdquo;). The Company shall provide the Investor and its legal counsel a reasonable
opportunity to comment on a draft of the Current Report including any exhibits to be filed related thereto, as applicable, prior to filing
the Current Report with the SEC and shall reasonably consider all such comments. Notwithstanding anything contained in this Agreement
to the contrary, the Company expressly agrees that from and after the filing of the Company&rsquo;s Annual Report on Form&nbsp;10-K for
the year ended December&nbsp;31, 2025 (&ldquo;Form&nbsp;10-K&rdquo;) with the SEC, the Company shall have publicly disclosed all material,
non-public information provided to the Investor (or the Investor&rsquo;s representatives or agents) by the Company or any of its Subsidiaries,
or any of their respective officers, directors, employees, agents or representatives (if any) in connection with the transactions contemplated
by the Transaction Documents.&nbsp;The Company shall not, and the Company shall cause each of its Subsidiaries and each of its and their
respective officers, directors, employees and agents not to, provide the Investor with any material, non-public information regarding
the Company or any of its Subsidiaries without the express prior written consent of the Investor (which may be granted or withheld in
the Investor&rsquo;s sole discretion). Notwithstanding anything contained in this Agreement to the contrary, the Company expressly agrees
that it shall publicly disclose in the Form&nbsp;10-K or otherwise make publicly available any information communicated to the Investor
by or, to the knowledge of the Company, on behalf of the Company in connection with the transactions contemplated by the Transaction Documents,
which, following the date upon which the Company files with the SEC the Company&rsquo;s Form&nbsp;10-K would, if not so disclosed, constitute
material, non-public information regarding the Company or its Subsidiaries. The Company understands and confirms that the Investor will
rely on the foregoing representations in effecting resales of Common Shares. In addition, effective upon the filing of the Form&nbsp;10-K,
the Company acknowledges and agrees that any and all confidentiality or similar obligations with respect to the transactions contemplated
by the Transaction Documents under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, Affiliates, employees or agents, on the one hand, and Investor or any of its respective officers, directors,
Affiliates, employees or agents, on the other hand, shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.17<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Advance
Notice Limitation</U>. The Company shall not deliver an Advance Notice if a shareholder meeting or corporate action, or the record date
for any shareholder meeting or any corporate action, would fall during the period beginning two Trading Days prior to the date of delivery
of such Advance Notice and ending two Trading Days following the Closing of such Advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.18<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Use
of Proceeds; Subsidiary Guaranty</U>. <U>Use of Proceeds</U>. Neither the Company nor any Subsidiary will, directly or indirectly, use
the proceeds of the transactions contemplated herein to repay any advances or loans to any executives, directors, or employees of the
Company or any Subsidiary or to make any payments in respect of any related party obligations, including without limitation any payables
or notes payable to related parties of the Company or any Subsidiary whether or not such amounts are described on the balance sheets of
the Company in any SEC Documents and any Subsidiary or described in any &ldquo;Related Party Transactions&rdquo; section of any SEC Documents,
other than in connection with Permitted Related Party Payments. Neither the Company nor any of its Subsidiaries will, directly or indirectly,
use the proceeds from the transactions contemplated herein, or lend, contribute, facilitate, or otherwise make available such proceeds
to any Subsidiary, joint venture partner or other Person (a)&nbsp;for the purpose of funding or facilitating, directly or indirectly,
any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is
or whose government is, the subject of Sanctions or is a Sanctioned Country, or (b)&nbsp;in any other manner that will result in a violation
of Sanctions or Applicable Laws by any Person (including any Person participating in the transactions contemplated by this Agreement,
whether as underwriter, advisor, investor or otherwise). The Company shall not without the prior written consent of the Investor loan,
invest, transfer or &ldquo;downstream&rdquo; any cash proceeds, or assets or property acquired with cash proceeds from the issuance and
sale of the Promissory Note to any Subsidiary, unless such Subsidiary has entered into a subsidiary guaranty with the Investor in the
form of the Global Guaranty Agreement. For the avoidance of doubt, the Company may pay the operating expenses of any Subsidiary in the
ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.19<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Laws</U>. The Company shall comply in all material respects with all Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.20<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Market
Activities</U>. Neither the Company, nor any Subsidiary, nor any of their respective officers, directors or controlling persons will,
directly or indirectly, (i)&nbsp;take any action designed to cause or result in, or that constitutes or might reasonably be expected to
constitute or result, in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of Common Shares or (ii)&nbsp;sell, bid for, or purchase Common Shares in violation of Regulation M, or pay anyone any compensation for
soliciting purchases of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.21<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Trading
Information</U>. Upon the Company&rsquo;s request, the Investor agrees to provide the Company on any Trading Day that the Investor sells
Common Shares with a trading report by the following Trading Day setting forth the number and average sales prices of Common Shares sold
by the Investor on such Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.22<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Selling
Restrictions</U>. Except as expressly set forth below, the Investor covenants that from and after the date hereof through and including
the Trading Day next following the expiration or termination of this Agreement as provided in Section&nbsp;10.01 (the &ldquo;<U>Restricted
Period</U>&rdquo;), none of the Investor any of its officers, or any entity managed or controlled by the Investor (collectively, the &ldquo;<U>Restricted
Persons</U>&rdquo; and each of the foregoing is referred to herein as a &ldquo;<U>Restricted Person</U>&rdquo;) shall, directly or indirectly,
engage in any &ldquo;short sale&rdquo; (as such term is defined in Rule&nbsp;200 of Regulation SHO of the Exchange Act) of the Common
Shares, either for its own principal account or for the principal account of any other Restricted Person, solely to the extent such &ldquo;short
sale&rdquo; establishes a net short position in the Common Shares. Notwithstanding the foregoing, it is expressly understood and agreed
that nothing contained herein shall (without implication that the contrary would otherwise be true) prohibit any Restricted Person during
the Restricted Period from: (1)&nbsp;selling &ldquo;long&rdquo; (as defined under Rule&nbsp;200 promulgated under Regulation SHO) any
Common Shares; (2)&nbsp;selling a number of Common Shares equal to the number of Advance Shares that such Restricted Person is unconditionally
obligated to purchase under a pending Advance Notice but has not yet received from the Company or the transfer agent pursuant to this
Agreement; or (3)&nbsp;selling a number of shares of Common Shares equal to the number of Common Shares that the Investor is entitled
to receive, but has not yet received from the Company or the transfer agent, upon the completion of a pending conversion of the Promissory
Note for which a valid Conversion Notice (as defined in the Promissory Note) has been submitted to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.23<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Assignment</U>.
This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and permitted assigns.
No Party shall have any power or any right to assign or transfer, in whole or in part, this Agreement, or any of its rights or any of
its obligations hereunder, including, without limitation, any right to pursue any claim for damages pursuant to this Agreement or the
transactions contemplated herein, or to pursue any claim for any breach or default of this Agreement, or any right arising from the purported
assignor&rsquo;s due performance of its obligations hereunder, without the prior written consent of the other Party and any such purported
assignment in contravention of the provisions herein shall be null and void and of no force or effect. Without the consent of the Investor,
the Company shall not have the right to assign or transfer any of its rights or provide any third party the right to bind or obligate
the Company, to deliver Advance Notices or effect Advances hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.24<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Non-Public
Information</U>. The Company covenants and agrees that, other than as expressly required by &lrm;Section&nbsp;7.10 hereof, it shall refrain
from disclosing, and shall cause its officers, directors, employees and agents to refrain from disclosing, any material non-public information
(as determined under the Securities Act, the Exchange Act, or the rules&nbsp;and regulations of the SEC) to the Investor without also
disseminating such information to the public, unless prior to disclosure of such information the Company identifies such information as
being material non-public information and the Investor agrees in writing to accept such material non-public information for review. Unless
specifically agreed to in writing, in no event shall the Investor have a duty of confidentiality or be deemed to have agreed to maintain
information in confidence, with respect to the delivery of any Advance Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.25<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Frustration; No Variable Rate Transactions, Etc.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>No Frustration</U>. The Company shall not enter into, announce or recommend to its stockholders any
agreement, plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair
the ability or right of the Company to perform its obligations under the Transaction Documents to which it is a party, including, without
limitation, the obligation of the Company to deliver the Common Shares to the Investor in respect of an Advance Notice (including an Advance
Notice deemed delivered in respect of an Investor Notice).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>No Variable Rate Transactions or Related Party Payments</U>. From the date hereof until the date upon
which the Promissory Notes to be issued hereunder has been repaid in full, the Company shall not (A)&nbsp;repay any loans to any executives
or employees of the Company or to make any payments in respect of any related party debt (other than Permitted Related Party Payments),
and (B)&nbsp;effect or enter into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Shares or any
security which entitles the holder to acquire Common Shares (or a combination of units thereof) involving a Variable Rate Transaction,
other than involving a Variable Rate Transaction with the Investor. The Investor shall be entitled to seek injunctive relief against the
Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages, without
the necessity of showing economic loss and without any bond or other security being required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">From the date hereof until the Promissory Notes to be issued hereunder have been repaid in full, without
the prior written consent of the Investor, neither the Company, nor any Subsidiary shall, directly or indirectly (i)&nbsp;other than Permitted
Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any Indebtedness, or (ii)&nbsp;other than Permitted Liens,
enter into, create, incur, assume or suffer to exist any Lien on or with respect to any of its property or assets now owned or hereafter
acquired or any interest therein or any income or profits therefrom.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;7.26<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limited
Right of First Refusal</U>. For six (6)&nbsp;months following the date upon which the Promissory Notes to be issued hereunder has been
repaid in full, the Company shall not enter into or effect any Variable Rate Transaction without first giving prior written notice (the
&ldquo;<U>Notice</U>&rdquo;) to the Investor of its intention to enter into or effect such transaction, which Notice shall set forth the
material terms of such transaction. Upon receipt of a Notice, the Investor shall have five (5)&nbsp;Business Days from such receipt (the
&ldquo;<U>Notice Period</U>&rdquo;) to confirm to the Company whether it will participate (exclusively or otherwise, and including through
any affiliates if necessary for regulatory purposes) in such transaction in accordance with the terms set forth in the Notice (the &ldquo;<U>Right
of First Refusal</U>&rdquo;). If the Investor exercises the Right of First Refusal, within ten (10)&nbsp;Business Days from such exercise,
the Parties will enter into binding documentation in form and substance that are on the same terms as set forth in the Notice for such
transaction. If the Investor declines to exercise the Right of First Refusal with respect to a particular transaction or fails to exercise
the Right of First Refusal within the time period provided in this Section&nbsp;7.26, the Company is permitted to subsequently enter into
such transaction with a third party, provided, that such transaction (i)&nbsp;is consummated on terms (A)&nbsp;consistent with the Notice
for such transaction and (B)&nbsp;no more beneficial than those terms offered to the Investor in the Notice and (ii)&nbsp;is consummated
within 60 days of the Investor declining to exercise or failing to timely exercise the Right of First Refusal with respect to such transaction.
For the avoidance of doubt, during the six (6)&nbsp;months that this Section&nbsp;7.26 is in effect, the Company shall not enter into
or effect any Variable Rate Transaction unless (x)&nbsp;the Company provides the Notice for such Variable Rate Transaction, (y)&nbsp;the
Company provides the Investor with the opportunity to exercise the Right of First Refusal during the Notice Period and (z)&nbsp;the Investor
declines to exercise or fails to timely exercise the Right of First Refusal during the Notice Period. The Right of First Refusal contained
in this Section&nbsp;7.26 shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;VIII.<BR>
Non-Exclusive Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to Section&nbsp;7.25
hereof, this Agreement and the rights awarded to the Investor hereunder are non-exclusive, and the Company may, at any time throughout
the term of this Agreement and thereafter, issue and allot, or undertake to issue and allot, any shares and/or securities and/or convertible
notes, bonds, debentures, options to acquire shares or other securities and/or other facilities which may be converted into or replaced
by Common Shares or other securities of the Company, and to extend, renew and/or recycle any bonds and/or debentures, and/or grant any
rights with respect to its existing and/or future share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;IX.<BR>
Choice of Law/Jurisdiction; Waiver of Jury Trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;9.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement, and any and all claims, proceedings or causes of action relating to this Agreement or arising from this Agreement or the transactions
contemplated herein, including, without limitation, tort claims, statutory claims and contract claims, shall be interpreted, construed,
governed and enforced under and solely in accordance with the substantive and procedural laws of the State of New York, in each case as
in effect from time to time and as the same may be amended from time to time, and as applied to agreements performed wholly within the
State of New York. The Parties further agree that any action between them shall be heard in New York County, New York, and expressly consent
to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the United States District Court
of the Southern District of New York, sitting in New York, New York, for the adjudication of any civil action asserted pursuant to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;9.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>EACH
PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY&nbsp;HAVE TO A TRIAL BY JURY IN ANY LEGAL
PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN, THE PERFORMANCE
THEREOF OR THE FINANCINGS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A)&nbsp;CERTIFIES
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,&nbsp;IN
THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B)&nbsp;ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAVE BEEN INDUCED
TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS PARAGRAPH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;X. Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;10.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Unless earlier terminated as provided hereunder, this Agreement shall terminate automatically on the earlier
of (i)&nbsp;the 36-month anniversary of the Effective Date, provided that if any Promissory Notes are then outstanding, such termination
shall be delayed until such date that all Promissory Note that were outstanding have been repaid, or (ii)&nbsp;the date on which the Investor
shall have made payment of Advances pursuant to this Agreement for Common Shares equal to the Commitment Amount.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Company may terminate this Agreement effective upon five Trading Days&rsquo; prior written notice
to the Investor; provided that (i)&nbsp;there are no outstanding Advance Notices under which Common Shares have yet to be issued, (ii)&nbsp;there
is not an outstanding Promissory Note, and (iii)&nbsp;the Company has paid all amounts owed to the Investor pursuant to this Agreement.
This Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written
consent unless otherwise provided in such written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Nothing in this Section&nbsp;10.01 shall be deemed to release the Company or the Investor from any liability
for any breach under this Agreement prior to the valid termination hereof, or to impair the rights of the Company and the Investor to
compel specific performance by the other party of its obligations under this Agreement prior to the valid termination hereof. The indemnification
provisions contained in Article&nbsp;VI shall survive the termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;XI. Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than with respect to
Advance Notices, which must be in writing delivered in accordance with Section&nbsp;3.01 and will be deemed delivered on the day set forth
in &lrm;Section&nbsp;3.01(c), any notices, consents, waivers, or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered (i)&nbsp;upon receipt, when delivered personally; (ii)&nbsp;upon
receipt, when sent by e-mail if sent on a Trading Day, or, if not sent on a Trading Day, on the immediately following Trading Day; (iii)&nbsp;5
days after being sent by U.S. certified mail, return receipt requested, or (iv)&nbsp;1 day after deposit with a nationally recognized
overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications (except
for Advance Notices which shall be delivered in accordance with Exhibit&nbsp;C hereof) shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to the Company, to:</FONT></TD>
    <TD STYLE="width: 63%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">TransCode Therapeutics,&nbsp;Inc.<BR> 6 Liberty Square - #2382<BR> Boston, MA 02109<BR> Attn: Philippe P. Calais<BR> E-mail: </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2.5in">With copies (which shall not constitute notice or delivery of process) to:</TD>
    <TD STYLE="width: 63%">Orrick, Herrington&nbsp;&amp; Sutcliffe LLP<BR> 405 Howard Street<BR> San Francisco, California 94105<BR> Attn: Niki Fang,&nbsp;Esq.; David Schulman,&nbsp;Esq.<BR> E-mail:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to the Investor:</FONT></TD>
    <TD>YA II PN,&nbsp;Ltd.<BR> 1012 Springfield Avenue<BR> Mountainside, NJ 07092<BR> Attn:&#9;Mark Angelo<BR> E-mail: &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>With a copy (which shall not constitute notice or delivery of process) to:</TD>
    <TD>David Fine,&nbsp;Esq.<BR> 1012 Springfield Avenue<BR> Mountainside, NJ 07092<BR> E-mail: &nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or at such other address and/or e-mail and/or
to the attention of such other Person as the recipient party has specified by written notice given to each other party three Business
Days prior to the effectiveness of such change. Written confirmation of receipt (i)&nbsp;given by the recipient of such notice, consent,
waiver or other communication, (ii)&nbsp;electronically generated by the sender&rsquo;s email service provider containing the time, date,
and recipient email address or (iii)&nbsp;provided by a nationally recognized overnight delivery service shall be rebuttable evidence
of delivery in accordance with clause (i), (ii)&nbsp;or (iii)&nbsp;above, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Article&nbsp;XII. Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;12.01<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in identical counterparts, both which shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party. Facsimile or other electronically scanned and delivered
signatures (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the
Electronic Signatures and Records Act or other Applicable Law, <I>e.g.</I>, www.docusign.com), including by e-mail attachment, shall be
deemed to have been duly and validly delivered and be valid as originals and effective for all purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;12.02<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement; Amendments</U>. This Agreement and the other Transaction Documents supersede all other prior oral or written agreements between
the Investor, the Company, their respective Affiliates and Persons acting on their behalf with respect to the matters discussed herein
and therein, and this Agreement and the other Transaction Documents contain the entire understanding of the parties with respect to the
matters covered herein and, except as specifically set forth herein and therein, neither the Company nor the Investor makes any representation,
warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by
an instrument in writing signed by the parties to this Agreement. The&nbsp;failure of any party hereto to exercise any right, power or
remedy provided under this Agreement or otherwise available in respect hereof at law or in equity, or to insist upon strict compliance
by any other party hereto with its obligations hereunder, shall not constitute a waiver by such party of its right to exercise any such
right, power or remedy or any other right, power or remedy or to demand strict compliance with such obligations hereunder. No custom or
practice of the parties at variance with the terms hereof shall constitute a waiver by any party of its right to exercise any right, power
or remedy available to it hereunder or any other right, power or remedy or to demand strict compliance with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;12.03<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reporting
Entity for the Common Shares</U>. The reporting entity relied upon for the determination of the trading price or trading volume of the
Common Shares on any given Trading Day for the purposes of this Agreement shall be Bloomberg L.P. or any successor thereto. The written
mutual consent of the Investor and the Company shall be required to employ any other reporting entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;12.04<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Commitment
and Structuring Fee</U>. Each of the parties shall pay its own fees and expenses&nbsp;(including the fees of any attorneys, accountants,
appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby, except that the
Company has paid the Investor or its designee a structuring fee in the amount of $25,000. In addition, the Company shall pay a commitment
fee in an amount equal to 2.00% of the Commitment Amount (the &ldquo;<U>Commitment Fee</U>&rdquo;) which shall be paid on the earlier
of (i)&nbsp;the thirtieth Trading Day following the Effective Date, or (ii)&nbsp;the initial filing date of the initial Registration Statement
(the &ldquo;<U>Fee Due Date</U>&rdquo;). The Company may pay the Commitment Fee on the Fee Due Date either in cash, or by the issuance
to the Investor of such number of Common Shares that is equal to the Commitment Fee divided by the closing price of the Common Shares
as of the Trading Day immediately prior to the Fee Due Date (collectively, the &ldquo;<U>Commitment Shares</U>&rdquo;). Any Commitment
Shares issuable hereunder shall be included on the initial Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;12.05<FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Brokerage</U>.
Each of the parties hereto represents that it has had no dealings in connection with this transaction with any finder or broker who will
demand payment of any fee or commission from the other party. The Company on the one hand, and the Investor, on the other hand, agree
to indemnify the other against and hold the other harmless from any and all liabilities to any person claiming brokerage commissions or
finder&rsquo;s fees on account of services purported to have been rendered on behalf of the indemnifying party in connection with this
Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Standby Equity Purchase Agreement to be executed by the undersigned, thereunto duly authorized, as
of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-variant: small-caps"><B>TRANSCODE THERAPEUTICS,&nbsp;INC.</B></FONT> <FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Thomas A. Fitzgerald</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thomas A. Fitzgerald</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>YA II PN,&nbsp;Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yorkville Advisors Global, LP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Its:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment Manager</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 42%">Yorkville Advisors Global II, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Its:</TD>
    <TD>General Partner &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Matthew Beckman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Matthew Beckman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Manager</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX I TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STANDBY EQUITY PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>DEFINITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Additional Shares</U>&rdquo; shall have
the meaning set forth in Section&nbsp;3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Adjusted Advance Amount</U>&rdquo; shall
have the meaning set forth in Section&nbsp;3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Advance</U>&rdquo; shall mean any issuance
and sale of Advance Shares by the Company to the Investor pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Advance Date</U>&rdquo; shall mean the
first Trading Day after expiration of the applicable Pricing Period for each Advance, provided that, with respect to an Advance pursuant
to an Investor Notice, the Advance Date shall be the first Trading Day after the date of delivery of such Investor Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Advance Notice</U>&rdquo; shall mean
a written notice in the form of Exhibit&nbsp;C attached hereto to the Investor executed by an officer of the Company and setting forth
the number of Advance Shares that the Company desires to issue and sell to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Advance Notice Date</U>&rdquo; shall
mean each date the Company is deemed to have delivered (in accordance with Section&nbsp;3.01(c)&nbsp;of this Agreement) an Advance Notice
to the Investor, subject to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Advance Shares</U>&rdquo; shall mean
the Common Shares that the Company shall issue and sell to the Investor pursuant to an Advance Notice delivered in accordance with the
terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Affiliate</U>&rdquo; shall have the
meaning set forth in Section&nbsp;4.07.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Agreement</U>&rdquo; shall have the
meaning set forth in the preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Amortization Event</U>&rdquo; shall
have the meaning set forth in the Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Applicable Laws</U>&rdquo; shall mean
all applicable laws, statutes, rules, regulations, orders, executive orders, directives, policies, guidelines and codes having the force
of law, whether local, national, or international, as amended from time to time, including without limitation (i)&nbsp;all applicable
laws that relate to money laundering, terrorist financing, financial record keeping and reporting, (ii)&nbsp;all applicable laws that
relate to anti-bribery, anti-corruption, books and records and internal controls, including the United States Foreign Corrupt Practices
Act of 1977, and (iii)&nbsp;any Sanctions laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Black Out Period</U>&rdquo; shall have
the meaning set forth in Section&nbsp;7.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Closing</U>&rdquo; shall have the meaning
set forth in Section&nbsp;3.05.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Commitment Amount</U>&rdquo; shall mean
$14,000,000 of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Commitment Fee</U>&rdquo; shall have
the meaning set forth in Section&nbsp;12.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Commitment Shares</U>&rdquo; shall have
the meaning set forth in Section&nbsp;12.04.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Commitment Period</U>&rdquo; shall mean
the period commencing on the Effective Date and expiring upon the date of termination of this Agreement in accordance with Section&nbsp;10.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Common Share Equivalents</U>&rdquo;
shall mean any securities of the Company or its Subsidiaries which entitle the holder thereof to acquire at any time Common Shares, including,
without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Common Shares</U>&rdquo; shall have
the meaning set forth in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Company</U>&rdquo; shall have the meaning
set forth in the preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Company Indemnitees</U>&rdquo; shall
have the meaning set forth in Section&nbsp;6.02.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Condition Satisfaction Date</U>&rdquo;
shall have the meaning set forth in Annex III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Conversion Price</U>&rdquo; shall have
the meaning set forth in the Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Daily Traded Amount</U>&rdquo; shall
mean the daily trading volume of the Company&rsquo;s Common Shares on the Principal Market during regular trading hours as reported by
Bloomberg L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Effective Date</U>&rdquo; shall mean
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Environmental Laws</U>&rdquo; shall
have the meaning set forth in Section&nbsp;5.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Event of Default</U>&rdquo; shall have
the meaning set forth in the Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Exchange Act</U>&rdquo; shall mean the
U.S. Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Exchange Cap</U>&rdquo; shall have the
meaning set forth in Section&nbsp;3.02(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Excluded Day</U>&rdquo; shall have the
meaning set forth in Section&nbsp;3.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Fixed Price</U>&rdquo; shall have the
meaning set forth in the Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Floor Price</U>&rdquo; shall have the
meaning set forth in each Promissory Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Global Guaranty Agreement</U>&rdquo;
shall mean the global guaranty agreement in the form attached hereto as <U>Exhibit&nbsp;F</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Hazardous Materials</U>&rdquo; shall
have the meaning set forth in Section&nbsp;5.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Indebtedness</U>&rdquo; of any Person
means, without duplication (i)&nbsp;all indebtedness for borrowed money, (ii)&nbsp;all obligations issued, undertaken or assumed as the
deferred purchase price of property or services (including, without limitation, &ldquo;capital leases&rdquo; in accordance with GAAP)
(other than trade payables entered into in the ordinary course of business consistent with past practice), (iii)&nbsp;all reimbursement
or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (iv)&nbsp;all obligations evidenced
by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of
property, assets or businesses, (v)&nbsp;all indebtedness created or arising under any conditional sale or other title retention agreement,
or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even
though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale
of such property), (vi)&nbsp;all monetary obligations under any leasing or similar arrangement which, in connection with GAAP, consistently
applied for the periods covered thereby, is classified as a capital lease, (vii)&nbsp;all indebtedness referred to in clauses (i)&nbsp;through
(f)&nbsp;above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured
by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which
owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (viii)&nbsp;all Contingent Obligations
in respect of indebtedness or obligations of others of the kinds referred to in clauses (i)&nbsp;through (vii)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Indemnified Liabilities</U>&rdquo; shall
have the meaning set forth in Section&nbsp;6.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Investor</U>&rdquo; shall have the meaning
set forth in the preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Investor Notice</U>&rdquo; shall mean
a written notice to the Company in the form set forth herein as <U>Exhibit&nbsp;E</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Investor Indemnitees</U>&rdquo; shall
have the meaning set forth in Section&nbsp;6.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Lien</U>&rdquo; shall mean any (i)&nbsp;mortgage,
(ii)&nbsp;right of way, (iii)&nbsp;easement, (iv)&nbsp;encroachment, (v)&nbsp;restriction on use, (vi)&nbsp;servitude, (vii)&nbsp;pledge,
(viii)&nbsp;lien, (ix)&nbsp;charge, (x)&nbsp;hypothecation, (xi)&nbsp;security interest, (xii)&nbsp;encumbrance, (xiii)&nbsp;adverse right,
interest or claim, (xiv)&nbsp;community or other marital property interest, (xv)&nbsp;condition, (xvi)&nbsp;equitable interest, (xvii)&nbsp;encumbrance,
(xviii)&nbsp;license, (xix)&nbsp;covenant, (xx)&nbsp;title defect, (xxi)&nbsp;option, (xxii)&nbsp;right of first refusal or offer or similar
restriction, (xxiii)&nbsp;voting right, (xxiv)&nbsp;transfer restriction, or (xxv)&nbsp;receipt of income or exercise of any other attribute
of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Market Price</U>&rdquo; shall mean the
lowest daily VWAP of the Common Shares during the Pricing Period, other than the daily VWAP on an Excluded Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Material Adverse Effect</U>&rdquo; shall
mean any event, occurrence or condition that has had or would reasonably be expected to have (i)&nbsp;a material adverse effect on the
legality, validity or enforceability of this Agreement or the transactions contemplated herein, (ii)&nbsp;a material adverse effect on
the results of operations, assets, business or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole,
or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Material Outside Event</U>&rdquo; shall
have the meaning set forth in Section&nbsp;7.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Maximum Advance Amount</U>&rdquo; means
(A)&nbsp;in respect of each Advance Notice delivered by the Company pursuant to Section&nbsp;3.01(a)&nbsp;of this Agreement, the greater
of (i)&nbsp;an amount equal to one hundred percent (100%) of the average of the Daily Traded Amount during the five consecutive Trading
Day immediately preceding an Advance Notice, and (ii)&nbsp;five hundred thousand (500,000) Common Shares, and (B)&nbsp;in respect of each
Advance Notice deemed delivered by the Company pursuant to an Investor Notice, the amount selected by the Investor in such Investor Notice,
which amount shall not exceed the limitations set forth in Section&nbsp;3.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Minimum Acceptable Price</U>&rdquo;
shall mean the minimum price notified by the Company to the Investor in each Advance Notice, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Notice</U>&rdquo; shall have the meaning
set forth in Section&nbsp;7.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Notice Period</U>&rdquo; shall have
the meaning set forth in Section&nbsp;7.25.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>OFAC</U>&rdquo; shall have the meaning
set forth in Section&nbsp;5.32.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Ownership Limitation</U>&rdquo; shall
have the meaning set forth in Section&nbsp;3.02(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Permitted Indebtedness</U>&rdquo; shall
mean: (i)&nbsp;indebtedness in respect of the Promissory Notes; (ii)&nbsp;indebtedness (A)&nbsp;the repayment of which has been subordinated
to the payment of the Promissory Notes on terms and conditions acceptable to the Investor, including with regard to interest payments
and repayment of principal, (B)&nbsp;which does not mature or otherwise require or permit redemption or repayment prior to or on the 91st
day after the maturity date of the Promissory Note; and (C)&nbsp;which is not secured by any assets; and (iii)&nbsp;any indebtedness (other
than the indebtedness set out in (i)&nbsp;&ndash; (ii)&nbsp;above) incurred after the date hereof, provided that such indebtedness does
not exceed $500,000 at any given time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Permitted Liens</U>&rdquo; shall mean
(i)&nbsp;any security interest granted to the Investor, (ii)&nbsp;inchoate Liens for taxes, assessments or governmental charges or levies
(A)&nbsp;not yet due, as to which the grace period, if any, related thereto has not yet expired, or (B)&nbsp;being contested in good faith
and by appropriate proceedings for which adequate reserves have been established in accordance with GAAP; (iii)&nbsp;Liens of carriers,
materialmen, warehousemen, mechanics and landlords and other similar Liens which secure amounts which are not yet overdue by more than
60 days or which are being contested in good faith by appropriate proceedings for which adequate reserves have been established in accordance
with GAAP; (iv)&nbsp;licenses, sublicenses, leases or subleases granted to other persons not materially interfering with the conduct of
the business of the Company or any Subsidiary; (v)&nbsp; Liens incurred in the ordinary course of business in connection with workers
compensation claims, unemployment insurance, pension liabilities and social security benefits and Liens securing the performance of bids,
tenders, leases and contracts in the ordinary course of business, statutory obligations, surety bonds, performance bonds and other obligations
of a like nature (other than appeal bonds) incurred in the ordinary course of business (exclusive of obligations in respect of the payment
for borrowed money); and (vi)&nbsp;Liens in favor of a banking institution arising by operation of law encumbering deposits (including
the right of set-off) and contractual set-off rights held by such banking institution and which are within the general parameters customary
in the banking industry and only burdening deposit accounts or other funds maintained with a creditor depository institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Permitted Related Party Payments</U>&rdquo;
means payments of amounts due to the related parties for purchases of goods and services subject to usual trade terms, for ordinary business
travel and expense payments and for other transactions in the ordinary course of business, including compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Person</U>&rdquo; shall mean an individual,
a corporation, a partnership, a limited liability company, a trust or other entity or organization, including a government or political
subdivision or an agency or instrumentality thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Plan of Distribution</U>&rdquo; shall
mean the section of a Registration Statement disclosing the plan of distribution of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Pre-Advance Closing</U>&rdquo; shall
have the meaning set forth in Section&nbsp;2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Pre-Paid Advance</U>&rdquo; shall mean
have the meaning set forth in Section&nbsp;2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Pricing Period</U>&rdquo; shall mean
the three consecutive Trading Days commencing on the Advance Notice Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Principal Market</U>&rdquo; shall mean
the Nasdaq Stock Market; provided, however, that in the event the Common Shares are ever listed or traded on the New York Stock Exchange
or the NYSE American, the &ldquo;Principal Market&rdquo; shall mean such other market or exchange on which the Common Shares are then
listed or traded to the extent such other market or exchange is the principal trading market or exchange for the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Promissory Note</U>&rdquo; shall have
the meaning set forth in Section&nbsp;2.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Prospectus</U>&rdquo; shall mean any
prospectus (including, without limitation, all amendments and supplements thereto) used by the Company in connection with a Registration
Statement, including documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Prospectus Supplement</U>&rdquo; shall
mean any prospectus supplement to a Prospectus filed with the SEC pursuant to Rule&nbsp;424(b)&nbsp;under the Securities Act, including
documents incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Purchase Price</U>&rdquo; shall mean
(i)&nbsp;the price per Advance Share obtained by multiplying the Market Price by 97% in respect of an Advance Notice delivered by the
Company, or (ii)&nbsp;in the case of any Advance Notice delivered pursuant to an Investor Notice, the Purchase Price set forth in Section&nbsp;3.01(b)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Registration Limitation</U>&rdquo; shall
have the meaning set forth in Section&nbsp;3.02(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Registration Statement</U>&rdquo; shall
have the meaning set forth in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Registrable Securities</U>&rdquo; shall
have the meaning set forth in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Regulation D</U>&rdquo; shall mean the
provisions of Regulation D promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Right of First Refusal</U>&rdquo; shall
have the meaning set forth in Section&nbsp;7.26.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Sanctions</U>&rdquo; shall have the
meaning set forth in Section&nbsp;5.32.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Sanctioned Countries</U>&rdquo; shall
have the meaning set forth in Section&nbsp;5.32.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>SEC</U>&rdquo; shall mean the U.S. Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>SEC Documents</U>&rdquo; shall have
the meaning set forth in Section&nbsp;5.06.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Securities Act</U>&rdquo; shall have
the meaning set forth in the recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Settlement Document</U>&rdquo; in respect
of an Advance Notice delivered by the Company, shall mean a settlement document in the form set out on <U>Exhibit&nbsp;D</U>, and in respect
of an Advance Notice deemed delivered pursuant to an Investor Notice, shall mean the Investor Notice containing the information set forth
on <U>Exhibit&nbsp;E</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Shares</U>&rdquo; shall mean the Commitment
Shares and the Common Shares to be issued from time to time hereunder pursuant to an Advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Subsidiaries</U>&rdquo; shall mean any
Person in which the Company, directly or indirectly, (x)&nbsp;owns a majority of the outstanding capital stock or holds a majority of
the equity or similar interest of such Person or (y)&nbsp;controls or operates all or substantially all of the business, operations or
administration of such Person, and the foregoing are collectively referred to herein as &ldquo;<U>Subsidiaries</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Trading Day</U>&rdquo; shall mean any
day during which the Principal Market shall be open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Transaction Documents</U>&rdquo; means,
collectively, this Agreement, the Registration Rights Agreement, any Promissory Notes issued by the Company hereunder, and each of the
other agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated
hereby and thereby, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>Variable Rate Transaction</U>&rdquo;
shall mean a transaction in which the Company (i)&nbsp;issues or sells any Common Shares or Common Share Equivalents that are convertible
into, exchangeable or exercisable for, or include the right to receive additional Common Shares either (A)&nbsp;at a conversion price,
exercise price, exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common
Shares at any time after the initial issuance of Common Shares or Common Share Equivalents, or (B)&nbsp;with a conversion, exercise or
exchange price that is subject to being reset at some future date after the initial issuance of such equity or debt security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common
Shares (including, without limitation, any &ldquo;full ratchet,&rdquo; &ldquo;share ratchet,&rdquo; &ldquo;price ratchet,&rdquo; or &ldquo;weighted
average&rdquo; anti-dilution provisions, but not including any standard anti-dilution protection for any reorganization, recapitalization,
non-cash dividend, stock split or other similar transaction), (ii)&nbsp;enters into, or effects a transaction under, any agreement, including
but not limited to an &ldquo;equity line of credit&rdquo; or other continuous offering or similar offering of Common Shares or Common
Share Equivalents, (iii)&nbsp;issues or sells any Common Shares or Common Share Equivalents (or any combination thereof) at an implied
discount (taking into account all the securities issuable in such offering) to the market price of the Common Shares at the time of the
offering in excess of 30% or (iv)&nbsp;enters into or effects any forward purchase agreement, equity pre-paid forward transaction or other
similar offering of securities where the purchaser of securities of the Company receives an upfront or periodic payment of all, or a portion
of, the value of the securities so purchased, and the Company receives proceeds from such purchaser based on a price or value that varies
with the trading prices of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<U>VWAP</U>&rdquo; shall mean for any Trading
Day or specified period, the daily volume weighted average price of the Common Shares for such Trading Day on the Principal Market during
regular trading hours, or such specified period, as reported by Bloomberg L.P through its &ldquo;AQR&rdquo; function. All such determinations
shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar transaction
during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX II TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STANDBY EQUITY PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONDITIONS PRECEDENT TO THE INVESTOR&rsquo;S
OBLIGATION TO FUND A PRE-PAID ADVANCE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The obligation of the Investor to advance to the
Company a particular tranche of the Pre-Paid Advance hereunder at each Pre-Advance Closing is subject to the satisfaction, as of the date
of such Pre-Advance Closing, of each of the following conditions, provided that these conditions are for the Investor&rsquo;s sole benefit
and may be waived by the Investor at any time in its sole discretion by providing the Company with prior written notice signed by the
Investor thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The Company shall have duly executed and delivered to the Investor each of the Transaction Documents to
which it is a party, and the Company shall have duly executed and delivered to the Investor a Promissory Note with a principal amount
corresponding to the amount of the applicable tranche of the Pre-Paid Advance (before any deductions made thereto).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Company shall have delivered to the Investor a compliance certificate executed by the chief executive
officer of the Company certifying that Company has complied with all of the conditions precedent to the Pre-Advance Closing set forth
herein and which may be relied upon by the Investor as evidence of satisfaction of such conditions without any obligation to independently
verify.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The Investor shall have received an opinion of counsel to the Company, dated on or before the Pre-Advance
Closing Date, in form and substance reasonably acceptable to the Investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The Investor shall have received a closing statement in a form to be agreed by the parties, duly executed
by an officer of the Company, setting forth wire transfer instructions of the Company for the payment of the amount of the applicable
tranche of the Pre-Paid Advance, the amount to be paid by the Investor, which shall be the full principal amount of such tranche of the
Pre-Paid Advance <I>less</I> the purchase price discount and any other deductions that may be agreed by the parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">The Company shall have delivered to the Investor certified copies of its and each of its Subsidiaries&rsquo;
charter or certificate of formation, bylaws or operating agreement and any other material organizational documents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">The Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing
of the Company as of a date within ten (10)&nbsp;days of the applicable Pre-Advance Closing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">(I)&nbsp;The board of directors of the Company has approved the transactions contemplated by the Transaction
Documents, (II)&nbsp;said approval has not been amended, rescinded or modified and remains in full force and effect as of the date hereof,
and (III)&nbsp;a true, correct and complete copy of such resolutions duly adopted by the board of directors of the Company shall have
been provided to the Investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">Each and every representation and warranty of the Company shall be true and correct in all material respects
(other than representations and warranties qualified by materiality, which shall be true and correct in all respects) as of the date when
made and as of the date of the Pre-Advance Closing as though originally made at that time (except for representations and warranties that
speak as of a specific date, which shall be true and correct as of such specific date), and the Company shall have performed, satisfied
and complied in all respects with the covenants, agreements and conditions set forth in each Transaction Document required to be performed,
satisfied or complied with by the Company at or prior to the applicable Pre-Advance Closing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">On or before April&nbsp;15, 2026, the Company shall have filed with the SEC the Company&rsquo;s Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><U>No Suspension of Trading in or Delisting of Common Shares</U>. (I)&nbsp;Trading in the Common Shares
shall not have been suspended by the SEC, the Principal Market or FINRA, (II)&nbsp;the Company shall not have received any notice that
the listing or quotation of the Common Shares on the Principal Market shall be terminated, nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares that is continuing, and (III)&nbsp;the Company shall not have received any notice from DTC to the effect that a suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares is being imposed or is contemplated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify">The Company shall have obtained all governmental, regulatory or third-party consents and approvals, if
any, necessary for the sale of the Common Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify">No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental entity of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(m)</TD><TD STYLE="text-align: justify">Since the date of execution of this Agreement, no event or series of events shall have occurred that has
resulted in or would reasonably be expected to result in a Material Adverse Effect, or an Event of Default.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(n)</TD><TD STYLE="text-align: justify">(I)&nbsp;No material breach of this Agreement or any Transaction Document shall have occurred, (II)&nbsp;no
Event of Default shall have occurred (assuming that the applicable Promissory Note had been outstanding as of each Pre-Advance Closing,
and (III)&nbsp;no event has occurred and no condition exists that with the passage of time or the giving of notice, or both, would constitute
a material breach of this Agreement or any Transaction Document or an Event of Default (assuming that the applicable Promissory note had
been outstanding as of each Pre-Advance Closing).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(o)</TD><TD STYLE="text-align: justify">The Company shall have notified the Principal Market of the issuance of all of the Common Shares hereunder,
the Principal Market shall have completed its review of the related Listing of Additional Share form, and the Company shall have obtained
approval of the Principal Market to list or designate for quotation (as the case may be) the maximum number of Common Shares issuable
pursuant to the Promissory Note to be issued at the Pre-Advance Closing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(p)</TD><TD STYLE="text-align: justify">The Company and its Subsidiaries shall have delivered to the Investor such other documents, instruments
or certificates relating to the transactions contemplated by this Agreement as the Investor or its counsel may reasonably request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(q)</TD><TD STYLE="text-align: justify">Solely with respect to the Second Pre-Advance Closing (i)&nbsp;the initial Registration Statement shall
have been filed and shall have been declared effective in accordance with the provisions set forth in the Registration Rights Agreement,
and (ii)&nbsp;the Company shall have obtained the SEPA Shareholder Approval and the Promissory Note Approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX III TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STANDBY EQUITY PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONDITIONS PRECEDENT TO THE RIGHT OF THE
COMPANY TO DELIVER AN ADVANCE NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right of the Company to deliver an Advance
Notice and the obligations of the Investor hereunder with respect to an Advance are subject to the satisfaction or waiver (by the Investor
pursuant to prior written notice signed by the Investor to the Company thereof), on each Advance Notice Date (a &ldquo;<U>Condition Satisfaction
Date</U>&rdquo;), of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Accuracy of the Company&rsquo;s Representations and Warranties</U>. The representations and warranties
of the Company in this Agreement shall be true and correct in all material respects as of the Advance Notice Date, except to the extent
such representations and warranties are as of another date, such representations and warranties shall be true and correct as of such other
date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Issuance of Commitment Shares</U><B>.</B> The Company shall have paid the Commitment Fee or issued
the Commitment Shares to an account designated by the Investor on or prior to the Effective Date, in accordance with Section&nbsp;12.04,
all of which Commitment Fee shall be fully earned and non-refundable on the Effective Date, regardless of whether any Advance Notices
are made or settled hereunder or any subsequent termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Registration of the Common Shares with the SEC</U>. There is an effective Registration Statement pursuant
to which the Investor is permitted to utilize the prospectus thereunder to resell all of the Common Shares issuable pursuant to such Advance
Notice. The Current Report shall have been filed with the SEC, and the Company shall have filed with the SEC in a timely manner all reports,
notices and other documents required under the Exchange Act and applicable SEC regulations during the twelve-month period immediately
preceding the applicable Condition Satisfaction Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Authority</U>. The Company shall have obtained all permits and qualifications required by any applicable
state for the offer and sale of all the Common Shares issuable pursuant to such Advance Notice or shall have the availability of exemptions
therefrom. The sale and issuance of such Common Shares shall be legally permitted by all laws and regulations to which the Company is
subject.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Board</U>. (I)&nbsp;The board of directors of the Company has approved the transactions contemplated
by the Transaction Documents, (II)&nbsp;said approval has not been amended, rescinded or modified and remains in full force and effect
as of the date hereof, and (III)&nbsp;a true, correct and complete copy of such resolutions duly adopted by the board of directors of
the Company shall have been provided to the Investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>No Material Outside Event</U>. No Material Outside Event shall have occurred and be continuing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Performance by the Company</U>. The Company shall have performed, satisfied and complied in all respects
with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at
or prior the applicable Condition Satisfaction Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify"><U>No Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits or
materially and adversely affects any of the transactions contemplated by the Transaction Documents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><U>No Suspension of Trading in or Delisting of Common Shares</U>. (I)&nbsp;Trading in the Common Shares
shall not have been suspended by the SEC, the Principal Market or FINRA, (II)&nbsp;the Company shall not have received any notice that
the listing or quotation of the Common Shares on the Principal Market shall be terminated, nor shall there have been imposed any suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares that is continuing, and (III)&nbsp;the Company shall not have received any notice from DTC to the effect that a suspension
of, or restriction on, accepting additional deposits of the Common Shares, electronic trading or book-entry services by DTC with respect
to the Common Shares is being imposed or is contemplated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><U>Authorized</U>. All of the Common Shares issuable pursuant to the applicable Advance Notice shall have
been duly authorized by all necessary corporate action of the Company. All Common Shares relating to all prior Advance Notices required
to have been received by the Investor under this Agreement shall have been delivered to the Investor in accordance with this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><U>Other Agreements</U>. The Company shall not have breached or failed to observe any term of any debenture,
note, or other instrument held by the Investor in the Company or any other agreement between or among the Company and the Investor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><U>Executed Advance Notice</U>. The representations contained in the applicable Advance Notice shall be
true and correct in all material respects as of the applicable Condition Satisfaction Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>REGISTRATION RIGHTS AGREMEENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See attached.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONVERTIBLE PROMISSORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See attached</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;C<BR>
<U>ADVANCE NOTICE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; padding-left: 0.5in; width: 10%"><B>Dated:</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 15%"><B>&nbsp;</B></TD>
  <TD STYLE="width: 49%"><B>&nbsp;</B></TD>
  <TD STYLE="white-space: nowrap; width: 16%"><B>Advance Notice Number:</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 10%"><B>&nbsp;</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
undersigned, _______________________, hereby certifies, with respect to the sale of </FONT>Common Shares <FONT STYLE="font-size: 10pt">of
TransCode Therapeutics, inc. (the &ldquo;<U>Company</U>&rdquo;) issuable in connection with this Advance Notice, delivered pursuant to
that certain Standby Equity Purchase Agreement, dated as of [____________] (the &ldquo;<U>Agreement</U>&rdquo;), as follows (with capitalized
terms used herein without definition having the same meanings as given to them in the Agreement):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned is the duly elected ______________ of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
are no fundamental changes to the information set forth in the Registration Statement which would require the Company to file a post-effective
amendment to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company has performed in all material respects all covenants and agreements to be performed by the Company contained in the Agreement
on or prior to the Advance Notice Date. All conditions to the delivery of this Advance Notice are satisfied as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
number of Advance Shares the Company is requesting is _____________________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Minimum Acceptable Price with respect to this Advance Notice is ____________ (if left blank then no Minimum Acceptable Price will be applicable
to this Advance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
number of Common Shares of the Company outstanding as of the date hereof is ___________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned has executed
this Advance Notice as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>TransCode Therapeutics,&nbsp;Inc.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 45%">&nbsp;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please deliver this Advance Notice by email to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Trading Department and Compliance Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Confirmation Telephone Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SETTLEMENT DOCUMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>VIA EMAIL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TransCode Therapeutics, inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; white-space: nowrap; vertical-align: bottom; width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; vertical-align: top; width: 68%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below please find the settlement information with respect to the Advance Notice Date of:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 5pt; padding-left: 5.4pt; white-space: nowrap; width: 22%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Common Shares requested in the Advance Notice</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum Acceptable Price for this Advance (if any)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Excluded Days (if any)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted Advance Amount (if applicable)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market Price</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Price (Market Price x 97%) per share</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Advance Shares due to the Investor</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Purchase Price due to Company (row 6 x row 7)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>If there were any Excluded Days then add the following</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; width: 10%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; width: 68%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Additional Shares to be issued to the Investor</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional amount to be paid to the Company by the Investor (Additional Shares in row 9 x Minimum Acceptable Price x 97%)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Amount to be paid to the Company (Purchase Price in row 8 + additional amount in row 10)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 5pt; padding-right: 5.4pt; border-bottom: Black 1pt solid; padding-left: 5.4pt; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 5pt; padding-right: 5.4pt; border-bottom: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Advance Shares to be issued to the Investor (Advance Shares due to the Investor in row 7 + Additional Shares in row 9)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-top: 5pt; padding-right: 5.4pt; border-bottom: Black 1pt solid; padding-left: 5.4pt; white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please issue the number of Advance Shares due to the Investor to
the account of the Investor as follows:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Investor&rsquo;s DTC participant
#</B></FONT><B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACCOUNT NAME</B>:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACCOUNT NUMBER</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADDRESS</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CITY</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COUNTRY</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Contact person</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Number and/or email</B>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 3in"><B>Sincerely,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 3in"><B>YA II PN,&nbsp;LTD.</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Agreed and approved by:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">TransCode Therapeutics,&nbsp;Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INVESTOR NOTICE,</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CORRESPONDING ADVANCE NOTICE,</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AND SETTLEMENT DOCUMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YA II PN,&nbsp;LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="white-space: nowrap; text-align: left; width: 5%"><B>Dated:</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 15%"><B>&nbsp;</B></TD>
  <TD STYLE="width: 46%"><B>&nbsp;</B></TD>
  <TD STYLE="white-space: nowrap; width: 16%"><B>Investor Notice Number:</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 10%"><B>&nbsp;</B></TD>
  <TD STYLE="width: 8%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of YA II PN,&nbsp;LTD.
(the &ldquo;<U>Investor</U>&rdquo;), the undersigned hereby certifies, with respect to the purchase of Common Shares of <B>TRANSCODE THERAPEUTICS,&nbsp;INC.
</B>(the &ldquo;<U>Company</U>&rdquo;) issuable in connection with this Investor Notice, delivered pursuant to that certain Standby Equity
Purchase Agreement, dated as of [_____________], as amended and supplemented from time to time (the &ldquo;<U>Agreement</U>&rdquo;), as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; width: 10%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; width: 68%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advance requested in the Advance Notice</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Price (equal to the Conversion Price as defined in the Promissory Note)</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Shares due to Investor</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate purchase price of the Shares to
be paid by Investor pursuant to this Investor Notice and corresponding Advance Notice shall be offset against amounts outstanding under
the Pre-Paid Advance evidenced by the Promissory Note, dated [___________], (first towards accrued and unpaid interest, and then towards
outstanding principal) as follows (and this information shall satisfy the obligations of the Investor to deliver a Settlement Document
pursuant to the Agreement):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; width: 10%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; width: 68%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount offset against accrued and unpaid Interest</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[____________]</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount offset against Principal</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[____________]</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total amount of the Promissory Note outstanding following the Advance</FONT></TD>
    <TD STYLE="padding: 5pt 5.4pt; white-space: nowrap; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[____________]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Please issue the number of Shares due to the Investor to the account
of the Investor as follows:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Investor&rsquo;s DTC participant
#</B></FONT><B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACCOUNT NAME</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ACCOUNT NUMBER</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADDRESS</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CITY</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please deliver this Investor Notice by email to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: [_____________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With copy by email to: [_____________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: [_____________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned has executed this Investor Notice as of the date first
set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>YA II PN,&nbsp;Ltd.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yorkville Advisors Global, LP</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Manager</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="width: 42%">Yorkville Advisors Global II, LLC </TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Its:</TD>
    <TD>General Partner</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORM&nbsp;OF GLOBAL GUARANTY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See attached.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2611272d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TransCode Therapeutics Enters into Agreements for up to $20 Million
Flexible Financing, Extending Company&rsquo;s Runway into Late 2027/Early 2028</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BOSTON, April&nbsp;7, 2026 &ndash;&nbsp;<B>TransCode Therapeutics,&nbsp;Inc.
(NASDAQ: RNAZ, the &ldquo;Company&rdquo;)</B>, a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk
and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of
up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement
(SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The financing agreement provides TransCode with financial flexibility
and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, TTX-MC138,&rdquo;
said Dr.&nbsp;Philippe P Calais, Pharm.D., Ph.D., Chairman and CEO of TransCode. &ldquo;This runway extension should enable the Company
to complete the Phase 2a study and subsequently explore a strategic collaboration for the program,&rdquo; said Tom Fitzgerald, CFO of
TransCode.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About TTX-MC138</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit
microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's
Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic
activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138. In the Company&rsquo;s Phase
1a clinical trial, TTX-MC138 met its safety endpoint and was well tolerated by patients. A Phase 2a clinical trial with TTX-MC138 is expected
to begin in the second quarter 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Financing Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The pre-paid advance will be evidenced by convertible promissory
notes priced at 95% of face value. TransCode will issue a $1 million principal amount note concurrently with the Company&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2025, and, subject to certain closing conditions, will issue an
additional $5 million principal amount note upon shareholder approval of the transaction as required by Nasdaq rules. The advance
will accrue interest at a simple annual rate of 5% and may be converted into TransCode&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon conversion or repayment of the convertible notes, TransCode at
its option may sell up to $14 million of its common stock to the investor under terms specified in the financing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financing agreement can be found in TransCode&rsquo;s Form&nbsp;8-K
filed with the U.S Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tungsten Advisors acted as the Sole Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About TransCode Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TransCode
Therapeutics,&nbsp;Inc. </B></FONT>is a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced
cancer. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a
unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates
designed to mobilize the immune system to recognize and destroy cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0a0a0a">This release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements
concerning TransCode&rsquo;s technology and collaborations, statements concerning the therapeutic potential of TransCode&rsquo;s TTX-MC138
and other therapeutic candidates, and statements concerning the expected proceeds from the financing. Any forward-looking statements in
this press release are based on management&rsquo;s current expectations of future events and are subject to a number of risks and uncertainties
that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that
the results of clinical trials will not be consistent with TransCode&rsquo;s preclinical studies or expectations or with results from
previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode&rsquo;s financial condition
and its need to obtain additional funding to support its business activities, including TransCode&rsquo;s ability to continue as a going
concern; risks associated with the timing and outcome of TransCode&rsquo;s planned regulatory submissions; risks associated with obtaining,
maintaining and protecting intellectual property; risks associated with TransCode&rsquo;s ability to enforce its patents against infringers
and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for
similar uses; risks associated with TransCode&rsquo;s dependence on third parties; and risks associated with geopolitical events and pandemics,
including the COVID-19 coronavirus and military actions. For a discussion of these and other risks and uncertainties, and other important
factors, any of which could cause TransCode&rsquo;s actual results to differ from those contained in or implied by the forward-looking
statements, see the section entitled &ldquo;Risk Factors&rdquo; in TransCode&rsquo;s Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2024, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode
filings with the Securities and Exchange Commission. All information in this press release is as of the date of this release; TransCode
undertakes no duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0a0a0a"><B>For more information and partnering
opportunities, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0a0a0a">TransCode Therapeutics,&nbsp;Inc.&nbsp;<BR>
Tania Montgomery, VP of Business Development&nbsp;<BR>
tania.montgomery@transcodetherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>rnaz-20260406.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayLebOdzZR++YkxtmB/bXlarych55pSSSJDn4YW8WEG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:rnaz="http://transcodetherapeutics.com/20260406" elementFormDefault="qualified" targetNamespace="http://transcodetherapeutics.com/20260406">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://transcodetherapeutics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rnaz-20260406_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rnaz-20260406_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>rnaz-20260406_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>rnaz-20260406_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="rnaz-20260406.xsd#Cover" roleURI="http://transcodetherapeutics.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://transcodetherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 06, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  06,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRANSCODE
THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001829635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1065054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6
Liberty Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#2382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-3099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RNAZ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tm2611272d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://transcodetherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rnaz-20260406.xsd</File>
    <File>rnaz-20260406_lab.xml</File>
    <File>rnaz-20260406_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2611272d1_8k.htm">tm2611272d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2611272d1_8k.htm": {
   "nsprefix": "rnaz",
   "nsuri": "http://transcodetherapeutics.com/20260406",
   "dts": {
    "schema": {
     "local": [
      "rnaz-20260406.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rnaz-20260406_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rnaz-20260406_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2611272d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://transcodetherapeutics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-04-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2611272d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-04-06",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2611272d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://transcodetherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-26-040171-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-040171-xbrl.zip
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MZ%0O0\T*T$H^(U95@7Z7E:"B%MOOES<W78M/8K/:)/Y:X8R(+?\%4$L#!!0
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M"% K+[,'8G^+B=VO\Q6 OWEVX[L=6N#LMXH \?_Q6O ?J$6*P#U53"9V2%<
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M,B%B6=1V\E!KPU_/@BO_SLM'K#.POXPG'V_<@Q_;OZU"W!((5O;V_3 "-?;
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M9_0<%_G0"8$I(^[90)[(9Z$S'+N1Z7%_'+I3%D)L$O:F]+I\P>_"ZB)DD54
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MMK*<)H='<$L*LJU'GHW^&V?=*;,H\PIOW8!"I_.BF8RHX80,R G.'T[<9_W
MOXL&Z :.,$MJALSF/<<3/9'H ;*-:I/-ME<G7=4-MHI8;KT0N%)^2KT"B\'6
MC["G$C/AFD=9[Y;KQCV[MM/SHU>);\^L\$B>UP^6.%W>BXH+G('3'T2YG2W(
ML!VY2T9ZEP1X$LBY+9AJ@M?T?EN\GJ\:!M7.R7#_HU>K-18$2(^0S,HI2^>"
M/B^K]4SV_EX2VYLC@UB4RPBT00+MS%0W!B"NW(5 !,35\RDL&8><1L&RLH:"
M+4T.A2KB)"5N":WE3G'Q.P>61M'W "-X$O!;)X3W0 F8GH4)/].B\_K(AWBU
M@VT&=BBJ)W9^3*2"QE4S#HQTN:[,X]]T7U-G<A6#+TX!Y#.O%;S;;/QU^O6X
MO_W(S)L3S#>J.=P[ _C"(#Z/X;9^B'V-I70Q5+::Y(,\RBE(+7C)#6ZT4Y++
M.@7Y?9255%BJ=BBD+(+] E[Y.L8\#<Q,.)"'-$O-PFA0MSFU>DY7S2:M/GOZ
M,XVH/#T[LWK S9MREX., (0C@EA?<3-G083B@2OJ6UJ\F\O+KNC9E&RVY<>R
M*_?K<5H46L_F$6J4+.WN'45\R&J5:BWQ:/&_[EX'SRM@4=UG)E/U(7: ;IY#
M?5&M?L I&UA).\/+\(07X+ODM-WR8H4SSZ!S9@+ ^+ 9Z6IX6?4)L]D^X1)0
M69T+85IC>HFMHB7$9IQZ]85T:$KT8^V%^O4=CW\#MEC^TA\'\I=K!L66Y)W3
M=EZB008WH?-U#%:'G8\#L+.AMJ6I12\[YRTUDS#\'UOLZ(B=GY;8\=4!0MXV
MIT >=A2Z,'&(S7-#(*WK#!UT,D9F$'D\" ?.R%B5DW[T@YM;QT7/7LQ<2OD$
M(J^$0$B4R6LA1P9]7^KQ #G#/^.9V'B$/_]1VQ#DARUT97^'O"I%NA5MY1#+
M!B>+DBW  (L2+26VFFP$OD*YF9@VX;C[!7P9!,(",30A%B(2R"PYD ;]!ML1
M/X8\0E<!R GC "P#Z5QBO< ?L@C8#*>A/VT(<\#E0LAA%X=Q6 7#L\P!B]'V
MM8;H>RG *NS2=!/T$V+H6*1(:6A=!005PDX  #[8/=,CYR\<PR:%.'<).\&8
M&>71E_DCP<EJ$K6E$(6)=3Q?[\=1>PM#C'O RM*P/I]X[I&T#/@\8++!^P>\
M,>ON![LH+GC&]7KD>P9M,34\F9;>WZ2QGDZ^>)=&2@MH6Y'E4<D-0CI%%R (
MA0D;TY?';2*\I" L&:O.&HCL+?4(QL&'F!/;I8E+5;(8!Q6VL<AT00F3#.:0
MHI.T3DR/5SPO-@_%"OC'%,6 .<SOA*!ZNC/,E%HHX;@+'9]+A4^BR9#15QV@
M #!VUW3Q8CNCRTEPQA%%0PG** AMWR.[C0"<^A#"K6H9%6I^DXI7J14^L3@)
M%7 )0BA-C!(L"YD(A-&)0G3K0(4XH15PDD+#=@)44@DVP WQWB>'6TU2(;.4
M6J4: $D^G1=';!6%6O8MXAHK1# Q-G?!6: MOI.M31!S.D"0E S3K#E3(3D<
M;4; '0/+P*:'1!.E%T-=,5;0Q"9H@4V&X;$>IV"6\)#+8'X+>1UHMK/UIYH(
MZ(['XFT3I)3=^B[$7NR.H_U!^@!6Z%F*J95=^/M]ZSP&5E?< ["L*(*A:BN/
M9.7'-J<A[#%H"@]C95_(&1YY!WL65UBH3)@B"6I/25R 1N?3<X (9Q819,*5
M!1Q$W!I34K*0(647?R74MU#+0"(&%L 9CH<"\PK3(W+EY1<IJ/<#/-*&BH+@
M!_$88FH@\L'55-,*QDOXSI J/VTX KQ[+Q#=GG,Y6O<JR&8!6FZ6F,1Y&?H.
MS2FE1\3L1O[LINR)3CL9*8%!2G-;$1,\+/2E<12J2'3R%;LICI(_"K93;"+8
MST@\F&0!^ LRN\B0LW2Z.F9,\32/-7O(C06<69;)'V<X!!0 <(!H!.0@?(Q9
MFDD]%.N_9K5: A>J@#05UKH?VUC1&# *E1.3<06TK0&U*2$*LYK\#@: P(S
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MA:)ZUU5_FM[I%G_(<#LG?E'I;4/_'@\V2:.K=>>$/'L/GRHAQ*Z.&:%K*M*
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MW[W0R:BM9O7/N1Z6&G:O41N988_I"B_9U=N?[L[S31>9VR+?=7D KH?K$*?
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M;_U;YS)\79_L>)\:_OK=Q][^^N&[+W>O7@F*K'=]>XI_#J*AN_?_4$L#!!0
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MJ_N<P;WX_KB\97N7K46R[WXH6\&)0G9(3@-0(A7$\24(X\H3O/UNRL6""H9
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M%>VB99$*>UQ=MMPB(Y$?39*3?\G>V8S=.?F$RU8&L5_E,N@)&D<A4$H3<1Q
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MB;^0,952Q9P[ 4TFNQL1XR/@2,MU$A8 @8>A1VMKV\VRR">HE&^>+RMK((C
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MY+H4N6 6?7"33PFQ@N>FZU;??O[YS<W-,3AIQY?U=:KAC]A1!PVK6;U2H.L
M&IJURG\[3ARHU-%"X!H8-YC\-]BOEM199T^$C+[_<,'Y\>?&HWEFTO181"LW
MEAZ)=1#Y7.@=Y/.1<(0-_5?N=P;2&7\>/^K(ZY,4(&2EY9;,515QFR!*N[T3
MESZ*AOO(+[D)%MJ"9\8CQ24>>-9ZQW193^>X(/JN=[@#)&_83Q4Y)8A^.BA6
M^G,,V<U[D?%,:FGGAV78% T(/Q/H!_J0DZOP!%>0JML]464J27!'G"5?XB:Y
M)$6H*MK$S;2C)'?.QE$V<"V:G*Y4R@7+15OF5#1QA\WX/4V3PQ3@65-$,;>H
M5"6&[-#\I^VV=*,>#YH?J+2=\<(TC:?-3"// +]>7^8,0U'7D ..%;FP%*UR
MMHT S!$7VI2;=/!6IS:J')D*=6]5CK,*1G.FP\<N>ZF.-I%VT_G<"U[;UW
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M8!WOTRVQTL +3J1O&,[2X(7%KM+&L+&@QR-K0J-:@NTS+BPV8S$=W7$DM\W
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M]_6*K^&\SMO@<O% O'H+H997.*AF*+[CE0\I[W &AZH 7=B2K2;59A7H:[Q
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M9:#YHW>:!7.F#_6G?X0/U358ZLJOBI6-2[UB9WJ0_B;=BD^!/YTO%G JN)#
M?)3IXXVREX0$:YD"88"@*1:D4<:C65E(%) +BMBWVZ)KW?MZY0'V&]7@5_!4
M"^9[[MK@R6]2QJSHX&( &(L^-*6?VY"&>=^%8-T2:F_#F<#;%0X%4UYL"M(M
M->UAW=R2A<L'J%"UBS1]^I?H,#CA7U9YHQBC.'Y2VU_NE4XU9I2CY[<D@Z9Y
M(S5L9 $)4J]P 'H_&T"/V;$.LCDT ;DM;%AH+1"*?W>757C;Q(^QG%^"_P-\
MR@KVI1FP>M!&1U3')O<ET7S8J^4B?[V+)$)DY^OAPG.O05Y(4PO@+^-CT_W
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M>#6"P@&ZMI[%9"0,R5^/G!PU2[,V'S)BL5]=Q-C&CO_YF 8SF<5F.# 9[(R
M/>=21<6BAV=_ZXRO,)P7R"6_/N@CS] T:?9NAF]"D,;ILG>"_/1\$>GRL*YT
M)R1647ZD.V9*6K&PS-X7R_72)3-$"''@>6-MX1:6JUV8!M$+8_/QU59Z*E%J
M*G7MI8B3N^4>8;$QWN'XT9[>T6$@ D/>D1$CV]VCT#79USO:Y?+TRPANX_0X
M$;C#ZTGB3H^-R4;ZO!@*L BI9]0WT3P!O\<9290O@JFU/](9\17T3@SPZ2-;
MAO,'^"!F( ,N2!)Z()Q,,OLT(%AZ)F_D+;_/XB7;29N\MS(P/K;%J_E[5'7I
MH2Q>X<=&BI6#6[RDE;T^%'^,Q?O<E;"C_*B8[5!L7N)ZBIE_86L7^Y3M=F$?
M^[N/6<CG:CR:6XZO!D1G(RLGI\[9%B)&NPU+\_U,^9Z]LLV2I[WY8TWY9!]+
M7L[KQS;E[9X,[)FUN-26<6^0G:;\;@N^__>HN>Z8#P;-V0^R75W7F>!%CY/0
M:O?'[6STS!M)WR2W0]]BDW]LIP/Y+^/S^C!CW<YA;V.=R;?&H\ (^ECV>G)K
M<QUC/9%AWF&#?;^$[]G)?<+W< G?LY/[A.]=N"M[.K>'P>"\I(HD;@J#=@4[
MLT@0LR(*T45'D.%97L!4",T7#??#3WW_@.N<3,432D7DB< S: UXP4Y*/SU;
M@HN@8@\JZ%?@1KYQI*IQ:8Q]\;M)A],5T?&GW-C:"N64%45*I#3"\\L,&?'W
ML2DD.6HQ\@O3897[DJB4D'6YF8T4,R?.?Q^/ G1 :D('1C%%OIY%FB+V=D$&
M]IC8'4G9.K[BEMIW8Q0@? -#:%5PNI&>'@7MJS-(=0C"GX%I41,:O-&I,*_M
M;W @I+" \; \5*G-CWR-%3M5K)&_1U281,1L(*>Y 6NF^PT$E@31_-0RAD#%
MY<9"-DT()O8U9D0I-[(5_#IL0+C,353!X387F)&S1X8>C]#/-@<C9=UQ*9TJ
MNK-V"*&')140.P\"M=C_ B2"$B7/A.VKQXI50]PX T&-B@:R/".R86AK.(C#
MN+V;RL[;QG!@FFMAGE>Y0,<7NG%Y/YO:Y+)6<$MKXN1&AMPJMX\FNN-;"0;3
M)!DQZ]/^Y>!QH)A(C4NH$[#UJJC$8C1#L)&K+4_CQW@>B;D'YC&A5;]K'HXN
M+7):;'EG4>G^B,BQWM5F&U &UWA?,)+ ;1'9[V5.8BPA[VYRTWTY/C"L3^BM
ML.%FXQO%([*S5R+ 3-TTNW8:P6=;V6,M^$3.:N;X0"+JTESN(:G4QSP0&!J<
ME<[UV3#WN5:-99T*8S42V7<C8LG3H*&)=[Q-XI=E$!MQK0!LL43H6N]>&?99
M.)[%;:DB<T!N7XH/VZHQV2#+F9*XH(P$2?580<27Q3MDNL&@E]P;=U=8JCEE
M'!N_P__$YF'_*F<F534-^.R;C/0I;I- "1+A+(*C?UU@T(/SSZIUZU6NSOIM
MKU],O+J>!)'MQ1 *3%_B"DA.(O72O2:EHN'6R,(5[!/?BT%E^2[/5[<]'_J8
M@:@H6FY=*P>->I.UH7:3J$*;=YWD^-6U:8,9<2B4R#B&!DYM_%RL,'RX9VQ*
M#,VW((5W4!%CH Z"V6#<1^PHS/!0#F5(!U)<87!M40>M*[5:^";,?) UEVVD
M($+R/04W^L,7;IVY2XE0@$(/F-(@K<S_EF?3?!,IG;GJQ'308%I4+O7LR-Z1
MBBN]WHWM1[1<$=VDE2.VV1&;^#EWMX6%L5-'JLN\65H+"$=^65RKH _M7\;O
M6978RQATCY5,VV>)@1_MHF14$HE7D!,EL%%EU(2O=8,/"KN:SJ]82&2@J2&J
M*>3J<J#&04.-3\N4JG.:VC+"XR_)3KJ]J.E+"*2>TB3K,!KDA6GY#-JN!?W6
MZ=S-R.&X>A/V.&=\:6,^HCO^Q'P#HXR-GS3=2!>:8N9(!64-I!.,.2OSM463
MNKZ,O,ZZ5:_3RZG771FVO612%<..PD:2B?O1:Q8<6 =3Z-,/T9W>A^@.&*([
MO0_1W86[LF>([D -1T"CSEV'P;?D!_*O(BR0D4"+:3*?OZ>4V'6N? K;SX,S
M7MPKI.$7;$3 2V)%>Q ,(;!BW9(38!VJM*1%$=]) S -2A%Q;/J+=,JP80#9
MN]S/O R'D(R::-?--4X+'/["N1K<I4WEN_Y"[,AP& _34^2%1=U0S-@:2H8L
MKT-#P_;P\))W6*5)++3&P,'FQERZR3]3)C/G5DBE:6^(R<S&40E(N3X]Q1K\
ME/$%HWR-_8$-Z50C0";#GBX6+;6V*SATD;^G-"78MH*6_V1.Q7#9V//C[YZ\
M_AYC*IP$;O]296,.0RJSL]0?NA"G%^CT/^XCV+)6ZLIL<M9]&C$456Z"*XWK
MHSC-JWQ16+=*1:G CE8F*(*)"BX'>D4&["=>HO;5H4K4+DQ3 .K&$0%UL0!Z
MMF7IXQC=@H /XB^ 9*C6];IU/0@,CP?E]E][>#&%)R-8F#U:V.C+**T>X,]O
M5\ (SQDX7'/' ]A#KG'+,:>\5 Q^//(#$#*5_-HZ*Z+^>RPKK>ZV%%L; \#2
MV##D>.&XQ'*9-T)<I(/;L'#4#91 8GNN[1:DG@5AJK:D0Z ^;Q-@>_[H7?AD
ME,7@53X,GMJ_142.Q!W#^LRG$I+/#+60C\WL:G.L3$:& 9U$1$98U%F9\1%K
MW?;SF?#AN6<6&F8"S1I]*PJE9M9/20E(-Q@X[*;?!Q9L8E@[ L"./<_9WQV1
M&7FI<#S,;&-;5-7$U-TA&!.^1?BA3L&H^LCB\,5'%,,1LSAGP&F+7**FI:\N
M &N\#U/(V7SZ=\Q= ,]JH*E)!&>MFA-C]B*G@4*:LN=7: "V=A P]+E)+, (
M R"OV 3F"U&TKVFDTZ_S\YHJDGP).\?$#HD2JJI45Q8N-:MFVU0/K)]J6\-I
M3\,GTB;#;6R>^P!)B69Q&2VRWW *%6EHL]4JS]BQ"_ "%H!G%ZU)8!(&#QDM
M$10X<F]U;$#/'JDY]Z><XU&<<;?=F!I:&2S*Q AJM/\RR7K SV=?)%<8Z;/E
MT0:N(B'!(PUB<+TF#*<6PI^Q[2J>2-D,?O$.79<H53<@H0CA/N7E8]PXKIY,
MO!)7)MRYNZM5]HPHGMU'% \843R[CRC>A;NRIP5V&-#?$[B=(+#?;88L+K)(
M5)(_E3YLY"TCJYTM!NF7K-)%HP;&4[+^LXKC++;ZGRV+?Z]A;9!5HZ^%"9"3
M11MI>2)<&_'XAVC[&S:V1(^9)G5!^DSPX,K'@&$P#Y=U 5#B*\,EL ]2CRY=
MVAQKM *7WR@S%,8O%5RX&PELAM1KC4<E,B<Z/22^'OAT&,F:18$D;4U[5O76
MB -GR J(?\'_;HM.]*MUX"KL*E#WV@%:9W&(3J)NQ#2W>6[)[A,!PHV8X4MC
M$ELJ^_&(;#I7?H#+\+Q2J4I\]),-+9Y7LB!DM)EDEEWISOXT@\GDO0S,'=L:
MGN2H/L4N^0T6MYT7 @@B][LPQ/G4X;LS#*:!8RW/)10F!YFX 9PO+6 @&PNN
M(>)&6I:\I-RWX:3KLO<"J5$5/WID3/SY'\-U6B"9AOVVROM+?RQ<$L))N'GV
M'AGTEPY,MP$#C*^DQ19[F\%GG+YHLL;]WI^YN"2MLT?1_//=&%Y:\Q!Y<-3\
MMX+'V=[1&SO%&]O:&YOPF5OT3@"Q">)3?!)*3-60!\4S9\X71-/Y,-T"H]G.
M&:-6/^8M"K9BX8O"57N'#<@]E>)ATFQO[$FBS,:6*./=76#^7PR7[Q-7?W!R
M?$:1=8RO@H("Y[.]DFHQA,6PR?W+VFB'VX98^[H',XDFB("?7 LL<F"UJ=0^
M]$D#!1<$/ /=-,_9W61^(]>QB#])UT9)$,^R075D<'Z$SF)31;HAK:D;BZNB
M14?:4GD[4*-0Q 8]PGB9_"=QZD'3^'+GES08N" B4RM;IFC0]$"(2JDYN"+5
M'/>9=;8TDU*MI-#$L(LV% D/OF(M POUJO8JY.:*T\[5+>]5K^QJ4.O]ZY5I
M?4O.>TMY1-& A8"1<=?&F'<'_@KG$94ZHI+2H-0YF62J*)\NSWCDWQY3DO\'
MBI#]O.)_/G_V]J?_^0Q]WL\^= 3LU)U$G+H]'.?/OL>QAIZH%4AQ1]7\>9(=
MA9^(*A:J;TK>@$8G@]W*#"7"MLHX.NKA)P("#>X(S?4%9#))(MNW+();J3V7
MWGUR-S E<Y"$)CZVC36\ULX5R%O?_&&_S> V4LOV/=1(?$='JN-^+.#^$'_H
M(=YNY$RF1\8TV?.D.V2&#<+&#W??3B<)O:1&!_C+\&N2681#7M;@C$D'P+.3
M9)YM6D-IX74,P.[U-6$HX206S/VRB\.% >/@G=+/1_P23AW"6-D!M\^CACT]
M;8\W1>:!*X#A@$7>A+?/4?$00DF;^" DT#*WY#3LA>=5P6 1).Y1+#9$^F/H
M>5*_58!;6%.GA[\U_2^XZM*XXK$UMP%\VT.DPD8V5F.2U# Z$351U;<^J(</
MX6?-BP:$66_#)0ID,T7%$O%F\"];$LK!!S4HA[KPET!]E83DD!_80VOUA_6G
MB9\_R<\Y%(*K9?8=+/G52HJEP[F#.P2G]1D98K+)*K1E/O:,."&B:5HTT9!#
M*G#R66%Y'H++LU%IJ6N<K%*[NS*X_:0CA0"QB.U:H)(VH15DJ[ +&&9A/%5)
M][WP_/.B114\^PLXVU\>J+DV>3%R"*D<RU2>%[6M:9ZK9B"6*:T?*"*48=&
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MJ?:?ZGZ %#53<(@^ZE3M!MX6EH(-:_JX%!+-\A >0L%=V1@.M/T"*:10%CN
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MTN2BFU')]A\GFO:[R_]\_NSM3__S&=[4SSYT!'P43R)'<8_K_MGW.-;P_IS
M/A;5X TW?YYD1^$GHF>$-BA1^[,-CD["@DF%$]/!G9/RPA5&2C&DR*)8F2I+
M D\-_4'L3W?IW#I5UL0]+^J%*H'C4O=.0O^F.1$'Q5*KTK&N,"^S#:$F%Z#8
M.\>$#',II+J84 JL=!O=)T.A#\1YZWEMSBJ+UV'9_DD<5,W8/XDYQ^.1]H[)
MN[/OB0S(=A0(P[L]<RY$'8<!/P]#V"-F%A/$T5/W'F=?Q-] 2LU09M]?VP^^
MMM/;7-MA,8IG.XYRYOO]@XEBZ(P:=SJSO\7HEE2IQ@*1AO9 Z'P<,9.-3R(
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MDW,=(9C"1!2D&YD]5O8J5'RFAVT1 H%?>H82EZ7$(IP=F,F_#K!Y'#S ]%O
MTKEIR9H/Z>LA@%])@VBV^G];2H-AZ\%PHLLK6Y,1IO+PKO'8G>8D'"NRI,*'
MZU/W\Y!:]] ,)-Y)R+ 3OJUN+]@"L80)&)KOYSW0?DW=@*;[;Y!TTXR$@-'A
M3=A7,XE9"3K@9M1=K<T1<2<M^00%SM5RY=/VUD6YV?[F?:HVJ^T&_>OXF_>U
M7/M2;<&K-KSVIZIW^OGLK-IJ>]5_M:LPQHMJ\[S6;E=///AI^>+BK%8A/^^L
M_+7DE>O?O&;MXZ>V5VM[Y^5O_(*?RE^J>+>RUV[6RF=XX7]^;G[S:G6ZX*SZ
ML7P&0VDV*M4J^HG>2:U9K;3/OGF-)OQ(_U5NUEKX=>-SVVN<XI?-ZEFYC1_1
M6&LMK_RQ6:V>XSCA6QQ]NUFNM\J5=JU1;WD5>/'J^05< \/'MZW52_0K>*G3
M1O.\7*]4M[?:^ W?G]Z_5H?/X2$YU\.;['S]5,4KO.-R"SYMU.E737@DSF"3
M!H)OV: ?P3\:S6^[>QY.O^?,O@X&5JK-=NVT5FWA4,IMK]Z ][QH5EOP6O"V
M7ZHPSQ_E%<MM>$:]^@WGPSQ%[EMNF0NK)R580?RCQ?-*O_Q::U5Q!N IK<\P
M(/ORKXW/9R?P\'9);)LZ38U7_4+//O7.:NW:QS+.+.R':O6?N C5.LQCI<H3
MUVA6/S9P=4BB<!I.3-"R7/EGO?'UK'KRL=KB$8#(X"_P4N<U1#A1B(ZKU3I*
MQ.=*]01&@\]K5U%&LNM__ VFZ;R!XB(SCTO(RWW^N?T9Y)"'U:*GRJ17RBPI
M()IT/Q@"W+)\\6F%]<YB89^7^YNPS].%?5[N;\(^J[!7%G/C_@7VGXD!KZ%O
MEK(PB,SC,4P,B^#*GK_/1P^H/O\2,*X%$>]<TP5>5@PND*%_H6IKDRRURG/'
M>57@^C+/!W<3"[*X.$Q2S')W\@Z<?I\OW[R@[!KBYS'$0<E^Q4RBVY.<$+#)
MM)FB'CJZK:*+1\'8$%P-[L)DK"@^2H8D101,==JF*K.^/R5G%J%K],,NT^RA
MTP:_R?"=$HEM@ ET\X@,CBT%X])X&@=-8Q)?%HYCX'<#A=>U:#!F5H*CPS2#
M,P*_"L?TRS*16F\0DT^ 4F^[(6MKTZ16,]68AX ]-MN_%-;G@IUT,$#)UH?4
MQK'W'\@PA]<=44[7@7.8AZ76%3*25V00L5%@)5?L8QA2R%PCOK,KTQNKI+ $
M84ZR&_%DA"/#;:*(V:/;G,Q!\2[)4EA(A,A6>E860?#H@\D8MU(!]E08YNUN
M2KZ.:*G6#EQIZ]R'R4/Q1I+C-_P_-D2%KDP]>K-YGP#N7!>JIUQ4 %.?64>*
M*ER.@W[@)RF&3;<IHB)VFWK]4$JQ3#<2(>90=5:.\#I-1)A!QX8AJ/P;_X8+
MONS,6ZI>)%,YSORV@U$ AZ+4>SLD'K([.&<D'1RRO!X_/W(.J&(4;##4'8FQ
M)[AFZW#:\J62L#^!T5A'\'&A.U+;4^I[#7V1_ AHPR#A4]G"[:W4D:5 N .X
MGY2L*/H#IY0OG:QP-O5+W--<C^)L:W,'L6Z[OD7E2"F*+/L&W@Q4#6>,AVJ4
MHM!QO)3A2TPC"ZM](PF[)O? (\X&)&+?2[AV:!5C$GXOI_%RWGSDO* B7"!K
MUKRM-APF%C29VNK9OV*J;C3^/UAV !?/N=?0X0=:)'@Q\,'R!H,^T5V'+6NG
M1'TJ5;_&@E_P0H0#&#ZBA_O3?,+A#[9Y\7I[BT")S*?)%45J3)_W6GNPN6)B
MY.@BX40?T]WC26Q V;HCNYCZJBO\@=4%NQL0&:'"@K+V(<\(BX2OAN!.=V&A
M,+E&>#1-4)$$H+@Z02H#Q@492+K1[6(.R)@_0ORC2=YT%HS5J/I]8A""*?E"
MO'8P&O/1D[8 >3?9+E/Q'JIR&V@)3'NJ<DY=_/XQW'K;/$F;+W=^J!-5+(P^
M_D*1K?F&"D6_,M;((:JXO)AE)@+3\P=A?_I^]J!_.4)<M@/6Q\3P>Q5LP;.N
M:"AO7N8&3W]V( 0]K43@TH(<QOXHF,"L)"I!,.P0^L%[XYV%EU1JU *_%5R2
M%][?#E_^?DA?'D=@D,"-S\O>_N'!_COZL#P>PZ1>7(/!-!H%WL6>5_'[?IC0
MEU52*>\]^WWI; <IR3W=M6 5'W#63Q8*GA]L@N=/&#P_^&L'SXOE>=V5Y"]'
M7ZEK431"G,6.?3*A@6!UY)#B+T*@&=HGPIXDR2ZKP]EZ$&S.. X[WTO>)VRS
M-;P:*W/N'_Y@A%T QYU^"'Z_![-'BN?5_FOO4X281J\U!JMK3)^VP&0]!3W8
M"9-.5$)%%8)P#$/?>_?J8/^UI<_JX??0._6'5Z(@J\G_[7T R^4&7*16YWK2
MQZDW7]G*SE9R=YAC6[QS/[S[+0LS!DLXS91[FG^4'7TK>[6:=U&7.3H;=WF.
M#O8/#KT6TE)?]7#C>&6"QM!WYQA,PHKYL OV5OT_O?VW^^\.S:+\XV_O/F #
M'*\\O KZD7/ /,P\+7])>-,@N\%HNM1-<\2R>0IN>%HN?W+.9T[M&KGF.G*$
MH1PI]6+/3HQQ!6L5_X?_TN%;?ZPJ3U7\T.E%*#@WL/9#4(084R$' ,.D$JUA
M'LA4)2Q[B@CA]?4=%6<H(M54&>+V5K9/K0YPJAZ%[$80\>*>]]7$*+%45(=9
M=+VI<KMX"!(],N-7]QM*E:NXQMB,3\"ON8ZQ'6P.D'HBCH:2>[J"@<:FQ5^
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M6 ;C]=+N'HY\H;!G*DGR-&&Z\"*+IT$S 99T'Q;,^1%[H/:'<@$!-C^0Y]_
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MJJ^ZT:Y<DZ!SQ&+7<6278H\E=ILGR$G'^<')^#J*$1-1(I(GNWJ.V=U-R):
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M/X:;7$[&;':C]14GU^%HG3>RI.P+@N8F2=>/;E%&&2SPY6OY(K>1A4K]"RS
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M6U7O\VQX!U,!]_LE(-=?4T44+9D4!*DQB$:UG_*KN86_>"&1]!@C.9F,1OV
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MP*8A53JR2]*;HGHCJ<R3H.?#11M!6J8@#>\8(P>%I\,_&#I4.#=;D%0GNMS
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MUMDVS]\4%^H060'C9R/9&[O^YZLX_($-\4X98XY5IPN6[<#)1O[7H*1C9CW
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MT(HTC%U+BL,(1HEL"FU"W+)G*6^2**@'J [1C&"=80W!:JW3"M7&D%6.!>3
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MHT^2$\0ZRC#1]E:;^:2GB\^P,1M=*KTK<3X0'KS:ADKO$DRB2$>52C:7-7X
ML&;K@A+EX%Q[*QQ<N')F@01Q#XAPLI@;@#N-XO7=?N_NIKSK=G0^)9UQ#(L
M#T;\BHP:M9N8AIS534[X$6Q;D:]:@=_=??'\YV"Z/=D.:1-_*\J/M(5DPEHM
MV["T?CKG8XT8U*,9=7]K,X44H^2P3UV#\2^8;VAR5P%BQ7VZ2H=I+?GO.&6_
MAWVC%:R#BNVY=B)DJJ;9R-B8:B:@8TMB*O'&[)"2BQ==OT<4<*D >35@W8K+
MG'J0<ZTL6B":#6*4"^<_IC 4?RE2UXQNPZDXHZH$G2M51Q\91WEIS9MZ4I,_
M6[U);(\8&)7=3E94[,\8UQPF8_P#-%8)N=?-,N,6Z!N,WXO=V&[%[Q67E*8L
M%F/>ML&^N!O;DHG;)'E7NFW\M]G9++F$+=-%HF:G.;MIFD4C;H,V,B4@E:1
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MDLXQS>[AIG%RKPJ:_;U\5+)FZ@*Z$$Q5@C2M43"-"*"IZZY2B0/5A<'REY*
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M!ST#!J<+B2UV;(]NC<_S'>.*3Q_CBBN.*S[].\<5U^6T?!N=TQV.K#IS(:@
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M]R[X7?!_/2NUJ!<<]W_I'7<[//<>3$JN-0_J]P[>PN#_J\]/D)L_G!Z_/[F
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M9TN>[)?B)D_*ZBJ=4J)[- 4C/6.$Y(;Y/)P[ !2ZW'&38\&DD'.OB'$ZKBD
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M<O9==K)M0X^BO,A2M8W=#I].=&>Q$PL1)OAHG&=)'(Z!"LI+X^_"@PGGM,A
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MP/.^L7+;IC_,+%03$X7E-O>4=34W%#T:=;DXFW),7PIZT8Z%9E+4^^C*$5>
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M*THRV@E[2B5VY)_+$)DWE4O&6575&QO^;.H[\1&AK+ELLN29%YF(HTJ&?,_
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MQ\>#WP[W^J_??PI^[P]_&YP$_8-/[/X-AJ/@0_\32ZQW_=\&/?AM/^B_/1[
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M%VGI)VKT2[9_ 5!+ 0(4 Q0    ( &=$AUS_VSWM,@,   D,   1
M      "  0    !R;F%Z+3(P,C8P-# V+GAS9%!+ 0(4 Q0    ( &=$AUQA
MTG?\_0H  '^&   5              "  6$#  !R;F%Z+3(P,C8P-# V7VQA
M8BYX;6Q02P$"% ,4    " !G1(=<&,ZD@V<'  #N5P  %0
M@ &1#@  <FYA>BTR,#(V,#0P-E]P<F4N>&UL4$L! A0#%     @ 9T2'7,X9
MWG/(*0  ==@  !(              ( !*Q8  '1M,C8Q,3(W,F0Q7SAK+FAT
M;5!+ 0(4 Q0    ( &=$AUST/Z?5$KT  $R?!  6              "  2-
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7;5!+!08     "  ( !,"  #9IP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm2611272d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rnaz-20260406.xsd" xlink:type="simple"/>
    <context id="AsOf2026-04-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001829635</identifier>
        </entity>
        <period>
            <startDate>2026-04-06</startDate>
            <endDate>2026-04-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-04-06" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-04-06" id="Fact000004">0001829635</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-04-06" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-04-06" id="Fact000010">2026-04-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-04-06" id="Fact000011">TRANSCODE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-04-06" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-04-06" id="Fact000013">001-40363</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-04-06" id="Fact000014">81-1065054</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-04-06" id="Fact000015">6 Liberty Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-04-06" id="Fact000016">#2382</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-04-06" id="Fact000017">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-04-06" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-04-06" id="Fact000019">02109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-04-06" id="Fact000020">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-04-06" id="Fact000021">837-3099</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-04-06" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-04-06" id="Fact000023">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-04-06" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-04-06" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-04-06" id="Fact000026">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-04-06" id="Fact000027">RNAZ</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-04-06" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-04-06" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-04-06" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
